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Abstract
Oxidative stress is a contributing factor to many neurodegenerative diseases. In
particular, mitochondria are a key source of oxidative stress due to electron leakage at the
level of the electron transport chain. To combat the endogenous production of reactive
oxygen and reactive nitrogen species mitochondria are equipped with several redoxcycling systems, such as glutathione (GSH). Mitochondrial GSH has been shown to be a
critical reservoir of this antioxidant, where selective depletion of mitochondrial GSH can
induce apoptosis in several systems. Many studies have intricately linked Bcl-2 to
cellular GSH status and it has been previously shown that Bcl-2 is a GSH binding
protein. Therefore, we hypothesize that Bcl-2 may play an important role in regulating
mitochondrial GSH transport.
Here, we show that inhibition of Bcl-2 in primary cerebellar granule neurons
(CGNs) induced apoptosis, mitochondrial oxidative stress, selective depletion of the
mitochondrial GSH pool, and led to inhibition of mitochondrial GSH transport.
Furthermore, we found that Bcl-2 is an interacting partner with a previously identified
mitochondrial GSH transporter, the 2-oxoglutarate carrier (OGC), and this interaction is
modulated by GSH. To further support a role for Bcl-2 in regulating mitochondrial GSH
transport, we show that Bcl-2 requires OGC for protection against apoptosis induced by
oxidative stress and to increase the mitochondrial GSH pool. These data suggest that Bcl2 plays a key role in regulating mitochondrial GSH transport and that the enhancement of
ii

the interaction between Bcl-2 and OGC by GSH may increase mitochondrial GSH
transport.
The mechanisms of mitochondrial GSH transport thus far have only been
extensively studied in liver and kidney, where the OGC and the dicarboxylate (DIC)
carrier have been identified as inner membrane mitochondrial GSH transporters. Most
studies examining mitochondrial GSH transport mechanisms in brain have not allowed
for the distinction between neuronal and glial cell mitochondrial GSH transport
mechanisms. Therefore, we employed primary cerebellar astrocytes and primary CGNs
as a system to study mitochondrial GSH transport mechanisms and differences between
neuronal and glial cells. It was found that cerebellar astrocytes use both the OGC and
DIC to transport GSH into mitochondria, while CGNs preferentially use the DIC. In
addition, discrete inhibition of one mitochondrial GSH transporter (DIC) using chemical
inhibition and genetic knockdown, in CGNs, led to increased susceptibility to both
oxidative and nitrosative stress. Overall, this suggests that inhibition of a single
mitochondrial GSH transporter is sufficient to predispose neurons to oxidative stress,
such as the conditions observed in neurodegenerative diseases.
Finally, the consequences of overexpressing a mitochondrial GSH transporter
were examined. Stable NSC34 motor neuron- like cell lines were produced which
overexpress OGC. The stable OGC cell lines had significantly increased mitochondrial
GSH levels and were markedly resistant to both oxidative and nitrosative stress. More
importantly, the stable OGC cell lines up-regulated Bcl-2 expression (a protein we have
shown previously to interact with OGC) and this phenomenon was due to increased
iii

mitochondrial GSH levels. The up-regulation of Bcl-2 was required to sustain increased
mitochondrial GSH levels and resistance to oxidative stress. Overall, this study
implicates the importance of not only the mitochondrial GSH pool, but mitochondrial
GSH transport for neuronal survival. These findings suggest that modulation of
mitochondrial GSH transport could be a novel therapeutic approach for neurodegenerative diseases.
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CHAPTER ONE: INTRODUCTION
Mitochondrial dysfunction, oxidative stress, and subsequent apoptosis are major
unifying themes in the pathology of neurodegenerative diseases. Particularly, oxidative
stress at the level of the mitochondria induces mitochondrial dysfunction and downstream
apoptosis. Glutathione (GSH) is a key endogenous antioxidant compartmentalized into
mitochondria, where it functions to combat reactive oxygen species (ROS) which are
produced by the electron transport chain (ETC) as a byproduct of aerobic energy
production. The mitochondrial GSH pool has been shown to be critical for cell survival in
numerous systems. However, the precise role that mitochondrial GSH transport plays in
the maintenance of cell viability remains to be understood. The mechanism of GSH
compartmentalization into mitochondria has been extensively studied in kidney and liver,
while limited studies have been completed regarding the same mechanisms within the
central nervous system (CNS). Furthermore there is a lack of focus on the regulation of
mitochondrial GSH transport. Prevalent evidence suggests a role for Bcl-2 in GSH
trafficking and metabolism, and it has been previously shown that Bcl-2 is a GSH
binding protein (Voehringer et al., 1998; Zimmermann et al., 2007). A major focus of this
thesis is to examine the possible role of Bcl-2 in the regulation of mitochondrial GSH
transport while also elucidating the importance of mitochondrial GSH transport in
neuronal survival.
1

1.1 Overview of Apoptotic Pathways and their Involvement in Neurodegenerative
Diseases
Apoptosis, or programmed cell death, plays important physiological roles in the
development and maintenance of an organism; however, aberrant signaling to or from
apoptotic pathways contributes to the pathogenesis of diverse diseases. An
overabundance of apoptosis for example, leads to neurodegenerative diseases while a
lack of apoptosis is observed in many types of cancer. Currently, it is understood that two
distinct apoptotic pathways exist, the extrinsic and intrinsic apoptotic pathways; both are
discussed below and reviewed in Figure 1.1.
1.1.1

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway initiates with an extracellular signal, such as
that from cytotoxic T cells of the immune system. This extracellular signal leads to the
recruitment and dimerization of death receptors (i.e. TNF or Fas receptors) which are
specific for the extracellular signal received (Elmore, 2007; Ow et al., 2008). The
oligomerization of the death receptors initiates the intracellular formation of the death
inducing signaling complex (DISC) which, subsequently recruits procaspase-8 and
activates it through a cleavage event (Chang et al., 2003; Donepudi et al., 2003; Cordeiro
and Bidere, 2013). Other procaspases are cleaved downstream and activated by caspase8, including caspase-3 and -9. In addition, caspase-8 cleaves the BH3-only protein, Bid,
producing its activated form, truncated-Bid (t-Bid) (Li et al., 1998). This mechanism is
considered a convergence point for the extrinsic and intrinsic apoptotic pathways, as tBid also translocates to the outer mitochondrial membrane, initiating the intrinsic or
mitochondrial apoptotic cascade, as discussed in detail below.
2

1.1.2 The Intrinsic Apoptotic Pathway
Intrinsic apoptosis, or the mitochondrial apoptotic pathway, is initiated by an
intracellular signal such as DNA damage, accumulation of misfolded proteins, or
oxidative stress. The exact mechanisms of this pathway are highly debated; here some of
the major hypotheses will be reviewed. The Bcl-2 family of proteins, both pro-survival
(Bcl-2, Bcl-XL, Bcl-w) and pro-apoptotic, (Bax and Bak multi-domain proteins; and
BH3-only proteins such as Bim, Bad, Hrk) have been shown to regulate the
mitochondrial apoptotic pathway (Figure 1.2; Burlacu, 2003). This pathway involves the
activation of BH3-only proteins, such as the dephosphorylation of Bad, which causes its
release from 14-3-3 plasma membrane anchoring proteins, thus allowing its translocation
to mitochondria (Masters et al., 2001; Yang et al., 2008). There are two main hypotheses
regarding the mechanism by which BH3-only proteins promote apoptosis at
mitochondria. BH3-only proteins are thought to either inhibit pro-survival Bcl-2 family
proteins (such as Bcl-2 and Bcl-XL) thus “sensitizing” mitochondria to the effects of Bax
and Bak (indirect model); or to directly activate Bax and Bak (direct model) (Cheng et
al., 2001; Vela et al., 2013). However, evidence has been provided which unifies both
hypotheses suggesting that certain BH3-only proteins may act as suppressors of prosurvival proteins while others may act as direct activators of Bax and Bak (Kuwana et al.,
2005; Kim et al., 2006). Following the activation of BH3-only proteins, the mitochondrial
outer membrane becomes permeabilized, leading to the release of pro-apoptotic proteins
such as cytochrome c and the apoptosis inducing factor (AIF) (Green and Reed, 1998;
Martinour and Green, 2001). Two main hypotheses dominate the mechanism by which
mitochondrial outer membrane permeabilization (MOMP) occurs. First, is direct pore
3

formation by the pro-apoptotic proteins Bax and Bak, where previous studies have shown
the ability of Bax to form pores in membranes and induce MOMP in isolated
mitochondria (Antonsson et al., 2000; von Ahsen et al., 2000; Desagher and Martinou,
2000; Suzuki et al., 2000). Second, in the mitochondrial permeability transition pore
(mPTP) model, matrix swelling is caused by the loss of mitochondrial membrane
potential and inward flow of ions, such as Ca2+. The mPTP is thought to be responsible
for the loss of mitochondrial membrane potential and is hypothesized to consist of
voltage dependent anion channel (VDAC), adenine nucleotide translocase (ANT), and
cyclophilin D (Crompton et al., 1998; Crompton et al., 1999). Finally, these two
hypotheses are linked by studies showing that Bax and Bak interact with components of
the proposed mPTP, VDAC and ANT, thus suggesting there is cooperation between proapoptotic Bcl-2 family proteins and the mPTP in the permeabilization of the outer
mitochondrial membrane and release of mitochondrially sequestered pro-apoptotic
proteins (Marzo, 1998; Shimizu et al., 1999; Tsujimoto and Shimizu, 2002). In addition
to the two hypotheses regarding MOMP mechanisms, the release of cytochrome c from
cardiolipin (the lipid which tethers cytochrome c to the inner mitochondrial membrane)
can also occur through several mechanisms. First, is the direct oxidation of cardiolipin by
enhanced ROS production or the cardiolipin-cytochrome c complex (Ott et al., 2002;
Orrenius and Zhivotovsky, 2005). Second, increased mitochondrial Ca2+ can weaken the
electrostatic interaction between cardiolipin and cytochrome c and lastly, hydrolysis of
cardiolipin by phospholipase A2 can lead to the release of cytochrome c from
mitochondria (Sedlack and Robinson, 1999; Ott et al., 2007). Overall, cytochrome c
discharge results in electron transport deficits, further production of ROS, and even
4

greater release of cytochrome c into the cytosol (Orrenius et al., 2007). Once released,
cytochrome c associates with the apoptotic protease-activating factor (Apaf-1), which
induces the cleavage and activation of procaspase-9, forming the apoptosome complex,
and downstream activation of other caspases and caspase activated DNAses (CADs) (Zou
et al., 1999; Adrain and Martin, 2001; Jiang and Wang, 2000; Kim et al., 2005; Riedl and
Salvesen, 2007). The apoptotic pathway culminates in membrane blebbing, degradation
of intracellular proteins and DNA, presentation of extracellular apoptotic markers
(phosphatidylserine) and phagocytosis of the apoptotic cell, thus preventing damage to
other neighboring cells and creating a “silent” death lacking significant inflammation
(Fadok et al., 1992; Lauber et al., 2004).

5

Figure 1.1 Overview of Apoptotic Pathways The extrinsic and intrinsic pathways are
depicted, showing the binding of the death receptor (Fas) by the death ligand (FasL),
intracellular signaling through the DISC complex, activation of caspases (Pro-Cas to
Cas), inhibition of inhibitor of caspase activated DNAses (ICAD) and thus activation of
caspase activated DNAses (CADs), leading to the degradation of DNA. Cleavage of Bid
into t-Bid represents a convergence point between the extrinsic and intrinsic pathways
where BH3-only proteins are activated leading to inhibition of pro-survival proteins (Bcl2/Bcl-XL) and activation of Bax/Bak. MOMP is induced either directly by Bax/Bak or
through the formation of the mPTP (VDAC, ANT, CyD). Cytochrome c (Cyt C) is
released from the mitochondria; the apoptosome (Cyt C, Apaf-1, caspase-9) is formed,
leading to the activation of caspases, CADs, and the degradation of DNA. PM=plasma
membrane. I acknowledge Aimee Winter for drawing the double helix DNA shown in the
nucleus.

6

Figure 1.2 Bcl-2 family members Pro-survival Bcl-2 family members are depicted in
blue, with transmembrane domain (TM) and Bcl-2 like homology domains (BH) 1-4.
Pro-apoptotic family members with multiple domains are depicted in red (BH1-3 and
TM), while BH3-only domain members are depicted in orange.

7

1.1.3

Apoptosis in Neurodegeneration

The means by which particular subsets of neurons degenerate in
neurodegenerative diseases has been shown to rely upon apoptotic pathways. The
pathology of Parkinson’s disease (PD) is due to the degeneration of dopamine neurons
found in the substantia nigra located in the midbrain, where signs of apoptotic DNA
damage have been observed in PD patients (Mochizuki et al., 1996). Substantia nigra
samples from postmortem PD patients also display increased caspase-3, Bax, and
apoptotic nuclei compared to age-matched control subjects (Hartmann et al., 2000; Tatton
2000). Furthermore, in PD models both in vitro and in vivo, inhibition of apoptotic
proteins affords protection to degenerating dopamine neurons (Eberhardt et al., 2000).
Indices of apoptosis have also been shown in amyotrophic lateral sclerosis (ALS), a
disease in which the alpha motor neurons in the lumbar spinal cord degenerate. Motor
neurons from spinal cord sections of ALS patients show decreased Bcl-2 mRNA but
increased Bax mRNA levels compared to control subjects and non-neuronal tissue
sections (Mu et al., 1996). An additional study showed an increase in pro-apoptotic
protein levels (such as Bax) and a decrease in Bcl-2 protein levels at the mitochondria
resulting in an increase in cytosolic Bcl-2 expression levels. Increased caspase-3
activation and apoptotic DNA damage were also observed (Martin 1999). Overall, the
underlying mechanism of apoptosis induced during neuronal degeneration is
hypothesized to be a consequence of mitochondrial dysfunction and oxidative stress, for
which substantial evidence has been observed in these neurodegenerative diseases.
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1.2 Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
The high energy demands of the central nervous system (CNS) induce the
dependence of neurons and glial cells on mitochondrial energy production. Mitochondria
produce ATP from molecular oxygen using oxidative phosphorylation, a process that is
driven by the ETC. Unfortunately; electron leakage from the ETC causes the formation of
highly reactive species, such as superoxide. In order to combat the endogenous ROS
produced at mitochondria, several free radical scavenging systems exist, including
superoxide dismutase, thioredoxin, and glutathione (GSH). However, if ROS production
exceeds the availability of the endogenous free radical scavengers, then indices of
mitochondrial oxidative stress (MOS) accumulate, leading to the damage of
mitochondrial lipids, DNA and proteins (Lin and Beal, 2006). It has been demonstrated in
cardiac myocytes that ROS accumulation leads to mitochondrial membrane
depolarization, a consequence dependent on cellular GSH concentrations. Furthermore,
ROS stimulated mitochondrial membrane depolarization leads to ROS stimulated ROS
release, inducing damage to surrounding mitochondria, propagating MOS signals, and
enhancing cellular injury (Zorov et al., 2000; Zorov et al., 2006).
Mitochondrial dysfunction and subsequent oxidative stress are major
contributing factors to many neurodegenerative diseases, such as ALS and PD. In
particular, increased oxidative stress has been demonstrated through the depletion of
GSH levels in postmortem studies of the substantia nigra of PD patients (Perry and
Young, 1986). Furthermore, in an ALS mouse model, depleted levels of GSH within
lumbar spinal cord tissue were correlated to the onset and progression of the ALS disease
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phenotype (Chi et al., 2007). Other indices of oxidative stress, such as damage to DNA,
lipids and proteins are also prevalent in these neurodegenerative diseases. For example,
sporadic ALS and PD patients have increases in oxidized Coenzyme Q10 and 8-hydroxy2’-deoxyguanosine (8-OHdG; oxidative modification to DNA) in cerebral spinal fluid
(CSF) samples (Murata et al., 2008; Isobe et al., 2010). Mitochondrial dysfunction is
shown through decreased protein levels of complex II, III, and V in mitochondria from
postmortem sporadic PD brain (Arthur et al., 2009). It is also well established that PD
patients have decreased complex I activity, within postmortem samples of the substantia
nigra (Schapira et al, 1990). The G93A mutant SOD1 mouse model of ALS displays
aggregation of mitochondria and reduced activity of complexes I, II and IV in spinal cord
tissues (Jung et al., 2002; Sotelo-Silveira et al., 2009). Furthermore, ALS patients also
have mitochondrial aggregates in spinal cord anterior horn sections, and decreased
cytochrome c oxidase activity (Sasaki and Iwata, 1996; Borthwick et al., 1999). The
involvement of oxidative stress and mitochondrial dysfunction within neurodegeneration
has been reviewed extensively (Lin and Beal, 2006; Federico et al., 2012).

1.3 Glutathione synthesis, functions and metabolism
Glutathione (GSH) is the most prominent cellular thiol with numerous functions
and a distinct synthesis pathway. This tri-peptide consisting of glutamate, cysteine and
glycine is present at higher concentrations than all other known free radical scavenging
systems. As discussed above, depletion of GSH has been observed in several
neurodegenerative diseases, and therefore its significance in neuronal survival is of
interest. Here, its synthesis, functions, regulation and metabolism are reviewed.
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1.3.1 Glutathione synthesis
The synthesis of GSH is limited to the cytosol and occurs in two ATP- dependent
reactions (Griffith and Meister, 1985). The first step in GSH synthesis requires Lglutamate to react with ATP, leading to the formation of L-glutamylphosphate, a reaction
intermediate, which then combines with L-cysteine to form γ-L-glutamyl-L-cysteine,
ADP, and phosphate (Griffith, 1999; Forman et al., 2009; Figure 1.3). This first step in
GSH synthesis is catalyzed by glutamate cysteine ligase (GCL; also known as γ-glutamyl
cysteine ligase) and occurs through the γ-carboxyl group of glutamate leading to the
formation of a γ-peptidic linkage with the amino group of cysteine (Griffith, 1999; Wu et
al., 2004). This γ-carboxyl linkage renders GSH uncleavable by all cellular proteases,
except for γ-glutamyltranspeptidase (Wu et al., 2004; Lu, 2009). The second step in GSH
synthesis is catalyzed by glutathione synthetase (GS), and begins with γ-L-glutamyl-Lcysteine reacting with ATP, to form the reaction intermediate γ-L-glutamyl-Lcysteinylphosphate, which then combines with L-glycine to form γ-L-glutamyl-Lcysteinyl-L-glycine or GSH, ADP and phosphate (Griffith, 1999; Forman et al., 2009).
GCL is considered the rate limiting enzyme in GSH synthesis based on data showing that
its overexpression, but not that of glutathione synthetase (GS), leads to an increase in
cellular GSH content (Forman et al., 2009). The bioavailability of cysteine is also a rate
limiting determinant for GSH synthesis (Griffith, 1999; Lu, 2009).
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Figure 1.3 Glutathione Synthesis L-glutamate and L-cysteine are substrates for γglutamate cysteine ligase (GCL) in the formation of L-γ-glutamylcysteine. Next, Lglycine and L-γ-glutamylcysteine are substrates for glutathione synthetase (GS) in the
formation of γ-glutamyl-cysteine-glycine, or GSH. The hydrolysis of ATP into ADP and
phosphate is a requirement for each enzymatic step in GSH synthesis.
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1.3.2 Regulation of glutathione synthesis
The regulation of GSH synthesis is modulated by several factors including;
feedback inhibition, the availability of amino acid precursors, and post-translational
modifications. The GCL holoenzyme has two subunits, GCLC (catalytic) and GCLM
(modulatory). GCLC contains all of the enzymatic activity for the holoenzyme while
GCLM regulates the holoenzyme (Huang et al., 1993). The GCL holoenzyme forms an
intermolecular disulfide bond between the GCLC and GCLM subunits which increases
the affinity of GCLC for glutamate under oxidizing conditions (Soltaninassab et al.,
2000; Filomeni et al., 2002). However, when cellular GSH levels are increased, GSH
reduces the intermolecular disulfide bond, decreasing the affinity of GCLC for glutamate,
thus allowing for feedback inhibition of GCLC by GSH (Soltaninassab et al., 2000;
Filomeni et al., 2002).
Second, the availability of amino acid precursors, particularly cysteine, affects
the rate of GSH synthesis, and therefore, contributes to its regulation. Amino acid
availability and preference for use in GSH synthesis is dependent on cellular activities
and cell type. For example, the availability of specific precursors in the liver is dependent
on several factors such as diet, amino acid transport, and the transsulfuration pathway. In
liver, the major sources of cysteine are either provided from the metabolism of
methionine, in which transsulfuration converts homocysteine to cysteine or through
protein degradation (i.e. diet) (Griffith, 1999; Wu et al., 2004; Lu, 2009). Previous studies
do not provide support for the use of the transsulfuration pathway within the brain, based
on low levels of enzymatic activity and RNA expression of its constituents, and the
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inability of methionine to increase GSH levels (Dringen and Hamprecht, 1999; Ishii et al,
2004). Overall, most tissues receive the precursors L-cysteine or L-cystine (disulfide
form of cysteine) from GSH excreted into the plasma from the liver; and amino acid
transport systems are important for maintaining cellular GSH in tissues other than liver
(Griffith, 1999). In particular, the Na+ independent Xc- amino acid transporter normally
exchanges intracellular glutamate for extracellular cystine such that elevated extracellular
glutamate concentrations can reduce the availability of cystine by inhibiting its transport
through this system (Griffith, 1999; Lu, 2009). In the brain, high extracellular
concentrations of glutamate and glycine are not present because these molecules function
as neurotransmitters. Therefore, GSH precursors are effectively transported into neurons
after their release from astrocytes (Dringen and Hirrlinger, 2003). Astrocytes export
approximately 10% of their total intracellular GSH within one hour, and the GSH
exported is broken down by γ-glutamyltranspeptidase and aminopeptidase N in order to
provide precursors to neurons for de novo GSH synthesis (Dringen et al., 1997; Dringen
et al., 1999; Dringen et al., 2001). Furthermore, differences in the precursors used
between astrocytes and neurons have been documented. Astrocytes use cystine and
glutamate as precursors transported through the Xc- amino acid transporter, while neurons
use cysteine and glutamine for GSH precursors transported by excitatory amino acid
transporters (EAAT) XAG-, these differences have been hypothesized to prevent
competition for precursors between neighboring cells (Kranich et al., 1996; Dringen et
al., 1999; Shanker et al., 2001; Dringen and Hirrlinger, 2003).
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Finally, post-transcriptional and post-translational modifications of GCLC and
GCLM also contribute to the regulation of GSH synthesis; however these effects have not
been elucidated for GS (Lu, 2009). For both subunits of the holoenzyme, GCL, mRNA
stabilization has been reported under oxidative conditions (Liu et al., 1998). GCLC
phosphorylation and S-nitrosylation (at the active site thiol) has been shown to decrease
its activity (Sekhar and Freeman, 1999; Griffith, 1999). During apoptosis, caspase-3
dependent cleavage of GCLC results in decreased activity (Franklin et al., 2003). Overall,
the post-transcriptional and post-translational modifications of GCLC are the best
characterized.
GCLC contains binding sites for the transcription factors AP-1, AP-2, NF-κB,
SP-1 and ARE/EpRE (antioxidant response element/ electrophile response element);
GCLM transcriptional binding sites have been less studied, but include AP-1 and
ARE/EpRE (Moinova and Mulcahy, 1998; Griffith 1999). In addition, Nrf1 and Nrf2 can
increase the transcription of GCLC by modulating AP-1 and NF-κB (Yang et al., 2005).
NF-κB can regulate the transcription of GCLM through AP-1 (Yang et al., 2005). Finally,
numerous oxidative stress inducers have been shown to increase either the transcription
of GCLC or GCLM and in some cases both, however this appears to be tissue specific,
and differences have been found between in vitro and in vivo studies (reviewed in
Griffith, 1999 and Lu, 2009). GS transcription is regulated by NF-κB, AP-1, Nrf1 and
Nrf2 (Yang et al., 2002; Yang et al., 2005; Lu, 2009).
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1.3.3 Functions of glutathione
The functions of GSH are as diverse as its cellular compartmentalization; it has
been shown to be present in the mitochondria, endoplasmic reticulum (ER), peroxisomes,
nucleus and cytosol. Therefore, GSH functions as more than an antioxidant; it has been
implicated in the control of the cell cycle, cell signaling, a store of cysteine, protein
folding, the detoxification of xenobiotics in addition to other functions, all of which are
reviewed below (Lu, 2009).
Within the mitochondrial matrix, GSH serves as an antioxidant, a function which
is linked to other enzymatic systems of the mitochondria. GSH functions in conjunction
with superoxide dismutase (SOD) to scavenge superoxide, where SOD converts
superoxide into water and hydrogen peroxide (H2O2) while GSH works to detoxify the
H2O2 produced. The reaction between H2O2 and GSH can occur both enzymatically and
non-enzymatically. Glutathione peroxidase (GPx) is a selenoenzyme which facilitates the
reduction of H2O2 into water, using GSH as an electron donor, forming glutathione
disulfide (GSSG) (Meister and Anderson 1983; Dringen et al., 2000; Lu 2009). Next,
glutathione reductase (GR) recycles GSSG at the expense of NADPH, into two GSH
molecules (Meister and Anderson 1983; Dringen et al., 2000; Lu 2009; Figure 1.4). GSH
can also scavenge the hydroxyl radical, peroxynitrite, and nitric oxide (Sjöberg et al.,
1982; Koppal et al., 1999; Yadav and Mishra 2013). Other antioxidant functions of GSH
include the reduction of lipid hydroperoxides and prevention of the fenton reaction from
occurring between metals (copper and iron) and oxygen (Filomeni et al., 2002). The
mechanism by which GSH prevents the fenton reaction has been hypothesized to rely
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upon its role in the detoxification of copper and cellular trafficking of copper (Ferreira et
al., 1993; Maryon et al., 2013).
Beyond its capacity as an antioxidant, GSH serves to detoxify certain cellular
components and by-products. Glutathione-S-transferase (GST) facilitates the conjugation
of GSH with proteins such as xenobiotics (quinones) and HNE (lipid radicals) (Meister,
1988). The addition of GSH to these toxic compounds induces their export to the
extracellular matrix, where they are then metabolized by γ-glutamyltranspeptidase
leading to the formation mercapturic acids and thus detoxifying these components
(Boyland and Chasseaud, 1969; Dickinson and Forman, 2002; Lu, 2009). Posttranslational modifications and protein conjugation are relevant to the cell signaling
function of GSH. For example, GSH will conjugate with NO to form S-nitrosoglutathione
(GSNO), which can participate in S-nitrosylation, form glutathione adducts with cysteine
residues of proteins, or serve as a cellular NO reservoir and targeting (Ji et al., 1999;
Andre and Felley-Bosco, 2003). In particular, GSNO has been shown to act as a
neuroprotective agent during oxidative stress conditions (Rauhala et al., 1998). In
addition, GST assisted GSH conjugation to proteins can either lead to the activation or
loss of function of proteins due to structural changes (Filomeni et al., 2002).
In the ER, GSH is present in its oxidized form, GSSG, where it is necessary for
protein folding and the formation of disulfide bonds within nascent proteins (Hwang et
al., 1992; Mari et al., 2009). GSH is also important for the regulation of intracellular Ca2+
levels, in which the inhibition of GSH synthesis and thus depleting cellular GSH levels
caused an increase in intracellular Ca2+ levels and a decrease in PC12 cell viability
17

(Jurma et al., 1997). GSH has also been shown to protect the protein sulfhydryl groups on
Ca2+ transporters from oxidation (Rimpler et al., 1999).
Nuclear localized GSH has a role in DNA synthesis and cell cycle control.
Glutaredoxin is an enzyme which utilizes GSH as a reducing mechanism for
ribonucleotide reductase (the rate limiting enzyme in DNA synthesis) which converts
nucleotide diphosphates to deoxyribonucleotide disphosphates, an essential step in DNA
synthesis (Holmgren, 1981; Pallardό et al., 2009). When GSH is depleted, it has been
shown to inhibit DNA synthesis further implicating the requirement for GSH in this
process (Dethlefsen et al., 1988; Pallardό et al., 2009). Inhibition of GSH synthesis and
subsequent reductions in cellular GSH content induces a decrease in telomerase activity,
as well as, decreased expression of the cell cycle regulatory proteins Id2 and E2F4
(Borrás et al., 2004). In addition, inhibition of GSH synthesis leads to cell cycle arrest,
consistent with several studies that have shown GSH is required for cell cycle entry into
the S phase (Shaw and Chou 1986; Messina and Lawrence 1989; Poot et al., 1995; Lu,
2009).
GSH also has CNS specific functions as shown in recent studies which have
provided evidence that GSH may play a role in synaptic transmission, through an
interaction with the glutamatergic receptors, NMDA and AMPA (Varga et al., 1997). The
consequences of GSH binding to NMDA receptors in neurons is dependent on the
concentration of GSH. For example, low concentrations of GSH (μM) prevent the
binding of excitatory agonists, while high concentrations of GSH (mM) modulate redox
sites of the NMDA receptor, increasing its currents (Janáky et al., 1999). In addition,
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GSH appears to bind currently non-identified receptors, a phenomenon linked to sodium.
However, the importance of these findings is limited due to the variability of findings and
relatively few published studies (Janáky et al., 1999; Oja et al., 2000).
Finally, GSH affords protection from apoptotic stimuli. This function could be a
culmination of its numerous other actions discussed above. It has been proposed that one
of the earliest events in the induction of apoptosis is GSH depletion (Esteve et al., 1999;
Franco et al., 2007). GSH depletion in the nucleus has been shown to increase cell
susceptibility to DNA alkylating agents (Britten et al., 1991). Furthermore, GSH
depletion in the cytosol and more specifically in the mitochondria has been shown to play
a role in the apoptotic pathway, at the level of mitochondrial permeability transition
(Armstrong and Jones, 2002). Mitochondrial DNA oxidation has been shown to correlate
with a decrease in GSH and an increase in oxidized GSH levels, while total cellular GSH
depletion is an event which occurs prior to DNA fragmentation (Esteve et al., 1999).
These studies indicate that mitochondrial GSH plays an important role in cell survival,
which is discussed in the next section.
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Figure 1.4 Glutathione detoxification of H2O2 Superoxide (O2-) is dismutated into
hydrogen peroxide (H2O2) and water (H2O) via superoxide dismutase (SOD). H2O2 is
broken down into H2O at the expense of two GSH molecules using the enzyme GSH
peroxidase (GPx), forming oxidized GSH, or GSH disulfide (GSSG). GSH reductase
(GR) uses NADPH as an electron donor to form two GSH molecules from GSGG,
leading to the formation of NADP+. Glucose-6-phosphate dehydrogenase (G6PD) then
cycles NADP+ back into NADPH.
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1.4 The discrete mitochondrial glutathione pool is critical for cell survival
Although the mitochondrial GSH pool only constitutes 10-30% of total cellular
GSH (percentage is specific to cell type); the concentration of GSH in the mitochondria is
comparable to the cytosolic concentration of GSH which is ~1-10 mM (Smith et al.,
1996; Filomeni et al., 2002; Circu et al., 2008). Mitochondria contain several antioxidant
enzyme scavenging systems; however, GSH is present at a concentration that is 500-1000
times that of other antioxidant systems (Schafer and Buettner, 2001; Filomeni et al.,
2002). Furthermore, mitochondria from brain rely upon GSH detoxification of matrixgenerated H2O2, because catalase has only been found to be present on the outer
mitochondrial membrane (Vitorica et al., 1984; Mari et al., 2009). The specific depletion
of mitochondrial GSH in cerebellar granule neurons (CGNs), led to increased ROS
production, mPTP induction, and cell death. In the same system, depletion of the
cytosolic GSH pool did not recapitulate these effects (Wüllner et al., 1999). Furthermore,
specific depletion of mitochondrial GSH in astrocytes sensitized these glial cells to cell
death induced by either oxidative stress (H2O2) or nitrosative stress (SIN-1 or SNAP)
(Muyderman et al., 2007). The importance of mitochondrial GSH has not just been
demonstrated in the brain, but also in hepatocytes. For example, depletion of total cellular
GSH (both mitochondrial and cytosolic) led to an increase in cell death and lipid
peroxidation which was greater than when only the cytosolic pool of GSH was depleted
(Meredith and Reed, 1982; Meredith and Reed, 1983). Several models of cell death lead
to a specific decrease of mitochondrial GSH; and thus depletion and oxidation of this
reservoir has been hypothesized to be the mode of cell toxicity. These studies include
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toxicity induced by aromatic hydrocarbons in rat adrenal cells, hypoxia in hepatocytes,
cisplatin treated renal cells and cardiomyocyte apoptosis in streptozotocin induced
diabetes in rats and mice (Hallberg and Rydström 1989; Santos et al., 2003; Lluis et al.,
2005; Ghosh et al., 2005; and Santos et al., 2007). Studies on the exact contribution of the
mitochondrial GSH pool to cell survival have been relatively limited because the
understanding of how to discretely manipulate this pool of GSH was not previously
available. The recent identification of specific mitochondrial GSH transporters (discussed
below) will now allow for more specific depletion of mitochondrial GSH pools and thus a
better understanding of the involvement that this specific pool of GSH plays in cell
survival can be elucidated. Nonetheless, current evidence suggests that the mitochondrial
GSH pool is key to cell survival and resistance to apoptosis in numerous models.
1.5 Deciphering the mechanism by which glutathione is
compartmentalized into mitochondria
The transport of GSH into mitochondria first became of interest to researchers in
the late 1980s. At that time liver and kidney tissues were used primarily due to their high
mitochondrial content. The first study completed by Griffith in 1985 demonstrated that
mitochondria lack the enzymes required for the synthesis of GSH (Griffith and Meister,
1985). Moreover, the charge of GSH at physiological pH (-1 to -2), the relative negative
charge of the mitochondrial membrane space in relation to the cytoplasm, and the similar
mitochondrial and cytoplasmic GSH concentrations, do not allow for simple diffusion to
account for the observed mitochondrial GSH levels (Lash, 2006). These studies
suggested that either an active and/or facilitated process contributed to the movement of
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GSH into mitochondria, and two inner membrane anion carriers, dicarboxylate (DIC,
Slc25a10) and 2-oxoglutarate (OGC, Slc25a11) carriers, were subsequently identified as
mitochondrial GSH transporters in both liver and kidney. These carriers belong to a
mitochondrial super family, the solute carrier family that exhibit similar predicted 3D
structure, namely, this family is characterized by containing three transmembrane
domains and are believed to exist as homodimers (Lash, 2006). OGC is known to
transport 2-oxoglutarate in exchange for dicarboxylates, while DIC exchanges
dicarboxylates in exchange for phosphate. OGC functions to provide substrates for
several metabolic processes including the citric acid cycle, malate/aspartate shuttle, 2OG/isocitrate shuttle, nitrogen metabolism, and gluconeogensis from lactate (Lash,
2006). DIC supplies dicarboxylates to the citric acid cycle, while also transporting
thiosulfates into the cytoplasm for the enzymes rhodanese and thiosulfate reductase
(Lash, 2006). The early studies and identification of these carriers as mitochondrial GSH
transporters are reviewed below.
In the early studies regarding mitochondrial GSH transport, it was shown that
there were two components, high-affinity and low-affinity in rat liver mitochondria, and
both were inhibited by protonophores, glutamate, and the GSH analog, ophthalmic acid
(Mårtensson et al., 1990). Respiratory rates of mitochondria were also shown to affect
mitochondrial GSH transport in liver, while protonophores and antimycin A reduced
uptake of GSH (Kurosawa et al., 1990). Collectively, these early studies allowed for the
prediction that mitochondrial GSH transport may be determined by mitochondrial energy
dependency.
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Lash and colleagues were the first group to examine the potential contributions
of previously identified electro-neutral anion carriers to mitochondrial GSH transport.
Several molecules were found to inhibit GSH transport into isolated rat kidney
mitochondria, including glutamate, malate/butylmalonate, succinate/phenylsuccinate, and
phosphoenylpyruvate. In addition, GSH transport was also shown to be dependent on
phosphate and ATP production (Chen and Lash, 1998). These studies confirmed that both
the DIC and OGC were able to transport GSH into mitochondria (Chen and Lash, 1998).
The tricarboxylate carrier was ruled out, because its inhibitor, phosphoenylpyruvate
induced mitochondrial permeability transition, and thus decreased mitochondrial GSH
transport via a non-specific mechanism (Chen and Lash, 1998). Further investigation of
the effect glutamate exhibited on GSH transport into isolated mitochondria, ruled out the
involvement of the glutamate and glutamate/aspartate transporters in this process. It was
shown that GSH did not inhibit glutamate transport, that GSH transport was independent
of pH, and aspartame did not affect GSH transport. Therefore, it was concluded that the
glutamyl residue was important for GSH transport, thus elucidating the effect of
glutamate on GSH transport (Chen and Lash, 1998).
In a separate study, fractions enriched from rabbit kidney mitochondria were
reconstituted into proteoliposomes to study GSH transport mechanisms. One study
reported that, DIC and OGC were responsible for approximately 70-80% of
mitochondrial GSH transport in kidney (Chen et al., 2000). Finally, overexpression of
OGC or DIC in NRK-52E rat kidney cells, led to an increase in mitochondrial GSH
transport rates and increased resistance to apoptosis (Lash et al., 2002; Xu et al., 2006).
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Identification of DIC and OGC mediated GSH transport in kidney made a profound
impact on this field of research, and stimulated interest of mitochondrial GSH transport
mechanisms in other tissue types. Studies completed in isolated rat liver mitochondria
showed that GSH transport was only partially inhibited by phenylsuccinate and
butylmalonate, and was independent of ATP hydrolysis (Zhong et al., 2008).
Furthermore, overexpression of OGC in H4IIE rat hepatoma cells, led to a significant
increase in mitochondrial GSH uptake, and resistance to several apoptotic stimuli (Zhong
et al., 2008). Overall, mitochondrial GSH transport in liver may only be partially
dependent on OGC and DIC (approx. 45-50%), and therefore similar to kidney, other
carriers could play a role in this process (Lash, 2006).
Mitochondrial GSH transport mechanisms may vary among tissues and cell types
for several reasons. For example, although DIC has been found to have consistent
expression and amino acid sequence homology among various tissues and species, OGC
does not display the same consistency (Lash, 2006). Specifically, there are six amino acid
differences between kidney and brain OGC constructs, two of which are different in
charge or polarity, and three of which are in close proximity to transmembrane domains
(Lash, 2006). OGC mRNA levels are highest in heart, skeletal muscle, brain, liver and
kidney, but low in lung and pancreas. Consistent with this finding, expression of
mitochondrial carriers is dependent on the energy demand of the cell type (Lash, 2006).
Therefore, mitochondrial GSH transport mechanisms appear to be tissue and cell type
specific.
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More recent studies have emerged examining mitochondrial GSH transport in the
brain. Mitochondrial GSH transport in isolated mitochondria from whole rat brain was
shown to be inhibited by the substrates citrate, isocitrate, malate, and 2-oxoglutarate. In
the same system, the inhibitors of specific transporters, butylmalonate (DIC),
phenylsuccinate (OGC), and benzene 1,2,3-tricarboxylate (tricarboxylate carrier, TCC)
significantly prevented the uptake of GSH into isolated mitochondria (Wadey et al.,
2009). The authors of this particular study concluded that isolated rat brain mitochondria
were dependent on TCC for mitochondrial GSH transport, as butylmalonate (specific
DIC inhibitor) and phenylsuccinate (specific OGC inhibitor) had previously been shown
to have a weak inhibitory effect on TCC. However, the authors failed to explain the
effects of the substrates malate (DIC substrate) and 2-oxoglutarate (OGC substrate) on
mitochondrial GSH uptake within this study (Wadey et al., 2009). While cortical neurons
and astrocytes express both OGC and DIC, it appears that isolated mitochondria from the
cortex depend primarily on DIC for GSH transport (Kamga et al., 2010). Interestingly,
inhibition of DIC- mediated GSH transport in isolated mitochondria led to an increase in
ROS and H2O2 production, impaired complex I activity, and decreased mitochondrial
membrane potential (Kamga et al., 2010). Finally, PC12 cells (rat adrenal
pheochromocytoma cell line) were also found to be dependent on DIC, but not OGC, for
mitochondrial GSH transport (Kamga et al., 2010). Overall, studies examining
mitochondrial GSH transport mechanisms and mitochondrial GSH transport regulation in
brain are limited and warrant further investigation.
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1.6 Past studies linking Bcl-2 overexpression to cellular glutathione metabolism
1.6.1 The diverse functions of Bcl-2
Beyond its functions in inhibiting pro-apoptotic proteins, Bcl-2 is also involved
in the regulation of the cell cycle and Ca2+ homeostasis. These additional functions of
Bcl-2 in promoting cell survival were discovered as a consequence of numerous studies
examining Bcl-2-dependent protection from a variety of toxic insults (Table 1.1). Bcl-2
was found to protect from both free radical generators and toxic insults which lead to cell
death independent of free radicals or reactive intermediates (Table 1.1). However, the
protection Bcl-2 afforded from agents which act through Ca2+ mediated cell stress, was
found to rely upon the targeting of Bcl-2 to the endoplasmic reticulum (ER) and the
interaction between Bcl-2 and the inositol 1, 4, 5-trisphosphate (IP3) receptor. Previous
work indicated that the BH4 domain of Bcl-2 was responsible for interacting with and
inhibiting Ca2+ release from the endoplasmic reticulum (ER) via the IP3 receptor (Rong
et al., 2009). Overexpression of Bcl-2 was found to maintain ER Ca2+ uptake and inhibit
Ca2+ efflux, thus potentiating apoptosis induced by thapsgargin, an inhibitor of the ER
Ca2+ ATPase (He et al., 1997). Furthermore, Bcl-2 was also shown to regulate
mitochondrial Ca2+ uptake in a GT1-7 neuronal cell line, thus preventing mitochondrial
Ca2+ overload, mitochondrial permeability transition, and apoptosis (Murphy et al.,
1996). Bcl-2 also functions as a repressor of the cell cycle transition between G1 to S
phase, a phenomenon that is hypothesized to be dependent on the regulation of ROS by
Bcl-2 (Deng et al., 2003). The mechanism by which Bcl-2 suppresses cell cycle transition
was found to be dependent on increased expression of p27 and p130; both of which are
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repressors of the E2 family of transcription factors (E2F4; E2F1) which control the
expression of critical cell cycle proteins (Vairo et al., 2000). Interestingly, the functions
that Bcl-2 contributes to cell survival are similar to the previously identified functions of
GSH discussed above (i.e. cell-cycle, prevention of apoptosis, and Ca2+ signaling). Thus,
it is not surprising that Bcl-2 expression and GSH have been related in several ways, as
discussed below.
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Table 1.1 Bcl-2 protects from a variety of insults in diverse systems
Cell Type
PC12

Insult
Growth factor withdrawal, A23187,
Dopamine, Serum Withdrawal,
H2O2, Aβ25-35, FeSO4,HNE,
AMVN, Cycloheximide,
Actinomycin D, colchicine,EGTA,
Enediyne-5, cisplatin

Citation
Mah et al., 1993
Sato et al., 1994
Lindenboim et al. 1995
Cortazzo and Schor 1996
Ellerby et al., 1996
Offen et al., 1997
Kruman et al., 1997
Tyurina et al., 1997
Bruce-Keller et al., 1998
Jang and Surh et al., 2004
GT1-7
Potassium cyanide with glucose
Myers et al. 1995
deprivation, BSO, Diethyl maleate, Kane et al., 1993/1995
Ethacrynic acid, Serum Withdrawal Ellerby et al., 1996
Hippocampal Adriamycin,Glutamate,Glucose
Lawrence et al. 1996
neurons
deprivation
L929 cells
TNF
Hennet et al., 1993
Hematopoietic IL-3 withdrawal
Baffy et al., 1993
CSM14.1
Serum withdrawal, A23187,
Zhong et al., 1993
Glucose deprivation, menadione, tBOOH, BSO
Thymocytes
Dexamethasone, radiation, antiSentman et al., 1991
in vivo
CD3
Sympathetic
NGF withdrawal-delay in apoptosis Garcia et al., 1992
neurons
LY-ar
Gamma-radiation
Mirkovic et al., 1997
Transgenic
BSO-unweaned pups, adriamycin,
Martinou et al. 1994
mice
focal ischemia, 3-nitropropionic
Lawrence et al. 1996
acid, permanent ischemia induced
Merad-Saïdoune et al.,
by middle cerebral artery
1999
occlusion, natural occurring cell
Bogdanov et al., 1999
death
Astrocytes
Glucose deprivation, H2O2
Papadopoulos et al., 1998
FL15.12
IL-3 withdrawal, H2O2, menadione Nunez et al., 1990
Hockenbery et al., 1990
Hockenbery et al., 1993
FDC-P1, 32D IL-4, GM-CSF, IL-3 Withdrawal
Nunez et al., 1990
HL-60
CCCF, STS
Armstrong and Jones, 2002
Fibroblasts
H2O2, glucose withdrawal
Rimpler et al., 1999
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1.6.2 Bcl-2 expression influences glutathione
The first evidence presenting an influence of Bcl-2 on GSH metabolism
developed from early studies showing that its overexpression not only protected from
oxidative stress but also increased cellular GSH levels. These studies, originally
conducted to determine if the apoptotic pathway was conserved among various toxic
insults, found that enhanced Bcl-2 expression provided protection from oxidative stress
independent of inhibiting free radical generation (Hockenbery et al., 1993). A separate
study determined that Bcl-2 overexpression afforded protection from apoptosis induced
by GSH depleting agents such as, BSO, diethyl maleate, and ethacrynic acid, in a GT1-7
hypothalamic neural cell line (Kane et al., 1993). Finally, Bcl-2 overexpression in a
variety of cell types leads to an increase in cellular GSH concentration (reviewed in Table
1.2). One particular study aimed to evaluate the cell type specific involvement of Bcl-2
expression on GSH metabolism (Schor et al., 2000). However, upon close examination of
their data both cell types (PC12 and MCF-7) displayed increased basal cellular GSH
content, but no differences in antioxidant enzyme activities were observed (Schor et al.,
2000). After review of the literature regarding Bcl-2 overexpression and cellular GSH
status, it was found that only one cell type out of nine, HL-60 (Human promyelocytic
leukemia cells), did not show increased cellular GSH levels in the presence of increased
Bcl-2 (Table 1.2., Armstrong and Jones, 2002). In addition, two separate studies
examining HeLa cells showed a variation in the effects of Bcl-2 on cellular GSH levels;
Voehringer et al. only showed increased GSH in the nuclear compartment where as
30

Meredith et al., showed a total cellular GSH increase (Meredith et al., 1998; Voehringer
et al., 1998). These differences may be due to the different techniques used to
overexpress Bcl-2, such as retroviral gene transfer (in HL-60 cells) and two distinct
vectors used for stable transfection in the separate HeLa cell studies. Furthermore, the
strength of the promoter used to drive expression could cause variation in results in the
same cell line (Table 1.2). The most evident variable effect induced by the
overexpression of Bcl-2 in different cell types, is its effect on antioxidant enzymes, as
shown in Table 1.2. In vivo studies observed that knockout of Bcl-2 in mice led to a
decrease in the activities of several antioxidant enzyme systems, suggesting that Bcl-2
may have multiple effects regarding cellular antioxidant status (Hochman et al., 1998).
Overall, most studies which have examined the effects of Bcl-2 overexpression have
correlated it with an increase in cellular GSH content (Table 1.2). A few possible
mechanisms have been suggested in regards to how enhanced Bcl-2 expression leads to
increased cellular GSH content. First, Bcl-2 overexpression in PC12 cells led to
constitutive activation and enhanced transcriptional activity of NF-κB which led to
downstream increases in GCLC levels (Jang and Surh, 2004). Therefore, Bcl-2
overexpression in this system appeared to induce an increase in de novo GSH synthesis.
Second, enhanced Bcl-2 expression in HeLa cells did not alter the levels of GSH
synthesizing enzymes, but inhibited methionine dependent GSH extrusion from cells at
the plasma membrane, which correlated with an increase in cellular GSH, levels
(Meredith et al., 1998). Finally, Bcl-2 overexpression in PC12 and GT1-7 cells led to an

31

increase in NADPH and decrease in NAD+ levels, as well as a decrease in the ratio of
ATP/ADP (Ellerby et al., 1996). If Bcl-2 overexpression induced an increase in NADPH
production, this could lead to an increase in cellular GSH by the reduction of GSSG (see
Figure 1.4). However, after examining flux through the pentose-phosphate pathway, it
was concluded that Bcl-2 overexpression did not exert an effect on the production of
NADPH (Ellerby et al., 1996).
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Table 1.2 Effects of Bcl-2 overexpression on glutathione levels and antioxidant enzymes
in various systems
Cell Type

Effect on antioxidant
enzymes

PC12

Increase in Cu/Zn
SOD1
and GPx
No change in GR,
GSH
synthesis
ND
ND

Increase

Mechanism of
Bcl-2
expression
Retroviral

Increase

Plasmid/Stable

Schor et al.,
2000

Increase

Retroviral

Increase in SOD and
CAT
Increase in SOD and
GR
ND

Increase

Retroviral

Kane et al.,
1993
Ellerby et al.,
1996

ND

Increase

Tet-repressible
promoter/Stable
Plasmid/Stable

LY-ar

ND

Increase

Endogenous

HL60

ND

Decreased

Retroviral

Astrocytes Increase in SOD and
GSH Px

Increase

Retroviral

NT-2/D1
Increase in Cu/Zn
SK-N-MC SOD
Increase in Cu/Zn
SOD,
CAT, GPx
HeLa
ND

Increase
Increase

Plasmid, stable

Lee et al., 2001

Increase

Fibroblast

Increase

Stable
transfection
Retroviral

Meredith et al.,
1998
Rimpler et al.,
1999

PC12
MCF-7
GT1-7
PC12
GT1-7
HeLa

ND

Effect on
GSH

Citation

Bruce-Keller
et al., 1998

Increase

Increase
Increase
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Voehringer et
al., 1998
Meredith et al.,
1998
Mirkovic et al.,
1997
Armstrong and
Jones, 2002
Papadopoulos
et al., 1998

The next major finding correlating an effect of Bcl-2 expression on GSH showed
that cellular trafficking of Bcl-2 influences the cellular localization of GSH. Voehringer
and colleagues observed that overexpression of Bcl-2 in HeLa cells caused a significant
increase in nuclear Bcl-2 levels and a subsequent relocalization of GSH to the nucleus. In
addition, the increased nuclear localization of Bcl-2 led to enhanced nuclear GSH
transport (Voehringer et al., 1998). Therefore, the trafficking of Bcl-2 appears to
influence the cellular compartmentalization of GSH. The major effects of Bcl-2 on
cellular GSH are reviewed in Figure 1.5.
Further evidence linking Bcl-2 expression with GSH metabolism derived from
cancer studies. It was found that cancer cells which overexpressed Bcl-2 (LY-ar; mouse
lymphoma cells and HeLa cells) were highly resistant to gamma radiation-induced
apoptosis. However, upon culturing these cells in cysteine/methionine free media or
treatment with diethyl maleate which reduces GSH levels, resensitization of these cells to
gamma-radiation induced apoptosis occurred (Mirkovic et al., 1997; Voehringer et al.,
1998). In contrast, Bcl-2 overexpression in PC12 cells caused the chemotherapeutic drug,
neocarzinostatin (NCS) to significantly increase apoptosis. NCS requires reduction by
thiols in order to be activated and the increased GSH due to Bcl-2 overexpression could
therefore account for the increased toxicity of NCS in these cells. Indeed, BSO pretreatment prevented Bcl-2 from rendering the PC12 cells more susceptible to NCS and
Bcl-2 conferred protection from both enedicine-5 and cisplatin, which are insensitive to
cellular redox status (Cortazzo and Schor, 1996). Upon depletion of GSH in HL-60 cells
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overexpressing Bcl-2, both the mitochondrial membrane potential and the ratio of
GSH/GSSG were significantly decreased while ROS species production and apoptosis
were increased compared to control cells (Armstrong and Jones, 2002).
More recently, it has been shown that the use of BH3 mimetics, which inhibit the
pro-survival functions of Bcl-2, affect mitochondrial function and GSH. For example, in
HeLa cells overexpressing Bcl-2, ABT-737 BH3-mimetic treatment leads to an increase
in caspase-dependent apoptosis and ROS production, with a decrease in cellular GSH
content (Howard et al., 2009). Furthermore, our lab has shown that inhibition of Bcl-2
using two distinct BH3 mimetics leads to mitochondrial oxidative stress, disruption of
mitochondrial membrane potential, and displacement of GSH from mitochondria. Finally,
Bcl-2 was shown to be a GSH binding protein, providing a unifying hypothesis for the
antioxidant function of Bcl-2 and its effect on GSH metabolism in various systems
(Zimmermann et al., 2007).
Based on the lack of studies examining the regulation of mitochondrial GSH
transport and its involvement in neuronal survival, the major aims of this thesis are to
provide novel data in these areas. Here it is shown that Bcl-2 is a novel interacting
partner for OGC and this interaction is dependent on GSH. Furthermore, discrete
inhibition of a mitochondrial GSH transporter (DIC) in primary neurons induces
significant sensitization to both oxidative and nitrosative stress conditions. Conversely,
stable overexpression of OGC induces specific increases in mitochondrial GSH and,
strikingly, increased resistance to oxidative and nitrosative stress. Finally, increased
mitochondrial GSH leads to an upregulation of Bcl-2 in stable OGC overexpressing cell
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lines while knockdown of Bcl-2 decreases mitochondrial GSH levels and resensitizes
these cells to oxidative stress. Therefore, Bcl-2 and OGC work in a synergistic manner in
the transport of mitochondrial GSH in order to promote neuronal survival.
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Figure 1.5 Overview of the effects of Bcl-2 on cellular GSH At the plasma membrane
(PM) Bcl-2 inhibits methionine-dependent GSH efflux. Inhibition of Bcl-2 with HA14-1
leads to mitochondrial GSH extrusion, while also inhibiting the binding of Bcl-2 to GSH.
Bcl-2 redistribution to the nucleus increases nuclear GSH content. Bcl-2 constitutively
activates NF-κB causing an increase in GCLC levels and thus de novo GSH synthesis.
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CHAPTER TWO: BCL-2 IS A NOVEL INTERACTING PARTNER FOR THE 2OXOGLUTARATE CARRIER AND A KEY REGULATOR OF
MITOCHONDRIAL GLUTATHIONE
2.1 Abstract
Despite making up only a minor fraction of the total cellular glutathione, recent
studies indicate that the mitochondrial glutathione pool is essential for cell survival.
Selective depletion of mitochondrial glutathione is sufficient to sensitize cells to
mitochondrial oxidative stress (MOS) and intrinsic apoptosis. Glutathione is synthesized
exclusively in the cytoplasm and must be actively transported into mitochondria.
Therefore, regulation of mitochondrial glutathione transport is a key factor in maintaining
the antioxidant status of mitochondria. Bcl-2 resides in the outer mitochondrial
membrane where it acts as a central regulator of the intrinsic apoptotic cascade. In
addition, Bcl-2 displays an antioxidant-like function that has been linked experimentally
to the regulation of cellular glutathione content. We have previously demonstrated a
novel interaction between recombinant Bcl-2 and reduced glutathione (GSH), which was
antagonized by either Bcl-2 homology-3 domain (BH3) mimetics or a BH3-only protein,
recombinant Bim. These previous findings prompted us to investigate if this novel Bcl2/GSH interaction might play a role in regulating mitochondrial glutathione transport.
Incubation of primary cultures of cerebellar granule neurons (CGNs) with the BH3
mimetic HA14-1 induced MOS and caused specific depletion of the mitochondrial
glutathione pool. Bcl-2 was co-immunoprecipitated with GSH after chemical cross38

linking in CGNs and this Bcl-2/GSH interaction was antagonized by preincubation with
HA14-1. Moreover, both HA14-1 and recombinant Bim inhibited GSH transport into
isolated rat brain mitochondria. To further investigate a possible link between Bcl-2
function and mitochondrial glutathione transport, we next examined if Bcl-2 associated
with the 2-oxoglutarate carrier (OGC), an inner mitochondrial membrane protein known
to transport glutathione in liver and kidney. After co-transfection of CHO cells, Bcl-2
was co-immunoprecipitated with OGC and this novel interaction was significantly
enhanced by glutathione monoethyl ester. Similarly, recombinant Bcl-2 interacted with
recombinant OGC in the presence of GSH. Bcl-2 and OGC co-transfection in CHO cells
significantly increased the mitochondrial glutathione pool. Finally, the ability of Bcl-2 to
protect CHO cells from apoptosis induced by hydrogen peroxide was significantly
attenuated by the OGC inhibitor phenylsuccinate. These data suggest that GSH binding
by Bcl-2 enhances its affinity for the OGC. Bcl-2 and OGC appear to act in a coordinated
manner to increase the mitochondrial glutathione pool and enhance resistance of cells to
oxidative stress. We conclude that regulation of mitochondrial glutathione transport is a
principal mechanism by which Bcl-2 suppresses MOS.
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2.2 Introduction
Mitochondrial oxidative stress (MOS) plays a key role in the pathology
underlying several neurodegenerative diseases, including amyotrophic lateral sclerosis
(ALS), Parkinson’s disease, and Alzheimers disease (Lin and Beal, 2006). Accordingly,
elucidating the pathways that regulate the mitochondrial oxidant/antioxidant balance is
essential to develop novel therapeutics for neurodegeneration. Glutathione is an
endogenous tripeptide antioxidant and a key player in averting MOS and evading
apoptosis (reviewed in Franco and Cidlowski, 2009). It has been previously shown that
selective depletion of mitochondrial glutathione sensitizes cells to oxidative or nitrosative
stress (Muyderman et al., 2004; Muyderman et al., 2007). Moreover, glutathione
depletion can induce apoptosis directly through opening of the mitochondrial
permeability transition pore (Armstrong and Jones, 2002). In addition, γ-glutamylcysteine
synthetase knockout mice, in which glutathione synthesis is inhibited and glutathione is
depleted, display significant
apoptotic cell death in multiple tissues (Dalton et al., 2004). These findings demonstrate
that maintenance of cellular glutathione and, in particular, the mitochondrial glutathione
pool is crucial for cell survival (Sims et al., 2004; Mari et al., 2009). Glutathione
synthesis occurs exclusively in the cytosol because the enzymes required for its synthesis
are absent within mitochondria (Griffith and Meister, 1985). Furthermore, glutathione has
an overall negative charge at physiological pH and mitochondria exhibit a large negative
membrane potential; consequently, glutathione transport into mitochondria cannot be
explained by simple diffusion (Griffith and Meister, 1985; Lash 2006). Previously, two
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inner mitochondrial membrane (IMM) anion carriers were identified in kidney and liver
as glutathione transporters, the 2-oxoglutarate carrier (OGC; Slc25a11) and the
dicarboxylate carrier (DIC; Slc25a10) (Chen and Lash, 1998; Chen et al., 2000; Coll et
al., 2003; Zhong et al., 2008). Overexpression of either OGC or DIC in a rat renal
proximal tubular cell line (NRK-52E cells) significantly enhanced mitochondrial
glutathione transport and protected these cells from chemically induced apoptosis, such
as that induced by tert-butylhydroperoxide (Lash et al., 2002; Xu et al., 2006). In the
context of the CNS, few studies have examined the mechanisms responsible for
mitochondrial glutathione transport. In one study, glutathione transport into isolated rat
brain mitochondria seemed to be influenced most by inhibitors of the tricarboxylate
carrier rather than OGC or DIC (Wadey et al., 2009). However, another study showed
that an inhibitor of DIC, butylmalonate, significantly decreased the glutathione content of
isolated mouse brain mitochondria, suggesting that DIC may be the major glutathione
transporter in mouse cerebral cortical mitochondria (Kamga et al., 2010). The authors of
this study also showed that both OGC and DIC are expressed in cortical neurons and
astrocytes. These studies suggest that multiple IMM anion transporters might be involved
in mitochondrial glutathione transport in the CNS. Yet, essentially nothing is known
about how the function of these IMM glutathione transporters is regulated. Previous
studies have shown that the antiapoptotic protein Bcl-2 displays an antioxidant-like effect
in response to either exogenous oxidative stress or glutathione depletion (Hockenbery et
al., 1993; Kane et al., 1993). Overexpression of Bcl-2 leads to an increase in the cellular
content of glutathione (Ellerby et al., 1996; Voehringer and Meyn, 2000). In contrast,
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Bcl-2 knockout mice show reduced glutathione levels and glutathione peroxidase activity
in brain tissue and demonstrate enhanced susceptibility to MOS-induced neuronal cell
death (Hochman et al., 1998). Thus, the antioxidant-like function of Bcl-2 depends, in
large part, on its potential to regulate the cellular glutathione status. In this context, we
have previously shown that recombinant Bcl-2 is capable of directly binding to GSH in
vitro, an interaction that is antagonized by the Bcl-2 homology-3 domain (BH3) mimetics
HA14-1 and compound 6, as well as the BH3-only protein, Bim (Zimmermann et al.,
2007). Interestingly, several BH3-only proteins are known to induce a pro-oxidant state at
mitochondria, suggesting that disruption of this Bcl-2/GSH interaction might be an
underlying factor in this effect (Ding et al., 2004; Liu et al., 2005). Collectively, these
findings prompted us to hypothesize that Bcl-2 might be a key regulator of the
mitochondrial glutathione pool. Here, we show that Bcl-2 interacts with GSH in intact
primary cerebellar granule neurons (CGNs). As we have shown previously using
recombinant proteins, this Bcl-2/GSH interaction is disrupted by the BH3 mimetic HA141. Consistent with a central role for Bcl-2 in maintenance of the mitochondrial
glutathione pool, both HA14-1 and Bim inhibited mitochondrial GSH transport. Most
significantly, in cotransfected CHO cells, Bcl-2 coimmunoprecipitates with OGC and this
novel interaction is markedly enhanced by glutathione monoethylester (GSH-MEE).
Moreover, Bcl-2 and OGC coexpression significantly increases the mitochondrial
glutathione pool. Finally, we show that the ability of Bcl-2 to protect cells from apoptosis
induced by hydrogen peroxide depends on OGC activity. We conclude that Bcl-2 is a
novel interacting partner for OGC and a central regulator of the mitochondrial glutathione
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pool. This newly discovered property of Bcl-2 suggests a molecular mechanism by which
Bcl-2 protects cells from oxidative injury.
2.3 Materials and Methods
2.3.1 Materials
Ethacrynic Acid, Triton X-100, DTT, anti-tubulin antibody, DAPI, and
phenylsuccinic acid were received from Sigma Aldrich (St. Louis, MO). HA14-1 was
purchased from Alexis Biochemicals (Enzo Life Sciences, Plymouth Meeting, PA).
Glutathione assay kit was obtained from Oxford Biomedical (Rochester Hills, MI).
Mitochondrial Cytosolic fractionation kit was purchased from Biovision (Mountain
View, CA). MDA assay kit was obtained from OxisResearch (Percipio Bioscience, Foster
City, CA). Anti-Cox-IV was purchased from Cell Signalling (Beverly, MA). Glutathione
monoethylester and rotenone were received from Calbiochem (San Diego, CA). Anti-V5
antibody was purchased from Abcam (Cambridge, MA). Recombinant BimL was
obtained from R&D systems (Minneapolis, MN). The anti-GSH antibody and protein
A/G beads were received from Santa Cruz Biotechnology (Santa Cruz, CA).
Disuccinimyidyl suberate (DSS) was purchased from Pierce Chemical (Rockford, IL).
Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA). Anti-Bcl-2 antibody
was from BD Pharmigen (Franklin Lakes, NJ). Mouse TrueBlot® ULTRA Anti-Mouse
Ig HRP secondary antibody was obtained from eBioscience (San Diego, CA). GST
tagged Slc25a11 (GST-OGC) recombinant protein and Slc25a11 (OGC) antibody were
purchased from Novus Biologicals (Littleton, CO). Recombinant Bcl-2 protein was
obtained from Calbiochem (Darmstadt, Germany). Optimem media was purchased from
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Gibco (Carlsbad, CA). Maxiprep Kit was obtained from Qiagen (Valencia, CA). Antiactive caspase-3 was purchased from Promega (Madison, WI). Fitc secondary antibody
for immunohistochemistry was from Jackson ImmunoResearch Inc (West Grove, PA).
ECL, Percoll, and secondary antibodies for immunoblotting were purchased from GE
Life Sciences (Piscataway, NJ). V5-OGC plasmid was a generous gift from Dr. Lash,
Wayne State University (Detriot, MI). The Bcl-2 plasmid was a generous gift from Dr.
Hardwick, Johns Hopkins University (Baltimore, MD).
2.3.2 Cerebellar Granule Neuron (CGN) Culture
CGNs were isolated from P7 Sprague Dawley rat pups and cultured as previously
described (Zimmerman et al., 2007). All animal manipulations were performed in
accordance with and under approval of the University of Denver Institutional Animal
Care and Use Committee.
2.3.3 Immunohistochemistry
CGNs or CHOs were transfected and/or treated as described under the Figure
Legends section and fixed with 4% paraformaldehyde. Next, cells were blocked and
permeabilized in PBS, pH 7.4 with 5% BSA and 0.2% Triton X-100 for 1 h, followed by
incubation with the primary antibody overnight at 4°C diluted in 0.2% Triton X-100 and
2% BSA in PBS. After which, the primary antibody was removed and cells were washed
5X with PBS over 30 min. Next, the cells were incubated with secondary antibody and
DAPI for 1 h at room temperature, diluted in 0.2% Triton X-100 and 2% BSA in PBS.
Cells were washed 5X with PBS over 30 min, and placed in anti-quench. Images were
captured using a Zeiss Axioplan 2 fluorescence microscope equipped with a Cooke
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Sensicam CCD camera and Slidebook Image analysis software (Intelligent Imaging
Innovations, Inc Denver, CO).
2.3.4 CHO cell culture
K1-CHO (Chinese Hamster Ovary) cells were plated on 35-mm diameter plastic
dishes in Ham’s F12 media containing 10% fetal bovine serum, 2 mM L-glutamine and
(100 U/mL/100 μg/mL) penicillin/streptomycin. Cells were cultured overnight at 37°C in
10% CO2. The following day cells were prepared for transfection or treatment, at which
point cultures were 60–80% confluent.
2.3.5 Plasmid Preparation
DsRed2, Bcl-2, and V5-OGC plasmids were transformed using 50 ng of plasmid
in JM109 Escherichia coli (E. Coli) cells, and grown on LB agar plates containing 35
μg/mL kanamycin sulfate or 100 μg/mL ampilicillin sodium salt at 37°C overnight.
Starter cultures were grown in LB broth with 35 μg/mL kanamycin sulfate or 100 μg/mL
ampilicillin sodium salt for 8 h at 37°C, and diluted 1:250 into overnight cultures, for
plasmid purification using the Qiagen Maxi Prep Kit (Valencia, CA). DNA
concentrations were determined using a ThermoScientific NanoDrop 2000.
2.3.6 Transfection
DsRed2 (Con), Bcl-2, or V5-OGC were used at a concentration of 5 μg/mL.
Plasmids were transfected using a standard Lipofectamine 2000 protocol. CHO cells
cultures were incubated with the plasmid/Lipofectamine 2000 mixture in Opti-MEM, for
6 h at 37°C and 10% CO2. Transfection media was removed and cell cultures were placed
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in 1 mL of Ham’s F12 media and incubated overnight at 37°C and 10% CO2. Indicated
treatments were administered 24 h post-transfection.
2.3.7 Mitochondrial/Cytosolic Fractionation
Cells were treated as indicated in the “Results” or “Figure Legend” sections after
which the media was aspirated and cells were washed 1X in ice cold PBS, pH 7.4. 200
μL of cytosolic buffer (provided in the kit, diluted 1:5 in ddH2O, with added protease
inhibitor cocktail and 1mM DTT as per the manufacturer’s recommendations) was added
to the cells and allowed to incubate on ice for 20 min. Cells were scraped and harvested,
then homogenized with 40 passes of a dounce homogenizer. Samples were spun down at
720 rcf for 10 min at 4°C. The supernatant from each sample was transferred to a new
tube labeled mitochondrial fraction and spun at 10,000 rcf for 30 min at 4°C. The
supernatant was then transferred to a new tube labeled cytosolic fraction and the pellet in
the mitochondrial fraction tube was resuspended in 150 μL mitochondrial buffer
(provided in the kit, with added protease inhibitor cocktail and 1mM DTT as per the
manufacturer’s recommendations). Samples were measured for glutathione content as
described below.
2.3.8 Glutathione Assay
Total Glutathione (GSH+GSSG) was measured using an assay kit (DTNB) from
Oxford Biomedical, following the manufacturer’s protocol. All glutathione measurements
were normalized to protein concentration.
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2.3.9 MDA Assay
MDA was measured using an MDA assay kit from OxisResearch, following the
manufacturer’s protocol. All MDA measurements were normalized to protein
concentration.
2.3.10 Immunoblot analysis
Immunoblot analysis was completed as previously described in (Zimmermann et
al., 2007).
2.3.11 GSH Transport Assay
GSH transport into isolated mitochondria was measured as previously published
(Zimmermann et al., 2007). 20 μL of rat brain mitochondria were added to 230 μL of
GSH transport buffer (5 mM HEPES, pH 7.2, 220 mM mannitol, 70 mM sucrose, 0.1
mM EDTA, 0.1% BSA (fatty acid-free), 5 mM succinate, and 1 mM potassium
phosphate) at room temperature. The isolated mitochondria were then preincubated for 20
min with either 0.5 μL Me2SO (vehicle, Con), 20 μM HA14-1 (HA14), or 2 μM
recombinant Bim (Bim). A trace amount (0.5 μCi) of radiolabeled [3H]GSH in buffer
containing unlabeled (cold) GSH at a final concentration of 50 μM was then added to the
isolated mitochondria, vortexed and incubated for 15 sec at room temperature. 1 mL
volume of ice-cold transport buffer was then added to each tube, and the samples were
pelleted and washed 2X with 500 μL ice-cold buffer, and then 100 μL of 1N NaOH was
added to dissolve the final pellets. [3H]GSH uptake into the isolated mitochondria was
counted by liquid scintillation. The data were calculated as percentages of [3H]GSH
uptake relative to Con.
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2.3.12 Isolation and treatment of rat brain mitochondria
Mitochondria were isolated as previously described in (Zimmermann et al., 2007).
Mitochondria were treated as follows; for 4 h GSH-MEE Co-incubation, mitochondria
were incubated with 2 mM GSH-MEE in combination with either vehicle (Con), 20 μM
HA14-1, or 10 μM rotenone for 4 h 37°C, 300 rpm. For the 2 h GSH-MEE pre-load/2 h
wash out, mitochondria were pre-incubated with 2 mM GSH-MEE for 2 h, 37°C, 300
rpm, washed 2X with mitochondrial isolation buffer, and then incubated with either
vehicle (Con), 20 μM HA14-1, or 10 μM rotenone for 2 h, 37°C, 300 rpm. All described
treatments were completed in mitochondrial isolation buffer; 0.64 M sucrose, 2mM
EDTA, and 20mM Tris-HCl, pH 7.4. The isolated mitochondria were then washed 3X in
mitochondrial isolation buffer and assayed for glutathione content (described above).
2.3.13 Immunoprecipitation
CHO cells transfected with Bcl-2 and V5-OGC (5 μg each) were treated with
either vehicle or 2 mM GSH-MEE for 4 h, 37°C, 10% CO2 and lysed with 0.1% Triton
X-100/Wahl buffer as described previously (Zimmermann et al., 2007), containing either
1 mM DTT or 2 mM GSH-MEE. Lysates were then immunoprecipitated using a
monoclonal V5 antibody in 0.1% Triton X-100/Wahl buffer containing either 1 mM DTT
or 2 mM GSH-MEE overnight, 4°C, mixing by inversion. Next, 50 μL or protein A/G
agarose beads were incubated with the samples for 4 h, 4°C, mixing by inversion.
Immune complexes were washed 3X and resolved by SDS-PAGE as previously
described (Zimmermann et al., 2007). Whole cell lysates contained 200 μg of protein.
Immunoblot analysis was completed for Bcl-2 (using Mouse TrueBlot® ULTRA Anti48

Mouse Ig HRP secondary antibody to eliminate the light chain) and V5. Primary CGNs
were pre-incubated with 20 μM HA14-1 or vehicle (0.4%DMSO) for 2 h, 37°C, 10%
CO2 and samples were cross-linked with 500 μM DSS for 30 min, 37°C, 10% CO2.
CGNs were lysed in 1% Triton X-100/Wahl buffer with 50 mM glycine (to quench the
cross-link), after which lysates were immunoprecipitated using a monoclonal GSH
antibody and Protein A/G agarose beads as described above, and subjected to SDS-PAGE
as described previously (Zimmermann et al., 2007). Recombinant immunoprecipitation
experiments were performed using 50 ng of both recombinant Bcl-2 and recombinant
GST-OGC, incubated in 0.1% Triton/Wahl buffer with 10 μM GSH overnight in the
presence of either a monoclonal Bcl-2 antibody or a monoclonal Slc25a11 (OGC)
antibody. Samples were immunoprecipitated as described above and subjected to SDSPAGE as described previously (Zimmermann et al., 2007). Total samples contained 50
ng of both Bcl-2 and GST-OGC recombinant proteins.
2.4 Results
2.4.1 The BH3 mimetic, HA14-1, induces MOS and apoptosis of CGNs
Consistent with our previous observations (Zimmermann et al., 2005;
Zimmermann et al., 2007), incubation of CGNs with the BH3 mimetic, HA14-1, induced
an increase in active caspase-3, degradation of the microtubule network, and nuclear
fragmentation indicative of apoptosis (Figure 2.1.A). Exposure of CGNs to HA14-1
significantly increased the concentration of malondialdehyde (MDA) in mitochondrial
fractions, demonstrating an induction of MOS (Figure 2.1.B).
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Figure 2.1 The BH3 mimetic, HA14-1, induces mitochondrial oxidative stress and
apoptosis of CGNs A. CGNs were treated for 24 h with either HA14-1 (HA14; 15 μM) or
vehicle, control (Con, 0.3% DMSO). Top panels: Fitc, tubulin; DAPI, nuclei; Cy3, active
caspase-3. Arrows indicate apoptotic cells with either condensed/fragmented nuclei, or
immunoreactivity for active caspse-3. Bottom panels: decolorized DAPI images to show
nuclear morphology. B. CGNs were treated with either vehicle (Con) or HA14-1 (HA14;
20 μM) for 4 h and then fractionated into cytosolic and mitochondrial fractions.
Mitochondrial fractions were then measured for MDA concentration, or lipid
peroxidation levels. Data are shown as μ moles of MDA present per μg of protein and
analyzed using a Student’s T-test, ***p<0.001, n=4.
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2.4.2 HA14-1 selectively depletes the mitochondrial glutathione pool in CGNs
We have previously shown that CGN apoptosis induced by HA14-1 is prevented
by glutathione (Zimmermann et al., 2005; Zimmermann et al., 2007). Therefore, we
measured mitochondrial and cytosolic pools of total glutathione in CGNs incubated in the
absence and presence of HA14-1. CGNs treated with HA14-1 for 4 h displayed selective
depletion of total mitochondrial glutathione to approximately 50% of the control level
(Figure 2.2.A). In contrast, CGNs incubated with ethacrynic acid, a compound that forms
nonfunctional adducts with GSH, showed significant depletion of both the mitochondrial
and cytosolic pools of glutathione (Figure 2.2.A). Cox-IV blots were performed to
demonstrate pure fractionation of mitochondria and cytoplasm (Figure 2.2.B). The
fraction of total cellular glutathione made up by mitochondrial (~10%) versus cytosolic
(~90%) pools were consistent with previous studies (Figure 2.2.C). In addition, control
levels of total mitochondrial glutathione were an average of 6.78 +/− 0.33 nmoles/mg of
protein (n=4) and these results are consistent with previous studies (Ravindranath et al.,
1989; Sagara et al., 1993; Huang and Philbert, 1995).
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Figure 2.2 HA14-1 selectively depletes mitochondrial glutathione in CGNs A. CGNs
treated with either vehicle (Con), HA14-1 (HA14; 20 μM), or ethacrynic acid (EA; 100
μM) for 4 h and then separated into mitochondrial and cytosolic fractions. Total
glutathione content of each fraction was measured using a DTNB colorimetric assay.
Data are shown as percent of control glutathione (GSH+GSSG) and analyzed using oneway ANOVA with a post-hoc Tukey’s analysis. *p<0.05, **p<0.01 vs Con, n=4. Control
levels of total mitochondrial glutathione were an average of 6.78 +/− 0.33 nmoles per mg
of protein. B. Immunoblot shown is for Cox-IV to demonstrate the purity of the
mitochondrial and cytosolic fractions in (A). C. Graph showing the representative pools
of cellular glutathione between mitochondrial and cytosolic fractions, n=4.
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2.4.3 Bcl-2 co-immunoprecipitates with GSH following chemical cross-linking in
CGNs; an interaction antagonized by the BH3 mimetic, HA14-1
We have previously shown that recombinant Bcl-2 directly interacts with GSH in
vitro (Zimmermann et al., 2007). To determine if Bcl-2 interacts with GSH in intact cells
we utilized a chemical cross-linking approach and measured the co-immunoprecipitation
of Bcl-2 with GSH from CGNs. Cultured CGNs were cross-linked using DSS
(disuccinimidyl suberate; a cell permeable, homobifunctional cross-linker possessing two
amine-reactive N-hydroxysuccinimide esters), and upon quenching the cross-link with
excess glycine, Bcl-2 was co-immunoprecipitated with GSH using a GSH antibody
(Figure 2.3). In CGNs pre-incubated with DMSO vehicle and then cross-linked and
immunoprecipitated with a GSH antibody, both monomeric and dimeric forms of Bcl-2
were co-immunoprecipitated with GSH. However, pre-treatment of the CGNs, prior to
cross-linking, with HA14-1 significantly decreased the amount of both the monomeric
and dimeric forms of Bcl-2 co-immunoprecipitated with GSH. These data strongly
suggest that Bcl-2 and GSH interact in intact CGNs, and this interaction can be
antagonized by the BH3 mimetic, HA14-1. Furthermore, we completed similar
experiments in isolated rat brain mitochondria and found that HA14-1 also antagonized
the interaction between Bcl-2 and GSH (data not shown). These findings are consistent
with our previously published data in which we showed that recombinant Bcl-2 and GSH
interact in a direct manner. Moreover, this interaction shows specificity between Bcl-2
and GSH, since other Bcl-2 family proteins, such as Bcl-xL and Bcl-w, did not interact
directly with GSH (Zimmermann et al., 2007).
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Figure 2.3 Bcl-2 co-immunoprecipitates with GSH following chemical cross-linking in
CGNs, an interaction antagonized by the BH3 mimetic HA14-1 CGNs were pre-incubated
with either vehicle (0.4% DMSO) or 20 μM HA14-1 for 2 h, after which they were crosslinked (x-link) with DSS, which was quenched upon lysing (see materials and methods).
Lysates were immunoprecipitated (IP) with a monoclonal antibody to GSH. Immune
complexes were resolved by SDS-PAGE and immunoblotted (IB) for Bcl-2.
Mono=monomeric, dimer=dimeric, WCL=whole cell lysate.
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2.4.4 HA14-1 depletes glutathione from isolated mitochondria. HA14-1 and Bim
inhibit mitochondrial GSH transport in vitro
We examined the effects of HA14-1 on glutathione pools in isolated rat brain
mitochondria. Incubation of isolated mitochondria with HA14-1 induced a significant
depletion of total glutathione (GSH+GSSG) when mitochondria were co-incubated in the
presence of GSH-MEE (Figure 2.4.A, n=3, **p<0.01 vs. Con) for 4h. HA14-1 has
previously been shown to have some uncoupling and inhibitory effects on mitochondrial
respiration at high concentrations (Milanesi et al., 2006). To exclude the possibility that
HA14-1 (used at 20 μM) was depleting glutathione in isolated rat brain mitochondria by
inhibiting mitochondrial respiration, and in turn inducing oxidative stress, we compared
its effects to those of the complex I inhibitor, rotenone, which we used at a concentration
significantly higher than its previously shown IC50 value for complex I (Chen et al., 2006;
Janssen et al., 2007). While HA14-1 (20 μM) significantly depleted total mitochondrial
glutathione content, rotenone (10 μM) had no such effect (Figure 2.4.A). In another series
of experiments, we pre-loaded isolated mitochondria with 2 mM GSH-MEE for 2 h and
then washed the mitochondria prior to adding HA14-1 or rotenone for an additional 2 h.
Following the 2 h pre-incubation with GSH-MEE, mitochondrial glutathione content was
increased by approximately 250% over non-loaded controls (data not shown). Incubation
with HA14-1 induced a marked reduction of total glutathione in the pre-loaded
mitochondria, suggesting that the Bcl-2 inhibitor actually stimulated glutathione efflux
(Figure 2.4.B, n=6, *p<0.05 vs. Con). In contrast, incubation with rotenone had no effect
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on mitochondria pre-loaded with GSH-MEE. We compared the amount of total
glutathione in freshly isolated mitochondria versus the Con samples in the treatment
paradigms of Figures 2.4.A and 2.4.B; no differences in the levels of total glutathione
were observed (an average of 17.84 +/− 1.69 nmoles/mg, n=3, data not shown). Finally,
we assessed the effects of HA14-1 or recombinant Bim on the transport of [3H]GSH into
isolated mitochondria. Both Bcl-2 inhibitors, HA14-1 (20μM) or Bim (2μM),
significantly inhibited GSH uptake into mitochondria (Figure 2.4.C, #p<0.01 vs Con and
*p<0.05 vs Con, n=3). These data show that HA14-1 and Bim suppress mitochondrial
GSH transport and that HA14-1 is capable of inducing efflux of glutathione from isolated
mitochondria.
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Figure 2.4 HA14-1 depletes glutathione from isolated rat brain mitochondria, in addition
HA14-1 and Bim inhibit mitochondrial GSH transport A. Isolated rat brain mitochondria
were incubated in mitochondrial buffer with a combination of 2 mM GSH-MEE and
either vehicle (Con), HA14-1 (20 μM), or rotenone (10 μM) for 4 h. Samples were then
washed 3X in mitochondrial buffer and assayed for glutathione (GSH+GSSG) content.
Data are shown as percent of control glutathione (GSH+GSSG) and analyzed using a
one-way ANOVA with a post-hoc Tukey’s analysis. ** p<0.01 vs Con, n=3. B. Isolated
rat brain mitochondria were incubated in mitochondrial buffer with GSH-MEE (2 mM)
for 2 h at 37°C, washed 2X, and then incubated in mitochondrial buffer with either Con,
HA14-1 (HA14; 20 μM), or rotenone (10 μM) for 2h at 37°C. After which samples were
washed 3X with mitochondrial buffer and assayed for glutathione (GSH+GSSG) content
using a DTNB colorimetric assay, data are normalized to protein concentration. Two
controls are shown because some of the experiments performed with HA14-1 were
carried out separately from several of the experiments performed with rotenone. Data are
represented as percent of the respective control glutathione (GSH/GSSG) and analyzed
using a Student’s T-test. *p<0.05 vs Con, n=6. Control total mitochondrial glutathione
levels for the isolated rat brain mitochondria experiments were an average of 17.84 +/−
1.69 nmoles/mg of protein. C. Isolated rat brain mitochondria were incubated with either
vehicle (Con; 0.4%DMSO), HA14-1 (HA14; 20 μM) or Bim (2 μM) for 20 min and then
0.5μ Ci of [3H]GSH for 15 sec at room temperature. [3H]GSH was measured as described
under Materials and Methods. Data are represented as percent of Con (CPM values) and
analyzed using a one-way ANOVA with post-hoc Tukey’s analysis. **p<0.01 vs Con,
*p<0.05 vs Con, n=3 experiments completed in triplicate. I acknowledge Kristin
Marquardt for assistance in generating the data for this figure.
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2.4.5 Bcl-2 co-immunoprecipitates with OGC and this interaction is enhanced by
GSH-MEE
HA14-1, a BH3 mimetic that binds Bcl-2 within the hydrophobic groove,
selectively depletes mitochondrial glutathione and antagonizes the interaction between
Bcl-2 and GSH in CGNs, and inhibits GSH uptake/stimulates glutathione efflux in
isolated brain mitochondria. These data suggest a possible role for Bcl-2 in regulating
mitochondrial glutathione transport. It has been previously shown that the IMM anion
transporters OGC and DIC are responsible for glutathione transport across the inner
mitochondrial membrane into the matrix in liver and kidney (Chen and Lash, 1998; Chen
et al., 2000). Therefore, we next examined the potential of Bcl-2 to interact with the OGC
in a transient co-transfection system. CHO cells overexpressing Bcl-2 and a V5-tagged
OGC were lysed in 0.1% Triton X-100 with 1 mM DTT, and immunoprecipitated with or
without a V5 antibody. Bcl-2 co-immunoprecipitated with V5-OGC upon addition of the
V5 antibody but did not precipitate in the presence of protein A/G agarose beads alone
(Figure 2.5.A). Next, we determined the effects of GSH-MEE on the interaction of Bcl-2
with OGC. CHO cells overexpressing Bcl-2 and V5-OGC were treated with 2 mM GSHMEE for 4 h, and cells were lysed and immunoprecipitated in buffer also containing 2
mM GSH-MEE. In control conditions, CHO cells overexpressing Bcl-2 and V5-OGC
were untreated, lysed, and immunoprecipitated in buffer containing 1 mM DTT. The
relative amount of Bcl-2 co-immunoprecipitated with V5-OGC was appreciably
increased in the presence of GSH-MEE versus DTT (Figure 2.5.B). Densitometric
analysis using normalization of the Bcl-2 band intensity to the V5-OGC band intensity
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revealed a significant increase (approximately five-fold) in Bcl-2 co-immunoprecipitation
with V5-OGC in the presence of GSH-MEE versus DTT (Figure 2.5.C, n=9, p<0.05 vs.
DTT). GSH-MEE enhanced the interaction between Bcl-2 and OGC irrespective of the
time in which it was added into the experiment, such as treating the cells only or simply
adding GSH-MEE to the immunoprecipitation buffer (data not shown). Moreover, in a
cell free system, recombinant Bcl-2 also interacted directly with recombinant GSTtagged OGC in the presence of GSH (Figure 2.5.D). Both recombinant Bcl-2 and
recombinant GST-OGC co-immunoprecipitated with a Bcl-2 antibody and a Slc25a11
(OGC) antibody (Figure 2.5.D). Finally, upon the addition of ethacrynic acid to the
immunoprecipitation buffer (which already contained GSH therefore ethacrynic acid was
used to deplete the GSH), the interaction between recombinant OGC and recombinant
Bcl-2 was antagonized (Figure 2.5.E). These results indicate that Bcl-2 is an interacting
partner for OGC and this novel protein-protein interaction is enhanced by GSH.
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Figure 2.5 Bcl-2 co-immunoprecipitates with V5-OGC from co-transfected CHO cells,
GSH-MEE enhances the interaction A. CHO cells were co-transfected with Bcl-2 and
V5-OGC (5μg each) lysed in Wahl buffer containing 0.1% TritonX-100 and 1 mM DTT,
and immunoprecipitated (IP) with a monoclonal V5 antibody. Immune complexes were
then resolved by SDS-PAGE, immunoblotted for V5 and Bcl-2. WCL= Whole cell
lysate, IP =immunoprecipitate, −V5 antibody=Protein A/G agarose alone was used in the
IP. B. Same as in (A), except at 24 h post-transfection cells were treated with 2 mM
GSH-MEE for 4 h (and GSH-MEE was added to the IP buffer). Alternatively, 1 mM
DTT was added to the IP buffer. C. Densitometry comparing pixel density of coimmunoprecipitated Bcl-2 with V5-OGC in the presence of either 1 mM DTT (Con) or 2
mM GSH-MEE. Data are normalized to the amount of V5 immunoprecipitated and are
expressed as a percent of Bcl-2 immunoprecipitated in the presence of DTT (Con). Data
was analyzed using a Student’s T-test, *p<0.05, n=9. D. Recombinant Bcl-2 and
recombinant GST-OGC were co-immunoprecipitated with either anti-Bcl-2 (Bcl-2 IP) or
anti-Slc25a11 (OGC IP) in 0.1% Triton X-100/Wahl buffer with 11.1 μM GSH. Immune
complexes were resolved by SDS-PAGE, immunoblotted for Bcl-2 and Slc25a11 (OGC).
E. Recombinant Bcl-2 and recombinant GST-OGC were co-immunoprecipitated with
anti-Bcl-2 in either 0.1% Triton X-100/Wahl buffer with 10 μM GSH (−EA) or 0.1%
Triton X-100/Wahl buffer with 10 μM GSH and 100 μM ethacrynic acid (+EA). Immune
complexes were resolved by SDS-PAGE, immunblotted for Bcl-2 and Slc25a11 (OGC).
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2.4.6 Co-expression of Bcl-2 and OGC increases mitochondrial glutathione
We next examined the effects of Bcl-2 and OGC expression on mitochondrial
glutathione content. Here, we utilized CHO cells expressing DsRed-2 (Con), Bcl-2, V5OGC, or a combination of Bcl-2 and V5-OGC. At 24 h post-transfection, cells were lysed
and mitochondrial and cytosolic fractions were obtained by differential centrifugation and
measured for total glutathione content. Control, Bcl-2, and OGC expressing CHO cells
showed similar mitochondrial glutathione content (Figure 2.6.A). However, with the coexpression of both Bcl-2 and OGC, total mitochondrial glutathione was significantly
increased compared to Bcl-2 expression alone (Figure 2.6.A, n=3, *p<0.05 vs. Bcl2/OGC). Immunoblot analysis confirmed the expression of Bcl-2 and OGC in the
appropriate mitochondrial fractions (Figure 2.6.B), and a Cox-IV blot demonstrated the
relative purity of the mitochondrial fractions (Figure 2.6.C). Control levels of total
mitochondrial glutathione were an average of 12.69 +/− 1.81 nmoles/mg of protein.
These data suggest that Bcl-2 and OGC work in a concerted manner to increase the
mitochondrial glutathione pool.

61

Figure 2.6 Co-transfection with Bcl-2 and V5-OGC significantly increases mitochondrial
glutathione content A. CHO cells were transfected with control (DsRed), Bcl-2, V5OGC, or a combination of Bcl-2 and V5-OGC (5μg each). After 24 h, cells were
fractionated and mitochondrial glutathione (GSH+GSSG) content was measured using
DTNB, and normalized to protein concentration. Data are expressed as percent of control
glutathione and analyzed using a one-way ANOVA with a post-hoc Tukey’s analysis
*p<0.05 vs Bcl-2/OGC, n=3. Control levels of total mitochondrial GSH were at an
average of 12.69 +/− 1.81 nmoles/mg of protein. B. Immunoblots of mitochondrial
fractions indicating expression of Bcl-2, V5-OGC, or a combination of both in
transfected CHO cells. C. Immunoblot for Cox-IV indicating purity of mitochondrial and
cytosolic fractions.
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2.4.7 Bcl-2 protection from hydrogen peroxide toxicity is dependent on the
function of OGC
Finally, we examined the consequences of increasing the mitochondrial
glutathione pool via co-expression of Bcl-2 and OGC in transiently transfected CHO
cells. In agreement with many previous studies (Hockenbery et al., 1993; Satoh et al.,
1996; Papdopoulous et al., 1998), overexpression of Bcl-2 alone significantly protected
CHO cells from hydrogen peroxide-induced apoptosis as assessed by measuring the
percentage of adherent cells expressing active caspase-3 (Figure 2.7.A, n=4, *p<0.05 vs
Con+H2O2, **p<0.01 vs Con+H2O2). In a similar manner, expression of either OGC
alone or OGC in combination with Bcl-2 also significantly protected cells from hydrogen
peroxide. Interestingly, co-incubation of CHO cells with the OGC inhibitor,
phenylsuccinate (PhS), at a concentration (500 μM) which was titrated down to a
maximally non-cytotoxic level, did not significantly enhance the active caspase-3
staining either on its own or in combination with the hydrogen peroxide exposure (Figure
2.7.B). Overexpression of OGC, in either the absence or presence of Bcl-2, maintained its
protective effect against hydrogen peroxide even in the presence of this low dose of PhS
(Figure 2.7.C, n=4, *p<0.05 vs Con+PhS and H2O2, #p<0.01 vs Bcl-2+PhS and H2O2).
These results are consistent with the low dose of PhS being sufficient to only inhibit the
transport capabilities of the endogenous OGC within CHO cells. In marked contrast to
the effects observed with OGC, Bcl-2 appeared to lose its protective effect against
hydrogen peroxide when the endogenous levels of OGC within CHO cells were
simultaneously inhibited by PhS. This point is demonstrated by the findings that Bcl-2
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alone was ineffective at attenuating caspase-3 activation in CHO cells treated
concomitantly with PhS and hydrogen peroxide (Figure 2.7.C). These results suggest that
Bcl-2 protects cells from hydrogen peroxide-induced apoptosis via an OGC-dependent
mechanism (i.e., via an increase in mitochondrial glutathione transport resulting in an
enhancement of the mitochondrial glutathione pool).
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Figure 2.7 Bcl-2 protection against H2O2-induced apoptosis is OGC-dependent A. CHO
cells transfected with DsRed, Bcl-2, V5-OGC, or a combination of Bcl-2 and V5-OGC
were treated with 100 μM H2O2 for 24 h and stained for active caspase-3. Data are
represented as mean +/− SEM. Data were analyzed using a one-way ANOVA with a
post-hoc Tukey’s analysis. *p<0.05 vs Con+H2O2, **p<0.01 vs Con+H2O2, *** p<0.001
vs Con+H2O2, and #p<0.001 vs Con, n=4. B. CHO cells transfected as in (A) and treated
with either vehicle, 100 μM H2O2 for 24 h alone or in combination with 500 μM
phenylsuccinate (PhS), or 500 μM phenylsuccinate (PhS) alone for 24 h and stained for
active caspase- 3. NS=not significant, data are represented as mean +/− SEM and
analyzed using a Student’s T-test. C. CHO cells transfected as in (A), treated with a
combination of 100 μM H2O2 and 500 μM phenylsuccinate (PhS) for 24 h and stained for
active caspase- 3. Data are represented as mean +/− SEM. Data were analyzed using a
one-way ANOVA with a post-hoc Tukey’s analysis. *p<0.05 vs Con+PhS and H2O2 and
**p<0.01 vs Con+PhS and H2O2, n=4.
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2.5 Discussion
Bcl-2 is a key sentinel of the mitochondria that acts to suppress the intrinsic
apoptotic cascade via its inhibitory interactions with pro-apoptotic family members
(Chipuk et al., 2008). Beyond its classical anti-apoptotic role, Bcl-2 is also known to have
a critical antioxidant-like function (Hockenbery et al., 1993). This antioxidant-like
property has been linked experimentally to the regulation of cellular glutathione content
(reviewed in Voehringer, 1999). For example, overexpression of Bcl-2 increases cellular
glutathione via an enhancement of glutathione synthesis and a diminution of cellular
glutathione efflux (Ellerby et al., 1996, Meredith et al., 1998; Jang et al., 2004).
Accordingly, overexpression of Bcl-2 protects cells from oxidative stress induced by
glutathione depleting agents (Kane et al., 1993; Merad-Saïdoune et al., 1999; Rimpler et
al., 1999). Furthermore, the protective effects of Bcl-2 against oxidative damage are
significantly diminished by depriving cells of glutathione precursors, for instance through
incubation in cysteine/methionine-deficient media (Mirkovic et al., 1997). Finally, Bcl-2
null mice show altered antioxidant enzyme activities in brain, such as decreased
glutathione peroxidase activity, and demonstrate increased sensitivity to neural oxidative
injury (Hochman et al., 1998). Many studies have provided evidence of a connection
between cellular glutathione status and the antioxidant-like action of Bcl-2. However, the
specific molecular mechanism(s) underlying this relationship between Bcl-2 and
glutathione has not yet been elucidated.
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Previously, a novel interaction between recombinant Bcl-2 and GSH in a cell-free
assay was demonstrated (Zimmermann et al., 2007). We showed that two dissimilarly
structured BH3 mimetics predicted to bind in the hydrophobic surface groove (i.e., the
BH3 groove) of Bcl-2, HA14-1 and compound 6, each antagonized this novel Bcl-2/GSH
interaction, as did recombinant Bim (Zimmermann et al., 2007) . From these previous
data, we concluded that Bcl-2 is a de facto GSH-binding protein and we hypothesized
that this newly discovered property of Bcl-2 might play a central role in its antioxidantlike function at mitochondria. Consistent with our hypothesis, we report here that HA141 induces a specific depletion of the mitochondrial glutathione pool in CGNs and this
BH3 mimetic inhibits the Bcl-2/GSH interaction in intact CGNs. In addition, HA14-1 and
Bim inhibit the mitochondrial uptake of [3H]GSH and HA14-1 induces glutathione efflux
in isolated rat brain mitochondria. Importantly none of these results are observed in
isolated mitochondria incubated with the complex I inhibitor, rotenone, demonstrating
that the effects of HA14-1 on mitochondrial glutathione transport are independent of any
inhibitory actions on the mitochondrial respiratory machinery.

To further establish a link between Bcl-2 function and mitochondrial glutathione
transport, we used a transient co-transfection system in CHO cells to demonstrate a novel
interaction between Bcl-2 and the IMM glutathione transporter, OGC. Significantly, this
unique protein-protein interaction is markedly enhanced by GSH-MEE. We also show the
interaction between OGC and Bcl-2 is direct through the use of recombinant proteins in
an immunoprecipitation and this interaction is dependent on glutathione because the
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addition of ethacrynic acid (which binds to GSH and forms non-functional adducts)
significantly abolished the ability of OGC and Bcl-2 to bind. Additional experiments
using co-transfected CHO cells reveal that Bcl-2 and OGC work in conjunction to
significantly increase the mitochondrial glutathione pool. Finally, we demonstrate that the
ability of Bcl-2 to protect cells from oxidative stress is largely dependent on an intact
transporter function of OGC because phenylsuccinate (an OGC inhibitor) abolishes the
protective effect of Bcl-2 against hydrogen peroxide-induced apoptosis in CHO cells.

Based on our current and previously published data, we propose the following
model to explain how Bcl-2 acts as a central regulator of the mitochondrial glutathione
pool. Under normal circumstances, OGC functions as an IMM glutathione transporter
that helps to maintain an adequate mitochondrial glutathione pool. We suggest that Bcl-2
localized to the outer mitochondrial membrane acts as a “sensor” of cytoplasmic
glutathione content, and upon GSH-binding, a conformational change is induced within
Bcl-2 that increases its affinity for OGC. The Bcl-2/OGC interaction in turn, enhances
the mitochondrial glutathione transporter function of OGC to increase the mitochondrial
glutathione pool. In this manner, an increase in cytoplasmic glutathione content, which
may occur via either enhanced synthesis or reduced efflux (Meredith et al., 1998; Jang et
al., 2004), may be transduced into the mitochondria to induce a corresponding elevation
in mitochondrial glutathione content. However, when HA14-1 or Bim binds to Bcl-2
within the BH3 groove, this antagonizes (either directly or allosterically) the interaction
between GSH and Bcl-2, and as a consequence lowers the affinity of Bcl-2 for OGC.
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Thus, BH3 mimetics and BH3-only proteins inhibit the capacity of Bcl-2 to regulate
mitochondrial glutathione transport through OGC, leading to a selective depletion of
mitochondrial glutathione, an increase in MOS, and activation of the intrinsic apoptotic
cascade.

Our proposed model is supported by several previously published observations.
First, in addition to our results showing that the BH3 mimetic, HA14-1, depletes
mitochondrial glutathione in CGNs, other BH3 mimetics have been shown to have
similar effects in different cell types. The highly selective Bcl-2 inhibitor, ABT-737, has
been shown to deplete cellular glutathione in Jurkat cells and HeLa cells, although
mitochondrial glutathione content was not explicitly measured in this study (Howard et
al., 2009). These findings, along with our data showing that Bim directly inhibits GSH
uptake into isolated mitochondria, strongly suggest that inhibition of Bcl-2 is a common
mechanism of depleting mitochondrial glutathione. Second, there is a precedent for Bcl-2
to interact with and modulate the activity of IMM transporters. For instance, Bcl-2 has
been shown to enhance the ADP/ATP exchange activity of the IMM adenine nucleotide
translocase in proteoliposomes, isolated mitochondria, and intact cells (Belzacq et al.,
2003). Interestingly, Bax displaces Bcl-2 from the translocase and acts to inhibit the
ADP/ATP exchange activity. Third, a previous study demonstrated a positive correlation
between an accumulation of Bcl-2 in the nuclear membrane and a redistribution of
glutathione into the nucleus, adding further support to a central role for Bcl-2 in the
regulation of glutathione transport that is not restricted to mitochondria (Voehringer et
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al., 1998). Finally, the ability of BH3 mimetics and BH3-only proteins (e.g., Bim) to
disrupt the Bcl-2/GSH interaction is entirely consistent with the pro-oxidant state induced
at mitochondria by pro-apoptotic Bcl-2 family members (Kirkland et al., 2002; Starkov et
al., 2002; Ding et al., 2004).

Collectively, the results described above suggest that Bcl-2 plays a central role in
the regulation of mitochondrial glutathione transport and maintenance of the
mitochondrial glutathione pool. Moreover, this key antioxidant-like function of Bcl-2
likely involves direct GSH-binding and a GSH-stimulated interaction with the IMM GSH
transporter, OGC. Gallo et al. found a similar interaction between the C. elegans
homolog of OGC (MISC-1) and the Bcl-2 homolog (Ced-9), further providing evidence
for an interaction between Bcl-2 and OGC (Gallo et al., 2011).

Given the substantial roles of glutathione depletion and MOS in
neurodegeneration, one could postulate how negatively impacting this novel function of
Bcl-2 might contribute to the pathophysiology of various neurodegenerative diseases. For
example, GSH depletion in the spinal cord of mice harboring a familial ALS mutation
(G93A) in the SOD1 gene has been shown to correlate with motor neuron degeneration
during disease progression (Chi et al., 2007). In transgenic mice and rats, as well as
human familial ALS patients, various mutant forms of SOD1 are apparently recruited to
spinal cord mitochondria (Liu et al., 2004). In general, these mutant forms of SOD1 are
observed as misfolded aggregates that have been localized to essentially every
compartment of the mitochondria; however, mutant SOD1 has also been shown to
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aggregate with Bcl-2 at mitochondria (Pasinelli et al., 2004). Most significantly, this
interaction of mutant SOD1 with Bcl-2 has been shown to induce a conformational
change in Bcl-2 that exposes its BH3 domain and converts Bcl-2 into a “toxic” protein at
mitochondria (Pedrini et al., 2010). Although the authors of this elegant study support a
direct toxic function of the conformationally altered form of Bcl-2 at mitochondria, it is
tempting to speculate that the interactions of Bcl-2 with mutant SOD1 may also interfere
with the novel role that Bcl-2 plays in regulating mitochondrial glutathione transport. For
instance, if only a fraction of Bcl-2 is actually altered in conformation by its interaction
with mutant SOD1, then this “toxic” form of Bcl-2 may in fact act like a BH3-only
protein and disrupt the ability of adjacent unaltered Bcl-2 molecules to bind GSH and
stimulate OGC-dependent glutathione transport into the mitochondria. In fact, this model
is consistent with findings in NSC34 motor neuronal cells stably expressing G93A
mutant SOD1. These cells demonstrate a significant depletion of the mitochondrial
glutathione pool with no effect on cytosolic glutathione content (Muyderman et al.,
2009). Moreover, these mutant SOD1-expressing cells demonstrate a more pronounced
depletion of mitochondrial glutathione and display an enhanced sensitivity to apoptosis in
response to ethacrynic acid when compared to non-transfected or wild type SOD1expressing NSC34 cells (Rizzardini et al., 2005; Muyderman et al., 2009). Thus, motor
neuron toxicity induced by mutant SOD1 likely involves the interaction of this protein
with Bcl-2 in the outer mitochondrial membrane. The precise consequences of this
interaction, if any, on the capacity of Bcl-2 to regulate mitochondrial glutathione
transport requires further study.
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In conclusion, we identify the regulation of mitochondrial glutathione transport
and maintenance of the mitochondrial glutathione pool as essential and novel functions of
Bcl-2. We establish Bcl-2 as a direct GSH-binding protein and a novel interacting partner
for the IMM glutathione transporter, OGC. Either BH3 mimetics or BH3-only proteins
(e.g., Bim) interfere with the Bcl-2/GSH interaction and result in inhibition of
mitochondrial glutathione transport. Bcl-2 and OGC appear to work in a concerted
manner to significantly increase the mitochondrial glutathione pool. Accordingly, the
ability of Bcl-2 to protect cells from oxidative stress is largely dependent on an intact
transporter function of OGC. These findings suggest a molecular mechanism for the well
established antioxidant-like function of Bcl-2, particularly at the level of the
mitochondria. Finally, this novel function of Bcl-2 may be a target of pathogenic
proteins, such as mutant SOD1, which result in devastating neurodegenerative disorders
like ALS.

72

CHAPTER THREE: MITOCHONDRIAL GLUTATHIONE TRANSPORT IS A
KEY DETERMINANT OF NEURONAL SUSCEPTIBILITY TO OXIDATIVE
AND NITROSATIVE STRESS
3.1 Abstract

Mitochondrial oxidative stress significantly contributes to the underlying pathology of
several devastating neurodegenerative disorders. Mitochondria are highly sensitive to the
damaging effects of reactive oxygen and nitrogen species; therefore, these organelles are
equipped with a number of free radical scavenging systems. In particular, the
mitochondrial glutathione (GSH) pool is a critical antioxidant reserve that is derived
entirely from the larger cytosolic pool via facilitated transport. The mechanism of
mitochondrial GSH transport has not been extensively studied in the brain. However, the
dicarboxylate (DIC) and 2-oxoglutarate (OGC) carriers localized to the inner
mitochondrial membrane have been established as GSH transporters in liver and kidney.
Here, we investigated the role of these carriers in protecting neurons from oxidative and
nitrosative stress. Immunoblot analysis of DIC and OGC in primary cultures of rat
cerebellar granule neurons (CGNs) and cerebellar astrocytes showed differential
expression of these carriers, with CGNs expressing only DIC and astrocytes expressing
both DIC and OGC. Consistent with these findings, butylmalonate specifically
reduced mitochondrial GSH in CGNs, whereas both butylmalonate and phenylsuccinate
diminished mitochondrial GSH in astrocytes. Moreover, preincubation with
butylmalonate but not phenylsuccinate significantly enhanced susceptibility of
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CGNs to oxidative and nitrosative stressors. This increased vulnerability was largely
prevented by incubation with cell-permeable GSH monoethylester but not malate.
Finally, knockdown of DIC with adenoviral siRNA also rendered CGNs more susceptible
to oxidative stress. These findings demonstrate that maintenance of the mitochondrial
GSH pool via sustained mitochondrial GSH transport is essential to protect neurons from
oxidative and nitrosative stress.

3.2 Introduction
Mitochondrial oxidative stress and mitochondrial dysfunction are convergence points in
the underlying pathologies of several devastating neurodegenerative disorders (Lin and
Beal, 2006). For instance, previous studies have provided significant evidence for
increased mitochondrial oxidative damage and organelle dysfunction in Parkinson
disease (PD) and amyotrophic lateral sclerosis (ALS) (Murata et al., 2008; Arthur et al.,
2009; Isobe et al., 2010). Overall, mitochondrial dysfunction leads to an increase in
reactive oxygen species (ROS), which damage mitochondrial DNA, lipids, and proteins
(Lin and Beal, 2006). Moreover, ROS induced alterations in mitochondrial membrane
potential and permeability can trigger a positive feedback mechanism known as ROSinduced ROS release, which has the potential to propagate oxidative stress signals from
mitochondria to mitochondria, thus exacerbating cellular injury (Zorov et al., 2006).
These findings indicate that mitochondrial free radical scavenging systems, such as the
essential antioxidant glutathione (GSH), are critical to protect neuronal cells from
mitochondrial oxidative stress. GSH exists as a discrete mitochondrial pool and a much
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larger cytosolic store. The mitochondrial GSH pool is considered to be an indispensable
antioxidant reservoir. For example, selective depletion of the mitochondrial GSH pool
within cerebellar granule neurons (CGNs) induced opening of the mitochondrial
permeability transition pore, increased ROS production, and caused significant cell death,
whereas depletion of the cytosolic GSH pool did not elicit these deleterious effects
(Wüllner et al., 1999). In a similar manner, specific depletion of mitochondrial GSH in
astrocytes rendered these glial cells more vulnerable to both oxidative and nitrosative
stress (Muyderman et al., 2007). Based on these previous studies, mitochondrial GSH
appears to be a critical antioxidant that supports both glial and neuronal cell viability.
Several factors indicate that GSH transport into mitochondria occurs via a facilitated
process. These factors include a lack of the enzymes necessary for GSH synthesis within
mitochondria, the negative potential of the inner mitochondrial membrane, the net
negative charge of GSH at physiological pH, and the approximately equal concentrations
of GSH in the cytosolic and mitochondrial compartments (Griffith and Meister, 1985;
Lash, 2006). Previous studies have shown that two inner mitochondrial membrane anion
transporters, the dicarboxylate carrier (DIC, Slc25a10) and the 2-oxoglutarate carrier
(OGC, Slc25a11), are capable of transporting GSH into renal and hepatic mitochondria
(Chen and Lash, 1998; Chen et al., 2000; Lash, 2006). Mechanisms of mitochondrial
GSH transport in the brain have only recently been investigated. Using isolated
mitochondria from whole brain, one study determined that mitochondrial GSH transport
may depend on the function of the tricarboxylate carrier (Wadey et al., 2009). A second
study showed that cortical neurons and astrocytes express both DIC and OGC. However,
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in isolated mitochondria from whole cortical tissue, only the activity of DIC appeared to
influence mitochondrial GSH content (Kamga et al., 2010). To date, the mechanism of
mitochondrial GSH transport utilized by neurons specifically has not been examined.
Furthermore, the effects of inhibiting either DIC- or OGC-dependent mitochondrial GSH
transport on neuronal susceptibility to oxidative or nitrosative stress are unknown. Here,
we demonstrate a key role for DIC-dependent mitochondrial GSH transport in the
maintenance of the mitochondrial GSH pool and protection of CGNs from oxidative and
nitrosative stress.
3.3 Materials and Methods
3.3.1 Materials
Butylmalonic acid, phenylsuccinic acid, primary antibody against β-tubulin, polyL-lysine, GSH monoethylester,L-malate, and Hoechst stain were purchased from SigmaAldrich. HA14-1 was acquired from Alexis Biochemicals (Enzo Life Sciences, Plymouth
Meeting, PA). The GSH assay kit was purchased from Oxford Biomedical (Rochester
Hills, MI). Anti-MAP2 was purchased from Santa Cruz Biotechnology, Inc.(Santa Cruz,
CA). The mitochondrial/cytosolic fractionation kit was from Biovision (Mountain View,
CA). Antibody against Cox-IV was obtained from Cell Signaling (Beverly, MA). Primary
rat astrocyte cultures were purchased from ScienCell (Carlsbad, CA). Anti-GFAP, antiGAPDH, anti-DIC (Slc25a10), and anti-OGC (Slc25a11) antibodies were purchased from
Abcam (Cambridge, MA). Sodium nitroprusside (SNP) was received from Calbiochem.
Horseradish peroxidase conjugated secondary antibodies and reagents for enhanced
chemiluminescence detection were purchased from Amersham Biosciences. The
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ViraBind® adenovirus miniprep kit and QuickTiterTM adenovirus titer immunoassay kit
were purchased from Cell Biolabs (San Diego, CA). Adenoviral siRNA1 and siRNA2
against DIC and the scrambled adenoviral control were constructed as described
previously (Huypens et al., 2011). siRNA1 targets DIC from bp 119GCU UCG AAU
GAC UGG AAU G, and siRNA2 targets DIC from bp 354GCA GAU UUG GUC AAU
GUC A, whereas the scrambled siRNA sequence (GAG ACC CTA TCC GTG ATT A)
has no known gene homology (Huypens et al., 2011).
3.3.2 CGN Cell Culture
CGNs were isolated and cultured from P7 Sprague-Dawley rat pups based on the
methods described previously (Zimmermann et al., 2007). CGNs were maintained in
basal modified Eagle’s medium, containing 10% heat inactivated fetal bovine serum, 25
mM potassium chloride, 2 mM L-glutamine and 100 units/ml/100 μg/ml
penicillin/streptomycin at 37 °C in 10% CO2.
3.3.3 Primary Rat Cerebellar Astrocyte Cell Culture
Primary rat cerebellar astrocyte cultures were grown on poly-L-lysine coated
flasks in basal modified Eagle’s medium containing 10% heat-inactivated fetal bovine
serum, 2mML-glutamine, and 100 units/ml/100 μg/ml penicillin/streptomycin. Cells were
plated on poly-L-lysine-coated 6-well plates and grown to ~80% confluence at 37 °C in
10% CO2, at which time cells were utilized for the described experiments.
3.3.4 Immunofluorescence Staining
CGNs and/or astrocytes were treated as described under “3.4 Results” and fixed with 4%
paraformaldehyde. Cells stained for β-tubulin were blocked and permeabilized in 5%
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BSA, 0.2% Triton X-100 in PBS for 1 h. Cells were then incubated with primary
antibody overnight at 4 °C, at a dilution of 1:500 in 2% BSA, 0.2% Triton X-100 in PBS.
Cells were then washed five times in PBS and incubated in secondary antibody for 1 h at
room temperature at a dilution of 1:250 in 2% BSA, 0.2% Triton X-100 in PBS. Cells
were then washed five times and placed in anti-quench solution. For cells with only
nuclei stained, cells were fixed as above and incubated with Hoechst dye (8 μg/ml) in
PBS for 1 h at room temperature. Cells were then washed five times with PBS and placed
in antiquench. Images were captured using a Zeiss Axiovert-zoom inverted
epifluorescence microscope.
3.3.5 Mitochondrial/Cytosolic Fractionation
Cells were treated as indicated under “3.4 Results” or in the figure legends, after
which the medium was aspirated, and cells were washed once in ice-cold PBS, pH 7.4.
200 μl of cytosolic buffer (provided in the kit, diluted 1:5 in double-distilled H2O, with
added protease inhibitor mixture and 1 mM DTT as per the manufacturer’s
recommendations) was added to the cells and allowed to incubate on ice for 20 min. Cells
were scraped and harvested and then homogenized with 40 passes of a Dounce
homogenizer. Samples were spun down at 720 relative centrifugal force for 10 min at 4
°C. The supernatant from each sample was transferred to a new tube labeled
“mitochondrial fraction” and spun at 10,000 relative centrifugal force for 30 min at 4 °C.
The supernatant was then transferred to a new tube labeled “cytosolic fraction,” and the
pellet in the mitochondrial fraction tube was resuspended in 150 μl of mitochondrial
buffer (provided in the kit, with added protease inhibitor mixture and 1 mM DTT as per
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the manufacturer’s recommendations). Samples were measured immediately for GSH
content as described below.
3.3.6 GSH Assay
GSH was measured using an assay kit (DTNB) from Oxford Biomedical
Research, following the manufacturer’s protocol. All GSH measurements were
normalized to protein concentration. GSH concentrations were determined using a GSH
standard in the DTNB assay and reported as nmol of GSH/mg of protein. The percentage
of mitochondrial GSH and percentage of cytosolic GSH was calculated using the slope of
the kinetic assay and the appropriate dilution factor.
3.3.7 Cell Lysis
CGNs were infected with the indicated adenoviral construct (shown under “3.4
Results”) as described below, after which CGNs were washed in 1 mL PBS over ice and
incubated with 1% Triton X-100 in Wahl buffer (20 mM HEPES, pH 7.4, 50 mM NaCl,
1 mM EGTA, 5 mM β-glycerophosphate, 30 mM sodium pyrophosphate, 100 μM
sodium orthovanadate, 10 μg/ml leupeptin, and 10 μg/ml aprotinin) for 10 min. Cells
were harvested by scraping and spun down at 10,000 rpm for 2 min, and the cell
supernatant was removed.
3.3.8 Immunoblot Analysis
Following mitochondrial/cytosolic fractionation or cell lysis, a BCA protein assay
(Pierce) was used to determine protein concentration. Equal concentrations of protein
were resolved by SDS-PAGE and immunoblotted as described previously (Zimmermann
et al., 2007).
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3.3.9 Purification and Titering of Adenoviral Constructs
Adenoviral constructs were amplified in a HEK 293 AD cell line by adding 10 μl
of the respective adenovirus to 4 ml of medium for 1.5 h, after which 16 ml of medium
was added to the flask, and cells were incubated at 5% CO2 and 37 °C for 48 h or until
the beginning signs of cytotoxicity were observed. Cells were harvested, and the
adenoviral constructs were purified as per the manufacturer’s recommendations in the
ViraBind® adenovirus miniprep kit. Adenoviral constructs were titered as per the
manufacturer’s recommendations in the QuickTiterTM adenovirus titer immunoassay kit.
3.3.10 Adenoviral Knockdown of DIC
CGNs were infected with adenoviral constructs at a multiplicity of infection of 100 for 48
h, after which experiments were completed.
3.3.11 Statistical Analysis
One-way analysis of variance tests followed by post hoc Tukey’s tests were
performed to determine statistical significance between data sets.A p value of less than
0.05 was considered statistically significant. A minimum of three independent
experiments were completed for each figure.

3.4 Results
3.4.1 Differential Expression of the Mitochondrial GSH Transporters,OGCand DIC,
within CGNs and Cerebellar Astrocytes
To determine the specific cellular expression of the previously identified
mitochondrial GSH transporters within the cerebellum, we employed primary rat CGN
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and primary rat cerebellar astrocyte cultures (Fig. 3.1.A). We first completed
immunoblots against DIC and OGC on mitochondrial fractions of these primary cultures.
Here, we show that CGNs express DIC but no detectable OGC. In contrast, cerebellar
astrocytes express both DIC and OGC (Fig. 3.1.B).
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Figure 3.1 Differential expression of the mitochondrial GSH transporters, OGC and
DIC, within CGNs and cerebellar astrocytes A. primary rat CGN cultures were fixed and
stained for β-tubulin (red),MAP2(green), and Hoechst (blue). Primary rat astrocyte
cultures were fixed and stained for GFAP (green) and Hoechst (blue). B. CGN and
cerebellar astrocyte cultures were subfractionated into mitochondrial and cytoplasmic
fractions using differential centrifugation as described under “Experimental Procedures.”
Protein lysates from the mitochondrial and cytosolic fractions were resolved using
SDSPAGE and immunoblotted for DIC and OGC. Immunoblotting for β-tubulin was
used as a measure of fraction purity.
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3.4.2 Inhibition of DIC but Not OGC Specifically Reduces the Mitochondrial GSH Pool
in CGNs
We next examined the effects of butylmalonate and phenylsuccinate, DIC and
OGC inhibitors, respectively, on mitochondrial GSH levels within CGNs. Dose responses
were initially completed in order to establish a maximal non-cytotoxic level of each of
these inhibitors (data not shown). Accordingly, CGNs were treated with 5 mM
butylmalonate or 5 mM phenylsuccinate overnight. After subfractionation of CGNs into
mitochondrial and cytoplasmic fractions, GSH was quantified using a DTNB colorimetric
assay. CGNs showed a significant reduction of the mitochondrial GSH pool when treated
with butylmalonate, but they displayed no decrement in the cytosolic pool (Fig. 3.2).
Interestingly, phenylsuccinate had no discernible effect on either the mitochondrial or
cytosolic pools of GSH within CGNs (Fig. 3.2). These results are consistent with the
immunoblot analysis, which demonstrated that the CGNs expressed DIC but not OGC
(Fig. 3.1.B). Immunoblot analysis of the subcellular fractions for cytochrome c oxidase
IV and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) verified the purity of the
mitochondrial and cytosolic fractions, respectively (Fig. 3.2). Furthermore, mitochondrial
GSH comprised 14.3 +/- 2.7% of total cellular GSH at a concentration of 6.9 +/- 1.10
nmol/mg, consistent with previous studies (mean +/- S.E., n = 6) (Ravindranath et al.,
1989; Sagara et al., 1993; Huang and Philbert, 1995; Wilkins et al., 2012).
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Figure 3.2 Inhibition of DIC but not OGC specifically reduces the mitochondrial GSH
pool in CGNs CGN cultures were treated with vehicle (DMSO;Con),5 mM butylmalonate
(BM), or 5 mM phenylsuccinate (PS) overnight. Cells were then subfractionated into
mitochondrial and cytoplasmic fractions using differential centrifugation. Mitochondrial
and cytosolic fractions were measured for total GSH content using a DTNB assay. Data
are represented as a percentage of control GSH. **, p <0.01 compared with control; NS,
not significant; n =4 experiments with each treatment performed in duplicate. Protein
lysates were resolved using SDS-PAGE and immunoblotted for cytochrome c oxidase IV
(Cox-IV) and GAPDH to indicate pure fractionations. Error bars, S.E.
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3.4.3 Inhibition of DIC or OGC Function Specifically Decreases the Mitochondrial GSH
Pool in Cerebellar Astrocytes
In order to resolve the mitochondrial GSH transporters utilized in cerebellar
astrocytes, these cultures were incubated overnight with 5 mM butylmalonate or 5 mM
phenylsuccinate, after which the cerebellar astrocytes were subfractionated, and GSH was
quantified as described above. Cerebellar astrocytes displayed a significant level of
mitochondrial GSH depletion with phenylsuccinate but no effect of this inhibitor on the
cytosolic pool of GSH (Fig. 3.3). Although the results for butylmalonate did not reach
statistical significance, the trend toward mitochondrial GSH depletion with this inhibitor
is in agreement with the previous immunoblot analysis showing that these astrocytes
express both DIC and OGC (Fig. 3.1.B). Furthermore, mitochondrial GSH comprised
13.4 +/- 3.9% of total cellular GSH at a concentration of 2.0 +/- 0.78 nmol/mg, consistent
with previous studies (mean +/- S.E., n=4) (Ravindranath et al., 1989; Sagara et al., 1993;
Huang and Philbert, 1995). Cytochrome c oxidase IV blots showed consistent
mitochondrial fractions. Although immunoblotting indicated that the mitochondrial
phenylsuccinate sample contains GAPDH, this finding alone does not definitively
demonstrate cytosolic contamination of this fraction. For instance, a previous study
showed that GAPDH can localize to the mitochondria under conditions of mitochondrial
permeability transition pore activation (Tarze et al., 2007). Given the significant
depletion of mitochondrial GSH observed with phenylsuccinate, this mitochondrial
perturbation may be occurring in astrocytes. Second, if the phenylsuccinate mitochondrial
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samples did indeed contain significant cytosolic contamination, then we would expect to
see a marked increase in mitochondrial GSH compared with controls because the
cytosolic GSH pool is much larger than the mitochondrial GSH pool. Instead, we observe
the opposite effect, where phenylsuccinate significantly reduces the mitochondrial GSH
pool in cerebellar astrocytes (Fig. 3.3).
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Figure 3.3 Inhibition of DIC or OGC function specifically decreases the mitochondrial
GSH pool in cerebellar astrocytes Cerebellar astrocyte cultures were treated with vehicle
(DMSO; Con), 5 mM butylmalonate (BM), or 5 mM phenylsuccinate (PS) overnight.
Cells were then subfractionated into mitochondrial and cytoplasmic fractions using
differential centrifugation. Mitochondrial and cytosolic fractions were measured for total
GSH content using a DTNB assay. Data are represented as a percentage of control GSH.
**, p < 0.01 compared with control; NS, not significant; n= 3 experiments with each
treatment performed in duplicate. Protein lysates were resolved using SDS-PAGE and
immunoblotted for cytochrome c oxidase IV (Cox-IV) and GAPDH to indicate pure
fractions. Error bars, S.E.
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3.4.4 Inhibition of DIC-dependent Mitochondrial GSH Transport Renders CGNs More
Susceptible to Oxidative Stress Induced by HA14-1
The unique dependence of CGNs on DIC-dependent transport provided a valuable
model for examining the effects of specific inhibition of mitochondrial GSH transport on
neuronal sensitivity to oxidative stress. To this end, CGNs were preincubated overnight
with either 5 mM phenylsuccinate or 5 mM butylmalonate. Incubation with these doses
of inhibitors are not cytotoxic on their own (Fig. 3.4.A (BM panels) and B
(quantification)). Next, CGNs were treated for an additional 4 h with 12.5 μM HA14-1,
alone or in combination with butylmalonate or phenylsuccinate. We have previously
shown that HA14-1 causes GSH-sensitive intrinsic apoptosis and mitochondrial oxidative
stress, through the inhibition of Bcl-2 in CGNs (Zimmermann et al., 2007). Therefore, we
utilized this Bcl-2 homology-3 domain (BH3) mimetic, HA14-1, as a model of oxidative
stress. Incubation with 12.5 μM HA14-1 alone for 4 h had no significant effect on CGN
survival (Fig. 3.4.A (HA14 panels) and B (quantification)). However, inhibition of
mitochondrial GSH transport through the DIC using butylmalonate rendered the CGNs
significantly more sensitive to this oxidative stressor (Fig. 3.4.A (BM + HA14 panels)
and B (quantification)). In contrast, preincubation with the OGC inhibitor,
phenylsuccinate, did not significantly impact the susceptibility of CGNs to oxidative
stress induced by HA14-1, again consistent with our data showing that CGNs do not
express OGC (Fig. 3.4.B, quantification).
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Figure 3.4 Inhibition of DIC-dependent mitochondrial GSH transport renders CGNs
more susceptible to oxidative stress induced by HA14-1 A. CGN cultures were treated
with vehicle (Con) or 5 mM butylmalonate (BM) overnight. The following day, cells
were either left untreated (BM or Con) or treated with 12.5 μM HA14-1 (HA14 or
BM_HA14) for 4 h. After treatment, cells were fixed, and β-tubulin (FITC; green) and
nuclei (Hoechst; blue) were stained (top four panels). The bottom panels show
decolorized nuclei from separate fields. Scale bar,10 μm. B. Cells were treated as in A,
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with the addition of a 5mM phenylsuccinate pretreatment and HA14-1 (PS+HA14) or no
treatment (PS) the following day. Cells were fixed, and nuclei were stained with Hoechst.
Apoptosis was quantified by determining the percentage of cells with condensed and/or
fragmented nuclei. **p<0.01 versus butylmalonate alone; n = 4 experiments with each
treatment performed in duplicate. Error bars, S.E. I acknowledge Danielle Kirchhof for
assistance in generating the data for this figure.
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3.4.5 Inhibition of DIC-dependent Mitochondrial GSH Transport Renders CGNs More
Susceptible to Nitrosative Stress Induced by the Nitric Oxide Donor, SNP
We next examined the effects of selective mitochondrial GSH depletion, through
the inhibition of mitochondrial GSH transport, on the vulnerability of CGNs to
nitrosative stress. As described above, CGNs were preincubated overnight with either 5
mM phenylsuccinate or 5 mM butylmalonate. Incubations with these doses of inhibitors
were not cytotoxic to CGNs on their own (Fig. 3.5.A, BM panel and PS panel). Next,
CGNs were treated for an additional 6 h with the nitric oxide donor SNP, at a
concentration (25 μM) that was also not cytotoxic on its own (Fig. 3.5.A, SNP panel).
Some CGNs were also treated with SNP in combination with butylmalonate or
phenylsuccinate. Consistent with the results described above for HA14-1, preincubation
with butylmalonate but not phenylsuccinate rendered CGNs more susceptible to
nitrosative stress-induced apoptosis (Fig. 3.5.A, compare BM + SNP and PS + SNP
panels). Quantification of these data showed a statistically significant increase in CGN
apoptosis induced by SNP in cells preincubated with butylmalonate versus cells
incubated with butylamalonate alone (Fig. 3.5.B).
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Figure 3.5 Inhibition of DIC-dependent mitochondrial GSH transport renders CGNs
more susceptible to nitrosative stress induced by the nitric oxide donor, SNP A. CGN
cultures were treated with vehicle (Con), 5 mM phenylsuccinate (PS), or 5 mM
butylmalonate (BM) overnight. The following day cells were either left untreated (Con,
PS, or BM) or treated with 25 μM SNP (SNP, PS +SNP, or BM +SNP) for 6 h. Cells
were then fixed and stained with Hoechst dye. Scale bar, 10 μm. B. cells were treated as
in A, and apoptosis was quantified by determining the percentage of condensed and/or
fragmented nuclei. **p<0.01 versus butylmalonate alone; n=4 experiments with each
treatment performed in duplicate. Error bars, S.E. I acknowledge Danielle Kirchhof for
assistance in generating the data for this figure.
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3.4.6 Inhibition of DIC-dependent Mitochondrial GSH Transport Does Not Render CGNs
More Susceptible to Apoptosis Induced by Deprivation of Depolarizing Potassium
Previous studies have shown that removing depolarizing potassium (5K; 5 mM
potassium) induces CGN apoptosis and that this insult is insensitive to the addition of
GSH-MEE(D’Mello et al., 1993; Zimmermann et al., 2005). Therefore, to determine if
incubation of CGNs with the DIC inhibitor, butylmalonate, nonspecifically enhances the
sensitivity of CGNs to any toxic insult, we examined the effects of 5K within this system.
Incubation with 5K alone for 10 h had a significant deleterious effect on CGN survival
(Fig. 3.6.A(5K panel) and B (quantification)). However, inhibition of mitochondrial GSH
transport through the DIC, using butylmalonate, did not render the CGNs more sensitive
to 5K (Fig. 3.6.A (BM+5K panel) and B (quantification)). Therefore, inhibition of GSH
transport through the DIC does not indiscriminately render CGNs more susceptible to
GSH-insensitive insults.
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Figure 3.6 Inhibition of DIC-dependent mitochondrial GSH transport does not render
CGNs more susceptible to apoptosis induced by deprivation of depolarizing potassium A.
CGN cultures were treated with vehicle (Con) or 5 mM butylmalonate (BM) overnight.
The following day, medium was either changed to 25mM potassium minus serum (Con
orBM) or changed to 5 mM potassium minus serum (5K or BM+5K). Cells were then
fixed, and nuclei (Hoechst; blue) were stained. Panels show decolorized nuclei from
representative fields. Scale bar, 10 μm. B. cells were treated as in A, after which cells
were fixed, and nuclei were stained with Hoechst. Apoptosis was quantified by
determining the percentage of cells with condensed and/or fragmented nuclei. ## p < 0.01
versus butylmalonate alone; ** p <0.01 versus control; NS, not significant; n = 3
experiments with each treatment performed in duplicate. Error bars, S.E.
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3.4.7 Effects Induced by Inhibition of DIC-dependent Mitochondrial GSH Transport
Next, we used a cell-permeable form of GSH, GSH monoethylester, to determine
if the sensitization of CGNs to oxidative and nitrosative stress induced by the inhibition
of DIC-dependent mitochondrial GSH transport was indeed due to the observed reduction
in mitochondrial GSH (see Fig. 3.2). CGNs were preincubated with 5mM butylmalonate
overnight, after which they were treated with either 12.5 μM HA14-1 (for 4 h) or 25 μM
SNP (for 6 h) in the absence or presence of 2mM GSH monoethylester. Again, incubation
with butylmalonate, SNP, and HA14-1 individually did not induce significant levels of
apoptosis compared with control conditions (Fig. 3.7.B). However, as shown previously,
preincubation with butylmalonate induced significant susceptibility to both oxidative and
nitrosative stress caused by these insults (Fig. 3.7.A (BM+HA14 panels) and B
(quantification)). Moreover, the cell-permeable form of GSH significantly protected
CGNs from the sensitizing effects induced by inhibition of DIC-dependent
mitochondrial GSH transport (Fig. 3.7.A BM + HA14 + GSHMEE panels).
Quantification of these data showed statistically significant protection upon the addition
of GSH monoethylester, when compared with the sensitizing conditions of pretreatment
with butylmalonate and the subsequent addition of HA14-1 or SNP (Fig. 3.7.B).
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Figure 3.7 A cell-permeable form of GSH protects CGNs from the sensitizing effects
induced by inhibition of DIC-dependent mitochondrial GSH transport A. CGN cultures
were treated with vehicle (Con) or 5 mM butylmalonate (BM) overnight. The following
day, cells were either left untreated (Con orBM) or treated with 12.5 μM HA14-1 in the
presence or absence of 2mM GSH monoethylester (GSHMEE) for 4 h, after which cells
were fixed, and nuclei (Hoechst; blue) were stained. The left panels show decolorized
nuclei from representative fields. The right panels show corresponding bright field
images. Scale bar, 10 μm. B. Cells were treated as in A; in addition, some cells were
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incubated with 25 μM SNP in the presence or absence of 2 mM GSH monoethylester.
Cells were fixed, and nuclei were stained with Hoechst. Apoptosis was quantified by
determining the percentage of cells with condensed and/or fragmented nuclei. **p< 0.01
versus butylmalonate alone; + p < 0.05 versus butylmalonate + SNP; ## p < 0.01 versus
butylmalonate + HA14-1; n = 3 experiments with each treatment performed in duplicate.
Error bars, S.E. I acknowledge Danielle Kirchhof for assistance in generating the data for
this figure.
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3.4.8 The Addition of Malate Fails to Protect CGNs from the Sensitizing Effects Induced
by Inhibition of DIC-dependent Mitochondrial GSH Transport
Mitochondrial anion transporters work in concert with one another in order to
transport critical molecules into and out of the mitochondria for energy production.
Previous studies have shown that the DIC has the ability to transport malate
bidirectionally in exchange for phosphate (Mizuarai et al., 2005). However, the
tricarboxylate carrier transports malate into the mitochondria in exchange for citrate.
Therefore, the DIC and the tricarboxylate carrier work in tandem, where DIC transports
malate out of the mitochondria and the tricarboxylate carrier transports malate into the
mitochondria (Kajimoto et al., 2005). These transport processes are critical for cell
survival because citrate is a crucial component of fatty acid synthesis within the
cytosol,whereas malate is required for the citric acid cycle in the mitochondrial matrix.
Therefore, an important control experiment when inhibiting DIC-dependent transport
function is to examine if malate is capable of protecting CGNs from the sensitizing
effects of butylmalonate. This experiment is necessary to demonstrate that the sensitizing
effects induced by inhibiting DIC-dependent transport function are not due to disruption
of the malate transport capacity of the DIC. Here, we preincubated CGNs with 5mM
butylmalonate in the absence or presence of 5 mM malate. Following these
preincubations, CGNs were then treated for 6 h with 25 μM SNP. In the presence of
malate, preincubation with butylmalonate and subsequent SNP treatment induced an even
greater amount of CGN apoptosis as compared with butylmalonate in the presence of
SNP alone (Fig. 3.8.A, compare BM+ SNP panel with BM +MA + SNP panel).
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However, preincubation with malate alone followed by SNP treatment did not increase
apoptosis beyond control levels (Fig. 3.8.A, MA +SNP panel). Quantification of these
data showed a statistically significant increase in vulnerability to nitrosative stress after
CGNs were preincubated with both malate and butylmalonate compared with
butylmalonate preincubation alone (Fig. 3.8.B).
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Figure 3.8 The addition of malate fails to protect CGNs from the sensitizing effects
induced by inhibition of DIC-dependent mitochondrial GSH transport A. CGN cultures
were treated with vehicle (Con), 5 mM butylmalonate (BM), or 5 mM malate (MA)
overnight. The following day, cells were either left untreated or were treated with 25 _M
SNP (SNP, BM+SNP, MA+SNP, or BM+MA+SNP) for 6 h, after which cells were
fixed, and nuclei (Hoechst; blue) were stained. Scale bar, 10 μm. B. cells were treated as
in A. Apoptosis was quantified by determining the percentage of cells with condensed
and/or fragmented nuclei. **p<0.01 versus SNP alone; ## p<0.01 versus butylmalonate+
SNP; n =5 experiments with each treatment performed in duplicate. Error bars, S.E.

100

3.4.9 Adenoviral siRNA-mediated Knockdown of DIC Renders CGNs More Susceptible
to Oxidative Stress
Finally, we utilized two distinct adenoviral constructs encoding siRNA against rat
DIC and a scrambled control construct to examine their effects on neuronal vulnerability
to oxidative stress. After 48 h of infection with the adenoviral constructs, CGNs were
treated with 12.5 μM HA14-1 for 4 h. In addition, a parallel group of cells from each
adenoviral infection was lysed and analyzed for DIC protein levels. As expected, the
siRNA DIC adenoviral constructs consistently induced a significant knockdown of DIC
expression compared with CGNs infected with the scrambled control (Fig. 3.9.A,
siRNA1, 33.6+/-16%, n=3; siRNA2, 48+/-11%, n =9; mean +/-S.E., reduction in DIC
protein level normalized to β-tubulin). Neither of the adenoviral constructs caused any
significant apoptosis on their own (Fig.3.9.B, Scram, siRNA1, and siRNA2 panels).
However, CGNs infected with either the DIC siRNA1 or DIC siRNA2 adenovirus and
subsequently treated with HA14-1 showed a significant increase in apoptosis compared
with CGNs infected with the scrambled control virus and then incubated with HA14-1
(Fig. 3.9.B, compare Scram +HA14 with siRNA1 + HA14 and siRNA2 +HA14 panels).
Quantification of these data showed that knockdown of DIC with either of two distinct
adenoviral siRNA constructs significantly sensitized CGNs to oxidative stress-induced
apoptosis when compared with infection with the scrambled control construct (Fig.
3.9.C).
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Figure 3.9 Adenoviral siRNA-mediated knockdown of DIC renders CGNs more
susceptible to oxidative stress A. CGNs were infected for 48 h with a scrambled (Scram)
or two distinct DIC-specific siRNA (siRNA1 or siRNA2) adenoviruses. Cells were lysed;
proteins were resolved by SDS-PAGE and immunoblotted for DIC (upper blots) and βtubulin (lower blots). B. CGNs were infected as described in A, after which cells were
then either left untreated (Scram, siRNA1, or siRNA2) or treated with 12.5 μM HA14-1
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(Scram+HA14, siRNA1+HA14, or siRNA2 +HA14) for 4 h. Cells were fixed, and nuclei
were stained with Hoechst. The panels show representative fields of decolorized nuclei.
Arrowheads indicate apoptotic nuclei. Scale bar, 10 μm. C. cells wereinfected/treated as
in B, and apoptosis was quantified as the percentage of cells with condensed and/or
fragmented nuclei. *p<0.05 versus scrambled+HA14; ** p<0.01 versus
scrambled+HA14; n=3 experiments with each treatment performed in triplicate. Error
bars, S.E.
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3.5 Discussion
Given that previous studies have demonstrated enhanced sensitivity of both
neurons and astrocytes to specific depletion of mitochondrial GSH it is perhaps not
surprising that inhibition of mitochondrial GSH transport would produce similar effects
(Wüllner et al., 1999; Muyderman et al., 2007). However, it is striking that the discrete
inhibition of a single inner membrane transport protein, DIC, is sufficient to significantly
sensitize neurons to both oxidative and nitrosative stress. We chose to use CGNs as a
model for inhibition of mitochondrial GSH transport based on their apparent dependence
on DIC-mediated GSH transport. Interestingly, a mere ~32% reduction in mitochondrial
GSH through specific inhibition of DIC leads to a dramatic increase in the susceptibility
of CGNs to both oxidative and nitrosative stress-induced apoptosis. We used both
chemical inhibition of DIC (butylmalonate) and molecular knockdown of DIC
(adenoviral siRNA) in order to show that discrete inhibition of this single transporter
could render CGNs more susceptible to apoptosis. As discussed previously, the
mitochondrial GSH pool is an indispensable reservoir of this critical antioxidant. Several
studies have shown that specific depletion of mitochondrial GSH versus depletion of the
cytosolic GSH pool leads to neuronal degeneration as well as increased vulnerability of
astrocytes to both oxidative and nitrosative stress (Wüllner et al., 1999; Muyderman et
al., 2007). Furthermore, depletion of mitochondrial GSH may occur upstream of
mitochondrial dysfunction and oxidative stress, suggesting that reductions in
mitochondrial GSH may act as a trigger for these pathological mechanisms (MeradBoudia et al., 1998). Based on our data, it becomes an interesting possibility that
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dysfunction of one or more mitochondrial GSH transport proteins could lead to the
enhanced susceptibility of neurons in the CNS to oxidative and nitrosative stress. This
may be particularly relevant within chronic neurodegenerative diseases (e.g. PD or ALS),
which have been hypothesized tooccur via multiple “hits” involving gene-environment
interactions as underlying pathological mechanisms (Sulzer, 2007). To date, a role for
DIC or OGC dysfunction in neurodegeneration has not been examined.
In the context of neurodegenerative diseases, the devastating triad of GSH
depletion, mitochondrial dysfunction, and oxidative stress has been implicated in the
underlying pathology of a large number of disorders, such as Alzheimer disease, PD, and
ALS (Castellani et al., 2002; Mattiazzi et al., 2002; Eckert et al., 2003; Lin and Beal,
2006; Henchcliffe and Beal, 2008; Murata et al., 2008). Specifically, GSH has been
shown to be depleted within the substantia nigra of PD patients (Perry et al., 1986).
Moreover, depletion of nigral GSH was detected in a mouse model of PD before the
onset of complex I deficiency and neurodegeneration (Chinta et al., 2007). Similarly, in a
familial mouse model of ALS, the G93A mutant hSOD1 mouse, GSH depletion in the
spinal cord was positively correlated with disease onset and progression (Chi et al.,
2007). Forced reduction of GSH levels in the G93A mutant hSOD1 mouse model,
through the knockdown of γ-glutamyl cysteine ligase modifier subunit (the rate-limiting
enzyme in GSHsynthesis) led to a decrease in life span, increased oxidative stress, and
accelerated motor dysfunction (Vargas et al., 2011). Furthermore, in sporadic ALS
patients, erythrocyte GSH levels were found to be diminished, whereas lipid peroxidation
levels were significantly increased compared with healthy age-matched controls (Babu et
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al., 2008). Despite this abundant and compelling evidence for a key role of GSH
depletion

within

neurodegenerative

diseases,

neither

mitochondrial

GSH

nor

mitochondrial GSH transport mechanisms explicitly have been studied within models of
these diseases.
To further support the role of DIC-dependent mitochondrial GSH transport as a
protective mechanism in neurons, while excluding the contribution of interference with
the malate transport function of DIC, we examined whether malate would protect CGNs
from the sensitizing effects of DIC inhibition to nitrosative stress. Our results show that
the addition of malate in the presence of the DIC inhibitor butylmalonate caused CGNs to
become more susceptible to nitrosative stress than in the presence of butylmalonate
alone. This result can be attributed to the competitive inhibition produced by
butylmalonate and malate together on DIC-dependent mitochondrial GSH transport.
Butylmalonate inhibits DIC through competitive inhibition by binding to the transport
site, and because it is an analog, it does not become transported or metabolized (Lash,
2006; Palmieri et al., 1971). Therefore, the addition of malate with butylmalonate at the
same concentration would allow malate to outcompete butylmalonate for transport.
However, by adding both of these chemicals together, GSH would have to compete with
both malate and butylmalonate, therefore causing an even more significant reduction in
mitochondrial GSH transport and a greater vulnerability to nitrosative stress. In contrast
to malate addition, the sensitizing effects induced by DIC inhibition with butylmalonate
could be rescued by adding back GSH as a cellpermeable esterified form. Therefore,
because malate was unable to protect CGNs from the enhanced susceptibility induced by
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DIC inhibition, whereas adding back GSH did prevent these effects, we are able to rule
out deficits in fatty acid synthesis and the citric acid cycle as the mechanism by which
CGNs become vulnerable to apoptosis, leaving mitochondrial GSH transport as the most
probable mechanism. Depletion of mitochondrial GSH and increased susceptibility to
oxidative and nitrosative stress did not occur in CGNs exposed to phenylsuccinate, ruling
out the possibility that chemical analogs of commonly transported anions are capable of
non-specifically inducing neuronal susceptibility to these insults. Furthermore,
butylmalonate did not render the CGNs more vulnerable to a GSH-insensitive insult, 5Kinduced apoptosis. The specificity of the sensitizing effects of butylmalonate is also
supported through the use of two distinct adenoviral siRNAs to knock down DIC, which
similarly induced increased susceptibility to oxidative stress compared with a scrambled
control virus.
Previous studies have shown that whole brain mitochondria utilize the
tricarboxylate carrier (Slc25a1) as a mitochondrial GSH transport protein, whereas
mitochondria isolated specifically from cerebral cortex, which express both DIC and
OGC, use primarily DIC as a mitochondrial GSH transport protein (Wadey et al., 2009;
Kamga et al., 2010). Our study shows that CGNs are dependent on DIC, whereas
cerebellar astrocytes use both DIC and OGC as mitochondrial GSH transport proteins.
CGNs appear to be unique because they are insensitive to phenylsuccinate; however,
based on the relatively small decrease in mitochondrial GSH (~32%) observed with
butylmalonate, it cannot be ruled out that a second inner membrane transporter, such as
the tricarboxylate carrier, is also being used to transport GSH into CGN mitochondria.
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Overall, more studies are necessary to determine the identity of a second transport protein
that contributes significantly to mitochondrial GSH transport within CGNs.
Several studies have shown that mitochondrial oxidative stress plays a key role
within neurodegenerative diseases, such as PD and ALS. In one such study, a partial
knockdown of the mitochondrial specific manganese-superoxide dismutase (SOD2) led
to a significant decrease in survival and a greater decline in motor function within the
G93A mutant hSOD1 mouse model (Andreassen et al., 2000). In addition,
overexpression of SOD2 in a differentiated human neuroblastoma cell line protected from
cell death induced by the overexpression of several different mutant SOD1 proteins
(Flanagan et al., 2002). These studies indicate the importance of maintaining the
mitochondrial redox status for neuronal viability. Mitochondrial SOD2 and mitochondrial
GSH (via the activity of GSH peroxidase) work in concert to abolish the free radicals
generated by leakage from the electron transport chain, and these antioxidants are equally
important in maintaining the redox balance within mitochondria. Therefore, the prior
mentioned studies focused on SOD2, in combination with our data, indicate that the
antioxidant repertoire of mitochondria is critical in protecting neurons from pathological
mechanisms common to many neurodegenerative diseases.
In addition to defining the specific transport proteins involved in mitochondrial
GSH transport in the CNS, the regulation of mitochondrial GSH transport is also an area
that is not well understood. We have previously shown that Bcl-2 plays a central role in
maintaining the mitochondrial GSH pool in CGNs and is also capable of directly binding
GSH(Zimmermann et al., 2007). Furthermore, Bcl-2 is an interacting partner of OGC,
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and co-overexpression of these proteins leads to a significant increase in mitochondrial
GSH (Wilkins et al., 2012). Finally, BH3-only proteins (e.g. Bim) and BH3 mimetics
antagonize the Bcl-2/GSH interaction and inhibit GSH transport into isolated rat brain
mitochondria (Zimmermann et al., 2007; Wilkins et al., 2012). Therefore, Bcl-2 appears
to play a crucial role in regulating mitochondrial GSH transport. This point becomes
particularly relevant when considering that Bcl-2 function is often compromised within
neurodegenerative diseases. For instance, Bcl-2 expression has been shown to be
significantly decreased within the spinal cord of ALS patients (Mu et al., 1996). In the
G93A mutant hSOD1 mouse model of familial ALS, the mutant SOD1 protein was found
to interact with Bcl-2 and form dysfunctional aggregates with Bcl-2 at mitochondria
(Pasinelli et al., 2004). This interaction between G93A mutant SOD1 and Bcl-2 was also
shown to induce a toxic conformational change in Bcl-2, which prevents it from
performing its anti-apoptotic function (Pedrini et al., 2010). Therefore, it would be of
interest to determine if these deficits in Bcl-2 protein expression or its interaction with
G93A mutant SOD1 lead to consequential decreases in mitochondrial GSH transport in
the context of specific neurodegenerative diseases like ALS.
In summary, we have shown that by modulating mitochondrial GSH transport
through the specific inhibition of a discrete inner membrane transporter, DIC, neurons
become more vulnerable to apoptosis induced by oxidative or nitrosative stress. This
study provides novel insights into the importance of mitochondrial GSH transport in
maintaining neuronal survival and suggests that understanding the mechanisms involved
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in the regulation of mitochondrial GSH transport in neurons may reveal novel therapeutic
targets for neurodegenerative disorders.
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CHAPTER FOUR: STABLE OVEREXPRESSION OF THE 2-OXOGLUTARATE
CARRIER ENHANCES NEURONAL CELL RESISTANCE TO OXIDATIVE
STRESS VIA BCL-2-DEPENDENT MITOCHONDRIAL GSH TRANSPORT
4.1 Abstract

4.1.1 Aims
Mitochondrial glutathione (GSH) is a key endogenous antioxidant pool and its
maintenance is critical for cell survival. Here, we generated stable NSC34 motor neuronlike cell lines overexpressing the mitochondrial GSH transporter, the 2-oxoglutarate
carrier (OGC), to further elucidate the importance of mitochondrial GSH transport in
determining neuronal resistance to oxidative stress.
4.1.2 Results
Two stable OGC cell lines displayed specific increases in mitochondrial GSH
content and resistance to oxidative and nitrosative stressors, but not staurosporine.
Inhibition of transport through OGC and reduced levels of mitochondrial GSH resensitized the stable cell lines to oxidative stress. The stable OGC cell lines displayed significant upregulation of the anti-apoptotic protein, Bcl-2. This result was reproduced in
parental NSC34 cells by chronic treatment with GSH monoethylester, which specifically
increased mitochondrial GSH levels. Knockdown of Bcl-2 expression with siRNA
decreased mitochondrial GSH and re-sensitized the stable OGC cells to oxidative stress.
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Finally, endogenous OGC was co-immunoprecipitated with Bcl-2 from rat brain lysates
in a GSH dependent manner.
4.1.3 Innovation
These data are the first to show that increased mitochondrial GSH transport is
sufficient to enhance neuronal resistance to oxidative stress. Moreover, sustained and
specific enhancement of mitochondrial GSH leads to increased Bcl-2 expression, a
required mechanism for the maintenance of increased mitochondrial GSH levels.
4.1.4 Conclusion
Modulation of mitochondrial GSH transport renders neuronal cells resistant to
oxidative stress, in a manner dependent on Bcl-2. These findings suggest that mitochondrial GSH transport may be deficient in neurodegenerative diseases where Bcl-2
expression and function have been shown to be compromised.

4.2 Introduction
Mitochondrial dysfunction and oxidative stress, particularly at the level of the
mitochondria, play key roles in the pathogenesis underlying several neurodegenerative
diseases (Lin and Beal, 2006). While the central nervous system (CNS) accounts for a
mere two percent of total body weight, it generates approximately twenty percent of the
resting metabolic rate (Silver and Erecinska, 1998). Furthermore, neurons require high
amounts of ATP production, most of which is generated from oxidative phosphorylation
at the level of the mitochondrial electron transport chain (ETC), and are thus particularly
vulnerable to reactive oxygen species (ROS) generated by electron leakage from the ETC
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(Kann and Kovács, 2007). If ROS production is not balanced by free radical scavenging
systems, such as GSH or thioredoxin, then mitochondrial oxidative stress (MOS) occurs
triggering damage to DNA, lipids and proteins, ultimately leading to apoptotic or necrotic
degeneration of neurons (Lin and Beal, 2006).
Glutathione (GSH), an endogenous tripeptide antioxidant, is the most prominent
cellular thiol present at concentrations which are 500-1000 times greater than other free
radical scavenging systems (Schafer and Buettner, 2001; Filomeni et al., 2002). There are
several reservoirs of GSH throughout the cell, but in particular the mitochondrial GSH
pool has been shown to be critical for cell survival in several different systems (Meredith
and Reed 1982; Meredith and Reed 1983; Muyderman et al., 2007; Wilkins et al., 2013).
GSH is compartmentalized into mitochondria via a facilitated transport process involving
inner mitochondrial anion transporters such as the dicarboxylate (Slc25a10; DIC), 2oxoglutarate (Slc25a11; OGC), and tricarboxylate (Slc25a1; TCC) carriers (Lash, 2006;
Wadey et al., 2009; Kamga et al., 2010). We have previously shown that mitochondrial
GSH transport is critical for cell survival in primary cerebellar granule neurons (CGNs);
discrete inhibition or molecular knockdown of a single mitochondrial GSH transporter
(DIC) significantly sensitized these neurons to both oxidative and nitrosative stress
(Wilkins et al., 2013). These previous findings indicate that not only is the mitochondrial
GSH pool critical, but that mitochondrial GSH transport is a major determinant of
neuronal susceptibility to oxidative stress.
To further elucidate the importance of mitochondrial GSH transport on neuronal
viability, we derived NSC34 motor neuron-like cell lines that stably overexpress V5113

tagged OGC. Here, we show that the stable OGC cell lines display a specific increase in
mitochondrial GSH levels. In addition, these OGC stable cell lines are significantly
resistant to oxidative and nitrosative stress, as well as to a GSH depleting agent,
ethacrynic acid, but not to a classically Bax- dependent apoptotic inducer, staurosporine.
Furthermore, the stable OGC cell lines showed a significant upregulation of Bcl-2 protein
expression, an effect that is dependent on enhanced mitochondrial GSH levels. Finally,
either chemical inhibition of OGC transport function or knockdown of Bcl-2 using
siRNA, led to a decrease in mitochondrial GSH levels and re-sensitization of the stable
OGC cell lines to oxidative stress. It has been previously shown in several systems using
either recombinant proteins or transient transfection that Bcl-2 and OGC can interact in a
GSH-dependent manner (Gallo et al., 2011; Wilkins et al., 2012). However, here we
provide the first evidence that endogenous Bcl-2 and OGC interact in a GSH-dependent
manner in lysates derived from rat brain. Overall, these findings suggest a synergistic
mechanism between Bcl-2 and OGC in facilitating mitochondrial GSH transport and
further establish the importance of mitochondrial GSH transport in sustaining neuronal
viability under conditions of increased oxidative and nitrosative stress.

4.3 Materials and Methods
4.3.1 Reagents
Phenylsuccinic acid, L-reduced glutathione, ethacrynic acid, staurosporine,
primary antibody against α-tubulin, and GSH monoethylester were purchased from
Sigma-Aldrich (St.Louis, MO). The MTT cell viability assay, Geneticin (G418) and
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Lipofectamine were obtained from Invitrogen (Carlsbad, CA). The GSH assay was
purchased from Oxford Biomedical (Rochester Hills, MI). The mitochondrial/cytosolic
fractionation kit was from Biovision (Mountain View, CA). Antibody against cytochrome
c oxidase IV (Cox-IV) was purchased from Cell Signaling (Beverly, MA). Antiglyceraldehyde 3-phosphate dehydrogenase (Anti-GAPDH), anti-Bcl-2, anti-OGC, nonimmune IgG, anti- neuron specific β3 tubulin and anti-V5 antibodies were purchased
from Abcam (Cambridge, MA). Sodium nitroprusside was purchased from Calbiochem
(Billerica, MA). Secondary antibodies for immunoblotting and reagents for enhanced
chemiluminescence were obtained from GE Life Sciences (Piscataway, NJ).
DharmaFECT Transfection Kit, Smart pool siRNA against mouse Bcl-2, and Non-target
siRNA were purchased from Thermoscientific Pierce Biotechnology (Rockford, IL).
Optimem and Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained from Gibco
(Carlsbad, CA). V5-OGC plasmid was a generous gift from Dr. Larry Lash (Wayne
State University). NSC34 cells were kindly provided by Dr. Neil Cashman (University of
British Columbia).
4.3.2 Establishment of stable OGC NSC34 cell lines
NSC34 cells were plated at 80% confluence in 10 cm cell culture dishes, and
transfected with 40 μg of V5-OGC plasmid DNA using a standard Lipofectamine 2000
protocol. At 24 h post transfection cells were split into two cell culture dishes and the
following day 500 μg/mL of G418 was added to the media to allow for the selection of
transfected cells. Media was changed every three days with the addition of 500 μg/mL of
G418. Clones were then selected and grown in a 24-well plate in duplicate, grown to
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confluence and immunoblotted for V5 expression. High expressing clones were
propagated for further experiments.
4.3.3 Cell culture of parental (wild-type, WT) and stable OGC NSC34 cell lines
NSC34 WT cultures were grown in DMEM high glucose medium containing 10%
heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 100 units/ml/100 μg/ml
penicillin/streptomycin. NSC34 stable OGC cell lines were grown in identical media
containing 500 μg/mL of G418. Cells were plated on 6-well plates and grown to ∼80%
confluence at 37 °C in 10% CO2, at which time cells were utilized for the described
experiments.
4.3.4 Mitochondrial/ Cytosolic Fractionation
Cells were treated as indicated in the 4.4 Results section. Media was aspirated
and cells were washed once with 1X ice-cold phosphate buffered saline (PBS), pH 7.4.
One ml of cytosolic buffer, provided in the kit was diluted 1:5 in ddH2O, with added
protease inhibitor cocktail and 1 mM DTT as per the manufacturer’s recommendations. A
100 μL aliquot of the cytosolic buffer was added per well and incubated on ice for 20
min, at which point cells were harvested and homogenized with 40 passes of a Dounce
homogenizer. Samples were then spun down at 720 rcf for 10 min at 4º C. The
supernatant was transferred to a new tube which was labeled “mitochondrial fraction”
and the supernatant was spun down at 10,000 rcf for 30 min at 4ºC. The supernatant was
transferred to a new tube which was labeled the “cytosolic fraction” and the pellet in the
mitochondrial fraction tube was re-suspended in 100 μL of mitochondrial buffer
(provided in the kit) with protease inhibitor cocktail and 1 mM DTT as per the
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manufacturer’s recommendations. Samples were immediately used for further
experiments.
4.3.5 Glutathione Assay
Total glutathione (reduced GSH+oxidized glutathione (GSSG)) was measured
using an assay kit (DTNB) from Oxford Biomedical, following the manufacturer's
protocol. All glutathione measurements were normalized to protein concentration.
4.3.6 Immunoblot Analysis
Protein concentrations of samples were determined by a BCA protein assay.
Equal protein concentrations were subjected to SDS-PAGE, transferred and
immunoblotted as previously described (Linseman et al., 2001). Briefly, PVDF
membranes were incubated in blocking solution (10% BSA and 0.01% sodium azide
diluted in PBS with 0.1% Tween 20; PBS-T) for 1 h at room temperature (RT). The
primary antibodies were diluted in blocking solution at the manufacturer’s recommended
dilution and membranes were either incubated with primary antibody for 1 h at RT or
overnight at 4°C, as per manufacturer’s recommendations. Membranes were then washed
5x over 30 min with PBS-T. Next, membranes were incubated for 1 h at RT with
horseradish peroxidase-conjugated secondary antibodies that were diluted to appropriate
concentrations with PBS-T. Membranes were then washed 5x over 30 min with PBS-T.
Proteins were detected by enhanced chemiluminescence.
4.3.7 MTT Viability Assay
After treatment as indicated in the Figure Legends or Results, cell were incubated
with 100 μL of 12 mM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
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bromide) reagent for 4 h at 37°C, 10% CO2. Next, 2 ml of dimethyl sulfoxide was added
to solubilize the formazan and the plate was read at 570 nm in a spectrophotometer.
4.3.8 SMARTPOOL ® siRNA mediated knockdown of Bcl-2
Stable NSC34 OGC cells were transfected with either the SMARTPOOL® siRNA
against mouse Bcl-2 or non-target siRNA pool using the DharamaFECT transfection
protocol. Briefly, 25 nM of appropriate siRNA per well was incubated with 5 µL of
DharmaFECT transfection reagent separately with serum free medium for 5 min at RT.
siRNA and DharmaFECT in serum free medium were mixed and incubated at RT for 20
min. The mixture of siRNA/DharamaFECT was then added to the cells and incubated for
48 h at 37ºC and at 10% CO2 before subsequent experiments were completed.
4.3.9 Immunoprecipitation
Whole rat brain was obtained from two P7 rats and homogenized with 8 passes of
the loose pestle and 4 passes of the tight pestle from a dounce homogenizer in 0.1%
Triton X-100 in lysis buffer containing protease inhibitors and 10 mM reduced GSH.
The immunoprecipitation reaction consisted of 200 µg of protein lysate with 4 µg
antibody to Bcl-2, OGC, or non-immune IgG; reactions were incubated overnight at 4°C
with mixing by inversion. Next, 100 µL of protein A/G agarose beads were incubated
with the immunoprecipitation reactions for 4 h, 4°C, mixing by inversion. Samples were
spun down and washed 3x with 0.1% Triton X-100 in lysis buffer, before being resolved
by SDS-PAGE and immunoblotted. Total lysate was loaded at 100 µg of protein. All
animal procedures were performed according to a protocol approved by the University
of Denver Institutional Animal Care and Use Committee.
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4.3.10 Statistical Analysis
One-way analysis of variance (ANOVA) followed by a post hoc Tukey’s test or
an unpaired Student’s T test was performed to determine statistical significance between
data sets. A p value of < 0.05 was considered to be statistically significant.

4.4 Results

4.4.1 Stable overexpression of OGC specifically increases the mitochondrial GSH pool
To establish the successful overexpression of V5-tagged OGC we used a parental
(un-transfected) NSC34 cell line to compare with two separate NSC34 cell lines which
showed resistance to geneticin. We immunoblotted all cell lines for both the V5 epitope
tag and OGC protein levels. Both stable OGC cell lines displayed abundant expression of
V5 and OGC compared to parental NSC34 cells (indicated as wild-type (WT) in Figure
4.1.A). Lysates were also blotted against β3 tubulin, a neuron specific loading control,
thus indicating that the overexpression of OGC did not appear to change the neuronal
phenotype of the NSC34 cells (Figure 4.1.A). Stable OGC cell lines were continually
monitored for maintenance of high V5-OGC expression throughout the course of the
experiments.
In order to examine the effects of stable OGC expression on mitochondrial GSH
levels, stable cell lines and WT NSC34 cells were fractionated into mitochondrial and
cytosolic fractions and GSH levels were measured. Both stable OGC cell lines displayed
a significant and specific approximate two-fold increase in mitochondrial GSH levels
compared to WT NSC34 cells (Figure 4.1.B). Mitochondrial GSH concentrations
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calculated as nmoles/mg of protein were as follows, for WT, 24.4 +/-3.4; OGC 3, 50.3 +/8.1; OGC 6, 57.6 +/- 14.7 (mean +/- SEM, n=6).The percentage of mitochondrial GSH
compared to cytosolic GSH was in a range consistent with previous studies, where the
mitochondrial GSH pool is between 5% and 30% of total cellular GSH (Lash, 2006). For
WT NSC34 cells, mitochondrial GSH comprised 4.6% +/- 1.1%, while for OGC 3
mitochondrial GSH was 7.2% +/- 3.1%, and for OGC 6 mitochondrial GSH was 12.2%
+/- 5.6%, of total cellular GSH (mean +/- SEM, n=7). These data further support the
purity of the cellular fractionations, along with the immunoblots against cytochrome c
oxidase IV (Cox-IV), a mitochondrial specific protein, and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), a cytosolic marker (Figure 4.1.B).
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Figure 4.1 Stable overexpression of OGC specifically increases the mitochondrial GSH
pool A. Whole cell lysates were resolved by SDS-PAGE and immunoblotted against V5,
OGC and neuron specific β3 tubulin. OGC stable cell lines are indicated as OGC 3 and
OGC 6; parental NSC34 cells are indicated as wild-type (WT). B. Cells were fractionated
by differential centrifugation and total GSH content was then measured using a DTNB
colorimetric assay. Data are represented as a percentage of WT GSH measurements. *
p<0.05 versus WT mitochondrial GSH; **p<0.01 versus WT mitochondrial GSH in an
unpaired student’s T-test, n=7, error bars indicate standard error. Cellular fractions were
resolved using SDS-PAGE and immunoblotted against Cox-IV and GAPDH.
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4.4.2 The stable OGC NSC34 cell lines are resistant to oxidative stress induced by
hydrogen peroxide
To determine if the stable OGC cell lines were more resistant than WT NSC34
cells to oxidative stress, the reactive intermediate hydrogen peroxide (H2O2) was used.
Here, we employed two doses of H2O2, 500 μM or 1 mM, for a period of 24 h. In Figure
4.2.A, brightfield images indicate the distinct cell death induced at both doses of H2O2 in
the WT NSC34 cell line, and the striking resistance of both OGC stable cell lines to this
oxidative stressor. In order to quantify the differences in cell viability between the WT
and stable OGC cell lines, an MTT assay was employed. The WT cells displayed a
significant loss of cell viability compared to the untreated controls at both 500 μM and 1
mM H2O2 (Figure 4.2.B). However, neither stable OGC cell line showed any significant
decrease in cell viability at either dose of H2O2 (Figure 4.2.B). Upon completion of these
experiments, it became clear that both OGC stable cell lines proliferated at a much higher
frequency compared to the WT NSC34 cells. While all cell lines were plated at one
million cells per well, increased proliferation of the stable OGC cell lines induced a
greater cell density compared to WT NSC34 cells. This is important, because we have
previously shown that increased cell density can lead to increased expression of prosurvival proteins, such as Bcl-2 and Bcl-XL (Zimmermann et al., 2005). This led us to
question the effect of the high proliferation frequency of the stable OGC NSC34 cell lines
on their resistance to oxidative stress.
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Figure 4.2 The stable OGC NSC34 cell lines are resistant to oxidative stress induced by
hydrogen peroxide A. After plating cells at one million cells per well, cells were treated
the following day with either vehicle control (Con); 500 μM H2O2 or 1 mM H2O2
overnight. Brightfield images were captured following treatment. B. Cells were plated
and treated as in A, after which an MTT cell viability assay was completed. Data are
represented as percent of Con for each cell line. * p<0.05 versus Con; ** p<0.01,
compared to Con WT; NS, not significant via a one-way ANOVA with posthoc Tukey’s
test, n=6, error bars indicate standard error. I acknowledge Samantha Brock for
assistance in generating the data for this figure.
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4.4.3 Resistance of OGC overexpressing cell lines to oxidative stress is not dependent on
cell density
To address the above possibility, we employed three different cell plating
densities to discern the dependence on cell density for resistance to oxidative stress.
Brightfield images are shown to indicate the relative difference in each of the cell
densities used (Figure 4.3.A). The WT NSC34 cell line showed significant loss of cell
viability with treatment of H2O2 at each cell density tested (Figure 4.3.B). In contrast,
neither stable OGC cell line showed any statistically significant decrement in cell
viability in response to H2O2 treatment at any of the aforementioned densities (Figure
4.3.C and 4.3.D). However, there was a trend towards loss of cell viability with H2O2 in
cells plated at 100,000 cells per well, although it did not reach statistical significance
(Figure 4.3.C and 4.3.D). As indicated by the brightfield images in Figure 4.3.A,
100,000 cells per well is a very sparse density, thus some sensitivity to H2O2 of all three
cell lines at this cell plating density should perhaps be anticipated. Furthermore, at the
250,000 and 500,000 cells per well densities this decline was not observed in either of the
stable OGC cell lines (Figure 4.3.C and 4.3.D). These results indicate that the observed
resistance of the OGC cell lines to H2O2 is not due to enhanced proliferation or higher
cell density.

124

Figure 4.3 Resistance of OGC overexpressing cell lines to oxidative stress is not
dependent on cell density A. Cells were plated at the indicated densities and brightfield
images were captured the following day. B. After plating of WT NSC34 cells at the
indicated densities, cells were treated with vehicle control (Con); or the indicated
concentrations of H2O2 for 24 h. An MTT cell viability assay was completed and data are
represented as a percent of Con for each cell line. * p<0.05 versus WT Con at 100,000
cells/well; + p<0.05 versus WT Con at 250,000 cells/well ; ## p<0.01 versus WT Con at
500,000 cells/well. C. OGC 3 cells were plated and treated as in B with an MTT cell
viability assay being completed. NS, not significant. D. OGC 6 cells were plated and
treated as in B with an MTT cell viability assay being completed. NS, not significant. For
B-D all statistical comparisons were analyzed by one-way ANOVA with posthoc tukey
test, n=3, error bars indicate standard error. I acknowledge Samantha Brock for assistance
in generating the data for this figure.
125

4.4.4 Stable overexpression of OGC prevents loss of cell viability in the presence of
ethacrynic acid
Ethacrynic acid has previously been shown to non-preferentially deplete both
mitochondrial and cytosolic pools of GSH, and thus induce cell death. Therefore, to
determine if enhanced mitochondrial GSH transport affords protection from this GSH
depleting agent, we examined the toxic effects of ethacrynic acid. Brightfield images are
shown of representative fields for each cell line at both doses of ethacrynic acid used
(Figure 4.4.A). The WT NSC34 cell line displayed significantly reduced cell viability
following exposure to two doses of ethacrynic acid (Figure 4.4.B). In contrast, stable
OGC overexpression prevented this loss of cell viability induced by ethacrynic acid
(Figure 4.4.B). Therefore, enhanced mitochondrial GSH transport prevents cell death
induced by the depletion of total cellular GSH levels, illustrating the key role of the
mitochondrial GSH pool in maintaining neuronal survival.
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Figure 4.4 Stable overexpression of OGC prevents loss of cell viability in the presence of
ethacrynic acid A. Cells were plated at one million cells per well, following which cells
were treated with vehicle control (Con); 50 μM or 70 μM ethacrynic acid (EA) for 24 h.
Brightfield images were captured following treatment. B. Cells were treated as in A,
following which an MTT cell viability assay was completed, Data are represented as a
percent of Con for each cell line. ** p<0.01 compared to WT Con; NS, not significant via
a one-way ANOVA with posthoc Tukey’s test, n=4, error bars indicate standard error. I
acknowledge Josie Gray for assistance in generating the data for this figure.
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4.4.5 Overexpression of OGC renders NSC34 cells resistant to nitrosative stress
The nitric oxide donor, sodium nitroprusside (SNP), was used to induce
nitrosative stress and determine if enhanced mitochondrial GSH transport would protect
from this insult. Brightfield images taken after SNP treatment indicated that the WT
NSC34 cells were sensitive to both doses of SNP used, but no toxic effect was observed
in either of the OGC stable cell lines (Figure 4.5.A). The WT cells displayed a significant
loss of cell viability as measured by an MTT assay at both SNP doses (Figure 4.5.B).
However, neither OGC cell line showed any significant decrement in cell viability in
response to SNP (Figure 4.5.B). Therefore, overexpression of the mitochondrial GSH
transporter, OGC, and thus enhancement of mitochondrial GSH transport, reduces
neuronal sensitivity to nitrosative stress conditions.
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Figure 4.5 Overexpression of OGC renders NSC34 cells resistant to nitrosative stress A.
Cells were plated at one million cells per well, following which cells were treated with
vehicle control (Con), 200 μM or 250 μM sodium nitroprusside (SNP) for 24 h.
Brightfield images were captured following treatment. B. Cells were treated as in A,
following which an MTT cell viability assay was completed, Data are represented as a
percent of Con for each cell line. ** p<0.01 compared to WT Con; NS, not significant via
a one-way ANOVA with posthoc Tukey’s test, n=4, error bars indicate standard error. I
acknowledge Samantha Brock for assistance in generating the data for this figure.
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4.4.6 Stable overexpression of OGC does not protect NSC34 motor neuron-like
cells from staurosporine-induced apoptosis
We next examined the ability of enhanced mitochondrial GSH transport, and thus
increased mitochondrial GSH content, to protect from a non-oxidative cell death
mechanism. Stable OGC cell lines and WT NSC34 cells were treated with two doses of
staurosporine (STS), a classically Bax-dependent method of inducing intrinsic apoptosis.
WT and OGC 3 NSC34 cells both displayed the caspase-generated cleavage product of
PARP in response to STS treatment, indicating an apoptotic mode of cell death (Figure
4.6.A). Furthermore, WT NSC34 cells and both stable OGC cell lines displayed similar
significant decreases in cell viability at both doses of STS (Figure 4.6.B). Therefore,
stable overexpression of the mitochondrial GSH transporter, OGC, did not afford
protection from this classical (non-oxidative) apoptotic insult. These data demonstrate the
specificity of increased mitochondrial GSH transport for enhancing the resistance of
neuronal cells to oxidative damage.
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Figure 4.6 Stable overexpression of OGC does not protect NSC34 motor neuron-like
cells from staurosporine-induced apoptosis A. Cells were plated at one million cells per
well, following which cells were treated with vehicle control (Con); 100 nM or 500 nM
staurosporine (STS) for 24 h. Cells were lysed and proteins were resolved by SDSPAGE, immunoblot against PARP was completed. FlPARP-full length PARP, ClvgPARP-cleavage of PARP. B. Cells were treated as in A, following which an MTT cell
viability assay was completed, Data are represented as a percent of Con for each cell line.
** p<0.01 compared to WT Con; *p<0.05 compared to OGC 3 or OGC 6 Con via a oneway ANOVA with posthoc Tukey’s test, n=4, error bars indicate standard error.
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4.4.7 Chemical inhibition of OGC transport function specifically reduces mitochondrial
GSH and re-sensitizes OGC stable cell lines to oxidative stress induced by hydrogen
peroxide.
Phenylsuccinate is a chemical analog of 2-oxoglutarate that specifically blocks
transport through the OGC. In order to show that enhanced mitochondrial GSH transport
was responsible for conferring resistance of both stable OGC cell lines to oxidative stress,
phenylsuccinate was used to inhibit OGC-dependent transport. First, we examined the
effects of phenylsuccinate on mitochondrial GSH levels. Both OGC stable cell lines
showed significant and specific decreases in mitochondrial GSH suggesting that
phenylsuccinate successfully reduced the transport of GSH into the mitochondria (Figure
4.7.A). Following phenylsuccinate treatment, the mitochondrial GSH concentrations
calculated as nmoles/mg were 29.8 +/- 5.3 for OGC 3 and 20.9 +/- 5.5 for OGC 6 (mean
+/- SEM, n=3). Therefore, phenylsuccinate lowered the mitochondrial GSH
concentrations in both OGC 3 and OGC 6 to approximately WT levels (24.4 +/- 3.4 as
discussed in Figure 4.1). Cox-IV and GAPDH immunoblots indicate the purity of the
mitochondrial fractions (Figure 4.7.A). Next, OGC stable cell lines were co-incubated
with phenylsuccinate and H2O2, phenylsuccinate alone, or H2O2 alone and cell viability
was measured. Following incubation with phenylsuccinate or H2O2 alone, neither OGC
cell line showed any significant decrease in cell viability (Figure 4.7.B and 4.7.C).
However, both cell lines showed significant reductions in cell viability at both doses of
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H2O2 when OGC was simultaneously inhibited with phenylsuccinate, as compared to
cells that were treated with H2O2 alone (Figure 4.7.B and 4.7.C).
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Figure 4.7 Chemical inhibition of OGC transport function specifically reduces
mitochondrial GSH and re-sensitizes OGC stable cell lines to oxidative stress induced by
hydrogen peroxide A. Stable OGC NSC34 cells were treated with 10 mM
phenylsuccinate (PS) overnight. Cells were then fractionated using differential
centrifugation. Cell fractions were measured for total GSH using a DTNB colorimetric
assay. Data are represented as a percent of untreated control (Con) GSH. *p<0.05
compared to OGC 3 Con** p<0.01 versus OGC 6 Con; NS, not significant via a
Student’s T-test. n=4, error bars indicated standard error. Cell fractions were resolved by
SDS-PAGE and immunoblotted against Cox-IV and GAPDH. B. Stable OGC 3 NSC34
cells were treated with 10 mM PS alone or in combination with 500 µM or 1 mM H2O2.
At 24 h after treatment an MTT assay was completed and data are represented as percent
of the representative Con. * p<0.05, **p<0.01 versus Con, NS, not significant; via a
134

one-way ANOVA with posthoc Tukey’s test n=3, error bars indicate standard error. C.
Stable OGC 6 NSC34 cells were treated with 10 mM PS alone or in combination with
500 µM or 1 mM H2O2. At 24 h after treatment an MTT assay was completed and data
are represented as percent of the representative control (Con). * p<0.05, ** p<0.01 versus
Con, NS, not significant; via a one-way ANOVA with posthoc Tukey’s test n=5, error
bars indicate standard error.
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4.4.8 Specific increases in mitochondrial GSH induce an increase of the anti-apoptotic
protein Bcl-2
Previous studies using recombinant proteins or transient overexpression
constructs have shown that Bcl-2 and OGC are interacting partners (Gallo et al., 2011;
Wilkins et al., 2012). Thus, Bcl-2 protein levels were examined in the OGC stable cell
lines and interestingly, both lines displayed increased Bcl-2 expression, compared to WT
NSC34 cells (Figure 4.8.A) (approximate 5 fold increase). In order to determine if the
increased Bcl-2 expression was generally due to stable OGC overexpression or more
specifically, to increased mitochondrial GSH, WT NSC34 cells were chronically treated
(for 48 h) with the cell-permeable GSH monoethylester (GSH-MEE). In Figure 4.8.B, we
show that chronic exposure to GSH-MEE specifically increased mitochondrial GSH
levels, with no significant effect on the cytosolic pool. Cox-IV and GAPDH immunoblots
indicate the purity of the mitochondrial and cytosolic fractions (Figure 4.8.B). Next, WT
NSC34 cells chronically pre-treated with GSH-MEE were immunoblotted for Bcl-2
protein levels, which were significantly increased compared to untreated WT NSC34
cells (Figure 4.8.C) (approximate 2 fold increase). Overall, these data show that an
upregulation of Bcl-2 protein expression occurs as a result of specifically increased
mitochondrial GSH levels.
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Figure 4.8 Specific increases in mitochondrial GSH induces an increase of the antiapoptotic protein Bcl-2 A. Lysates were resolved by SDS-PAGE and immunoblotted
against Bcl-2 and α-tubulin. Densitometry was completed for Bcl-2 and was normalized
to α-tubulin. Data are represented as percent of WT Bcl-2 levels. *p<0.05 versus WT via
a one way ANOVA with post-hoc Tukey’s test, n=3, error bars indicate standard error. B.
WT NSC34 cells were treated for 48 h with 2 mM GSH-MEE, fractionated by
differential centrifugation and total GSH was measured using a DTNB colorimetric
assay. Data are represented as a percent of Con GSH. **p<0.01 versus Con via an
unpaired student’s T-test n=7, error bar indicate standard error. Samples were resolved by
SDS-PAGE and immunoblotted against Cox-IV and GAPDH. C. WT NSC34 cells
treated as in B were lysed and proteins were resolved by SDS-PAGE. Immunblots against
Bcl-2 and α-tubulin were completed. Densitometry was completed for Bcl-2 and
normalized to α-tubulin. Data are represented as a percent of the Con Bcl-2 expression. *
p<0.05 versus Con via an unpaired student’s T-test; n=3, error bar indicate standard error.
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4.4.9 The siRNA mediated knockdown of Bcl-2 specifically decreases mitochondrial
GSH and re-sensitizes OGC overexpressing NSC34 cells to oxidative stress.
We have previously shown that inhibition of OGC-dependent GSH transport
prevents the ability of Bcl-2 overexpression to protect CHO cells from H2O2-induced
oxidative stress (Wilkins et al., 2012). Therefore, we hypothesized that Bcl-2 induction
may be reciprocally necessary for OGC-dependent protection of NSC34 cells from
oxidative stress. To determine if the increased expression of Bcl-2 was instrumental in
rendering the OGC stable cell lines resistant to oxidative stress, we used a
SMARTPOOL® siRNA to specifically knockdown Bcl-2 in the stable OGC 6 cell line.
OGC 6 cells were transfected with either non-target or Bcl-2 siRNA for 48 h and Bcl-2
protein levels were examined. As shown in Figure 4.9.A, the Bcl-2 siRNA markedly
reduced Bcl-2 protein levels compared to the non-target control (an average of 47.3% +/8.1 % reduction in Bcl-2 protein levels, mean +/-SEM, n=5). Next, we examined the
effects of reduced Bcl-2 levels on mitochondrial GSH content. Knockdown of Bcl-2
protein levels induced a specific 35% reduction in mitochondrial GSH content compared
to non-target transfected cells (Figure 4.9.B). Cox-IV and GAPDH blots indicate pure
cellular fractionations (Figure 4.9.B). Based on the specific reduction in mitochondrial
GSH with siRNA-mediated knockdown of Bcl-2 protein levels, we hypothesized that
these cells would be re-sensitized to oxidative stress. Indeed, OGC 6 cells transfected
with siRNA against Bcl-2 displayed a statistically significant reduction in cell viability
with both concentrations of H2O2, whereas no decrease in cell viability was observed
with the non-target control (Figure 4. 9.C). Experiments were also completed comparing
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the non-target siRNA against a no transfection control and no significant differences in
Bcl-2 protein levels, mitochondrial GSH content, or cell viability were observed (data not
shown).
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Figure 4.9 The siRNA mediated knockdown of Bcl-2 specifically decreases mitochondrial
GSH and re-sensitizes OGC overexpressing NSC34 cells to oxidative stress A. Stable
OGC 6 NSC34 cells were transfected with either non-target or Bcl-2 siRNA at 25 nM for
48 h. Cells were lysed, proteins were resolved by SDS-PAGE and immunoblotted against
Bcl-2 and β3-tubulin. Densitometry of Bcl-2 normalized to β3 tubulin showed a 43.3%
+/- 8.1% (mean +/- SEM, n=5) reduction in Bcl-2 levels in siRNA Bcl-2 transfected cells
compared to non-target transfection. B. Cells transfected as in A, then fractionated by
differential centrifugation and total GSH content was measured using a colorimetric
DTNB assay. Data are represented as a percent of the Non-target control. *p<0.05
compared to non-target via an unpaired student’s T-test, n=6, error bars indicate standard
error. C. Cells were transfected as in A, treated with vehicle control (Con); 500 μM or 1
mM H2O2. Cell viability was assed via an MTT assay. *p<0.05 versus Con siRNA; **,
p<0.01 versus con siRNA; NS, not significant via a one-way ANOVA with posthoc
Tukey’s test. n=5, error bars indicate standard error.
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4.4.10 Bcl-2 and OGC co-immunoprecipitate from rat brain lysates in a GSH-dependent
manner
As stated previously, Bcl-2 and OGC have been demonstrated to be interacting partners.
However, past studies have used recombinant and protein overexpression systems to
show the association between these two proteins (Wilkins et al., 2012). Therefore, we
aimed to determine if the Bcl-2 and OGC interaction could be observed in a system with
endogenous levels of protein expression. Here, we used whole rat brain lysates in the
presence of high (10 mM) GSH to perform co-immunoprecipitation reactions. As shown
in Figure 4.10.A, Bcl-2 co-immunoprecipitated with OGC and OGC coimmunoprecipitated with Bcl-2 in a GSH-dependent manner. The coimmunoprecipitation did not occur without the addition of high GSH (Figure 4.10.B).
Finally, an IgG immunoprecipitation is shown as a control for non-specific binding
(Figure 4.10.A).
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Figure 4.10 Bcl-2 and OGC co-immunoprecipitate from rat brain lysates in a GSHdependent manner A. Whole rat brain was homogenized in 0.1% Triton X-100 in lysis
buffer with protease inhibitors and 10 mM GSH-MEE. Immunoprecipitation reactions
were completed using either an IgG, Bcl-2, or OGC antibody. Samples were resolved by
SDS-PAGE and immunoblotted against Bcl-2 and OGC. Tot=total lysate. B. Samples
were prepared as in A except without GSH-MEE. Immunoprecipitation reactions were
completed using either an IgG or OGC antibody. Samples were resolved by SDS-PAGE
and immunoblotted against Bcl-2 and OGC. Tot=total lysate.
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4.5 Discussion
Previous studies have shown that the overexpression of mitochondrial GSH
transporters (OGC and DIC) renders kidney and liver derived cell lines resistant to
apoptotic stimuli (Xu et al., 2006; Zhong et al., 2008). However, very limited information
is available on the role of these mitochondrial GSH transporters in neuronal systems.
Here, we generated stable V5-tagged OGC cell lines using immortalized mouse NSC34
motor neuron-like cells. NSC34 motor neuron-like cells afforded ease of transfection,
however, because NSC34 cells are an immortalized cell line, they only approximate the
phenotypic characteristics of motor neurons. NSC34 cells differ from primary motor
neurons because they lack synaptic transmission; however they do share some similarities
with motor neurons such as, sensitivity to insults that block voltage-gated ion channels
and axonal transmission (Durham et al., 1993). Furthermore, the stable NSC34 OGC cell
lines appeared to retain their neuronal phenotype, as shown through the continued
expression of neuron-specific β3 tubulin, despite showing enhanced proliferation
compared to parental NSC34 cells. Stable overexpression of OGC in the NSC34 cells led
to a significant and specific increase in mitochondrial GSH levels and a corresponding
increase in resistance of these cells to oxidative stress. These data suggest an interesting
question of whether OGC might play a role in mitochondrial GSH transport within
primary motor neurons. Indeed, OGC is abundantly expressed in mouse spinal cord
(Wilkins and Linseman, unpublished data). Thus, further studies are warranted in primary
motor neurons, especially given the profound resistance observed with enhanced
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mitochondrial GSH transport against both oxidative and nitrosative stress, major
pathogenic factors in neurodegenerative motor diseases like ALS.
While it may be anticipated that overexpression of a mitochondrial GSH
transporter would lead to an increase in mitochondrial GSH and enhanced neuronal cell
resistance to oxidative and nitrosative stress, it is quite novel that stable OGC cells also
displayed a marked increase in Bcl-2 protein levels. Furthermore, the upregulation of
Bcl-2 could be recapitulated by chronic exposure of parental NSC34 cells to a cellpermeable form of GSH, which similarly produced a specific increase in mitochondrial
GSH levels. Our data are consistent with previous studies which showed that modulation
of total cellular GSH levels results in the alteration of Bcl-2 protein levels (Ho et al.,
1997; Celli et al., 1998). However, these prior studies only examined the relationship
between manipulating total cellular GSH content and Bcl-2 protein expression. To our
knowledge, this is the first study to demonstrate that Bcl-2 protein expression is explicitly
regulated by mitochondrial GSH levels.
Several mechanisms could lead to an increase in Bcl-2 protein levels, including
decreased proteasome-dependent degradation, de-repression of Bcl-2 transcription or
translation (such as through microRNAs), or upregulation of Bcl-2 transcription. Celli et
al. (1998) showed that Bcl-2 protein levels were down-regulated in response to depletion
of total cellular GSH levels in a liver cell line due to increased Bcl-2 protein degradation
by the proteasome. MicroRNA involvement has also been implicated in the regulation of
Bcl-2 expression. Two microRNAs, miR-15 and miR-16, have been shown to downregulate Bcl-2 expression, a process that is deficient in chronic lymphocytic leukemia
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lymphocytes (Cimmino et al., 2005). Whether microRNAs are relevant to the
upregulation of Bcl-2, demonstrated here in our model is unknown, however it is
interesting to note that chronic lymphocytic leukemia lymphocytes have been shown to
have an approximate two-fold increase in GSH, a common observation in most cancerous
cells which overexpress Bcl-2 (Ferraris et al., 1994).
While the above mechanisms may contribute to increased Bcl-2 protein levels in
response to changes in total cellular GSH, mitochondrial redox alterations specifically,
have been shown to modulate protein kinase A (PKA) and downstream cyclic AMP
response element binding protein (CREB) transcriptional activities (Lee et al., 2005; Ryu
et al. 2005). Importantly, CREB has been shown to contribute significantly to Bcl-2
transcriptional regulation and is known as a redox sensitive transcription factor (Wilson
et al., 1996). PKA is activated through an auto-phosphorylation event induced by cyclic
AMP (cAMP), and a discrete pool of PKA appears to localize to the outer mitochondrial
membrane where it is associated with A kinase anchoring protein (AKAP121) (Affaitati
et al., 2003; Ginsberg et al., 2003). It has been previously shown that cAMP generated
through a mitochondrial soluble adenylyl cyclase which is sensitive to ATP production,
allows for the phosphorylation and activation of mitochondrial localized PKA (AcinPerez et al., 2009). Furthermore, antioxidants such as the iron chelator deferoxamine, can
increase the activity of mitochondrial PKA/CREB, while inhibition of PKA prevented the
protective action of deferoxamine against GSH depletion (Ryu et al., 2005). Finally, the
association of PKA with AKAP121 has been shown to promote the translocation of
mRNA of nuclear encoded mitochondrial proteins from the cytosol to the outer
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mitochondrial membrane, thus allowing their translation to occur locally at that site
(Ginsberg et al., 2003). While, we have not yet elucidated the mechanism allowing for
the upregulation of Bcl-2 protein levels in response to chronically elevated mitochondrial
GSH, an increase in Bcl-2 transcription through the PKA/CREB axis, specifically at the
level of the mitochondria, is most supported by previous studies. Overall, our data
indicate a novel mitochondria-to-nucleus redox sensitive signaling mechanism in the
regulation of Bcl-2 protein expression.
We have previously shown that Bcl-2 interacts with OGC in a GSH-dependent
manner using both recombinant and protein overexpression systems (Wilkins et al.,
2012). The Bcl-2 homolog, CED9, was also shown to be an interacting partner for the
OGC homolog, MISC-1, in C. elegans, suggesting this interaction is evolutionarily
conserved (Gallo et al., 2011). Here, we show that Bcl-2 and OGC interact in a GSHdependent manner in rat brain lysates, thus verifying this interaction within an
endogenous expression system. We have previously demonstrated the dependence of the
protective effects of Bcl-2 on the transport function of OGC; treatment of CHO cells
overexpressing both Bcl-2 and OGC with the OGC inhibitor, phenylsuccinate, prevented
the ability of Bcl-2 to protect from oxidative stress (Wilkins et al., 2012). Our current
data show that the knockdown of Bcl-2 through siRNA prevents the ability of
overexpressed OGC to protect NSC34 cells from oxidative stress. The knockdown of
Bcl-2 also led to a significant and specific decrease in mitochondrial GSH levels in the
stable OGC overexpressing cell lines. Therefore, we have provided compelling evidence
that OGC and Bcl-2 are interacting partners that work in conjunction to modulate
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mitochondrial GSH transport and sensitivity to oxidative and nitrosative stress
conditions. Moreover, the protection against oxidative stress afforded by Bcl-2 or OGC
overexpression are reciprocally dependent upon one another.
Overall, we show that enhancing mitochondrial GSH transport through the
overexpression of OGC provides two main cytoprotective mechanisms. First,
overexpression of OGC specifically increased mitochondrial GSH content and rendered
NSC34 cells resistant to oxidative and nitrosative stress conditions. Second, the specific
increase in mitochondrial GSH induced by the overexpression of OGC produced a
corresponding increase in Bcl-2 protein levels. These findings are important to the field
of neurodegeneration especially, because Bcl-2 expression is often decreased in these
diseases. For example, Bcl-2 expression is diminished in spinal cord tissue from both
ALS patients and in a mutant SOD1 mouse model of familial ALS (Mu et al., 1996;
Vukosavic et al., 1999). Furthermore, it has been shown that the ratio of GSH/GSSG is
also decreased in mitochondria isolated from spinal cord of mutant SOD1 mouse models
of familial ALS, and we have recently found that total mitochondrial GSH content is
significantly decreased in lumbar spinal cord from end-stage G93A mutant SOD1 mice
(Ferri et al., 2006; Pesaresi et al., 2011; Wilkins and Linseman, unpublished data).
Therefore, modulating mitochondrial GSH transport could prove to be a significant
therapeutic target in neurodegenerative diseases like ALS in which Bcl-2 expression is
diminished.
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4.6 Innovation
Increased expression of Bcl-2 has previously been shown to enhance cellular
GSH content. Here, we show that specifically increasing mitochondrial GSH content
through OGC-dependent transport reciprocally induces Bcl-2 expression. Moreover, this
increased Bcl-2 expression is necessary for the enhanced resistance of neuronal cells to
oxidative stress provided by overexpression of OGC. These data suggest a novel redox
sensitive mitochondria-to-nucleus signaling mechanism for the regulation of Bcl-2
expression and identifies mitochondrial GSH transport as a new therapeutic target in
neurodegenerative diseases in which Bcl-2 expression is diminished.
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CHAPTER FIVE: DISCUSSION

Emerging evidence suggests that the discrete pool of mitochondrial GSH is
critical for cell survival. Despite this, the role mitochondrial GSH transport contributes in
determining cell resistance to apoptosis has not been elucidated, particularly in neurons.
Mechanisms of mitochondrial GSH transport within the CNS are not well understood and
this includes both the carriers responsible and their regulation. The pro-survival protein,
Bcl-2, which acts as a suppressor of pro-apoptotic proteins, also functions in an
antioxidant-like mechanism. However, studies indicating a significant correlation
between Bcl-2 and cellular GSH trafficking had not been furthered, until recently.
Zimmermann et al. described a novel role for Bcl-2 as a GSH binding protein and
depicted that inhibition of Bcl-2 led to mitochondrial GSH efflux (Zimmermann et al.,
2007). Thus, the major goals of this thesis were to provide insight into the role Bcl-2 may
contribute in maintaining the mitochondrial GSH pool, the carriers responsible for
mitochondrial GSH transport in neurons and astrocytes, and the significance of
mitochondrial GSH transport in neuronal survival.
5.1 Summary of Major Findings
Chapter 2 of this thesis provided evidence for a direct role of Bcl-2 in
mitochondrial GSH transport. Inhibition of Bcl-2 led to a specific and significant
reduction in mitochondrial GSH levels, induced MOS, prevented the interaction between
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Bcl-2 and GSH, and inhibited mitochondrial GSH transport. After these observations, a
mechanism in which Bcl-2 contributes to mitochondrial GSH transport was shown
through a novel GSH-dependent Bcl-2/OGC interaction. In addition, the observation that
Bcl-2 and OGC work in a concerted manner to enhance mitochondrial GSH transport and
that Bcl-2 is dependent on the transport function of OGC to protect against oxidative
stress, further demonstrates the importance of these proteins in regulating mitochondrial
redox status through GSH.
The main goals of Chapters 3 and 4 of this thesis were to examine the importance
of mitochondrial GSH transport in neuronal systems. Chapter 3 elucidated that
mitochondrial GSH transport mechanisms are variable between primary cerebellar
astrocytes and CGNs. In addition, discrete inhibition or molecular knockdown of a single
mitochondrial GSH transporter, in CGNs, rendered these primary neurons more
susceptible to oxidative and nitrosative stress conditions. Chapter 4 focused on the
protective ability of enhanced mitochondrial GSH transport. In order to examine this a
stable cell line overexpressing OGC was developed in the motor neuron-like cell, NSC34
(mouse neuroblastoma fusion with mouse motor neuron cultures). The stable OGC cell
lines were significantly resistant to oxidative and nitrosative stress, as well as the GSH
depleting agent, ethacrynic acid. The major finding in Chapter 4 was the ability of
enhanced mitochondrial GSH content to induce an upregulation of Bcl-2 protein levels.
Similar to the finding of Chapter 2, the ability of OGC to protect from oxidative stress
was dependent on enhanced Bcl-2 expression. Finally, Bcl-2 and OGC were shown to
interact endogenously from rat brain lysates in a GSH-dependent manner. The work
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completed in this thesis provides substantial evidence for a role of Bcl-2 in mitochondrial
GSH transport and the significant importance of mitochondrial GSH transport in
determining neuronal viability. However, what contribution does enhancing the
bioavailability of GSH, within the context of neurodegenerative diseases, provide in
regards to providing an efficacious treatment option? This question and the role of
mitochondrial GSH transport within ALS disease pathology are discussed below.
5.2 Enhancing Glutathione synthesis as a therapeutic approach for ALS
It is not surprising that antioxidant therapies have been examined in
neurodegenerative diseases, given the role oxidative and nitrosative stress contribute to
disease pathogenesis; however all of the various antioxidants attempted (including
enhancing GSH synthesis by providing GSH precursors) have failed in clinical trials
especially for ALS. The efficacy of modulating GSH levels within the context of ALS
has been previously studied through the use of GSH precursors, such as N-acetylcysteine
(NAC) and N-acetylmethionine (NAM). In the G93A mutant SOD1 mouse model of
ALS, NAC significantly delayed disease progression and prolonged survival (Andreassen
et al., 2000). However, in clinical trials NAC failed to show any discernible effect on
disease progression or survival in a randomized, double blind, placebo controlled study
(Louwerse et al., 1995). In a separate clinical trial, a combination therapy which included
NAC and NAM (among other antioxidants), reported no significant effect on survival for
ALS patients (Vyth et al., 1996). To further elucidate the efficacy of GSH precursors as
a therapeutic intervention for ALS, a whey protein supplement which has a high content
of double bonded cysteine (cystine), known as Immunocal®, was tested in the G93A
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mutant SOD1 mouse model. Immunocal® preserved GSH levels and the GSH/GSSG
ratio in blood and lumbar spinal cord from end-stage G93A mutant SOD1 mice,
compared to non-treated mutant mice (Figure 5.1). Immunocal® treatment led to a
significant delay in disease onset and slowed the rate of motor decline, as shown through
grip strength measurements (Figure 5.2). However, no effect was observed on survival
with Immunocal® in the G93A mutant SOD1 mouse model (Figure 5.2). Overall, these
data indicate two possible hypotheses, first being that antioxidant therapy particularly at
the level of increasing GSH synthesis is not an efficacious ALS therapy. The second
hypothesis, is that while providing precursors for GSH synthesis appears to delay disease
onset in animal models of ALS (this is not an effect that could be observed in human
patients), it is unable to provide an effect on disease survival because the available GSH
pool is unable to be transported into mitochondria. As discussed earlier, mitochondrial
GSH has been shown in diverse models to be the most critical reservoir of this
antioxidant for cell survival (Meredith and Reed, 1982; Meredith and Reed,
1983;Wüllner et al., 1999; Muyderman et al., 2007). Indeed, upon examination of
mitochondrial GSH levels in lumbar spinal cord of end-stage G93A mutant SOD1 mice,
it was found that Immunocal® failed to preserve this critical pool of GSH (Figure 5.3).
These findings suggest the interesting possibility that the failure of GSH synthesis
precursors within ALS clinical trials may stem from a failure of the newly synthesized
GSH to be efficiently transported into mitochondria.
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Figure 5.1 HPLC-EC detection reveals whole blood and lumbar spinal cord GSH is
depleted in the hSOD1G93A mouse model of ALS and is preserved at NonTG levels in
hSOD1G93A mice receiving Immunocal® A. Mean GSH concentrations from the whole
blood of end stage trial animals, ** p<.01, * p<.05, n=13. B. GSH/GSSG ratios from the
whole blood of end stage trial animals, ** p<.01, n=13. C. Mean GSH concentrations
from the lumbar spinal cord of end stage trial animals. * p<.05, n=17. D. GSH/GSSG
ratios from the lumbar spinal cord of end stage trial animals. * p<.05, n=17. I
acknowledge Erika Ross for assistance in generating the data for this figure.
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Figure 5.2 Immunocal® delays clinical onset and diminishes the rate of decline in grip
strength in the hSOD1G93A mouse model of ALS A. Median survival is not significantly
different between hSOD1G93A mice receiving Immunocal® ad libitum beginning at 60
days of age and untreated mutant mice (n= 13). B. hSOD1G93A mice receiving
Immunocal® ad libitum beginning at 60 days of age displayed a delay in disease onset
and clinical decline compared to untreated mutant mice (n=13). Onset curves are
significantly different (p<.001) determined by Gehan-Breslow-Wilcoxon Test. C. PaGE
hanging wire test represented as (mean ± SEM) latency to fall at indicated ages (n=13).
*** indicates p<.001 compared to NonTG, ** indicates p<.01 compared to NonTG, †
indicates p<.05 compared to hSOD1G93A mice (one-way ANOVA with a post-hoc
Tukey’s test). I acknowledge Erika Ross for assistance in generating the data for this
figure.
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Figure 5.3 Immunocal® fails to preserve mitochondrial GSH levels from lumbar spinal
cord of end-stage G93A SOD1 mice Mitochondria were isolated from lumbar spinal cord
using a Percoll gradient and differential centrifugation. Total GSH was measured using a
DTNB colorimetric assay. All measurements of total GSH are normalized to protein and
represented as nmols/mg. *p<0.05, **p<0.01, NS=not significant via a One-way
ANOVA with post hoc Tukey’s test, n=4, error bars indicated SEM.
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Mitochondrial GSH levels in this disease model were further examined at disease
onset (~90 days) and end-stage (~120 days) time points in lumbar spinal cord and cortex.
Mitochondrial GSH did not show a significant reduction in either lumbar spinal cord or
cortex at disease onset in the G93A mutant SOD1 mouse model (Figure 5.4). However,
end-stage animals displayed a significant decrease in mitochondrial GSH in lumbar
spinal cord. This effect was not significant in mitochondria isolated from cortex, but did
display a trend towards significant depletion (Figure 5.4). These data are consistent with
prior studies showing that G93A mutant SOD1, both in vitro (overexpression in NSC34
cells) and in vivo (mouse model) causes a disruption in mitochondrial GSH/GSSG ratios
(Ferri et al., 2006; Pesaresi et al., 2011). Next, the ability of mitochondria from this
mouse model to transport GSH was assessed. While mitochondria isolated from both
wild-type (NonTg) and G93A mutant SOD1 lumbar spinal cord displayed a large
increase in GSH content during the incubation period, there was an ~50% reduction in
the ability to take up GSH in mitochondria isolated from G93A mutant SOD mice (Figure
5.4). The effect observed was specific to isolated mitochondria from lumbar spinal cord
of G93A mutant SOD1 mice, as mitochondria isolated from mutant cortex did not show a
deficit in mitochondrial GSH uptake compared to NonTg controls (Figure 5.4). Overall,
these data strongly support the notion that mitochondrial GSH transport is compromised
in the G93A mutant SOD1 mouse model of ALS.
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Figure 5.4 Mitochondrial GSH levels and transport in the G93A mutant SOD1 mouse
model A. Mitochondria were isolated from WT (NonTg) G93A mutant SOD1
(hSOD1G93A) mice at onset (~90 days old) and end-stage (~120 days old) from lumbar
spinal cord and whole cortex as described in Figure 5.3. Total GSH was measured using a
DTNB colorimetric assay. All measurements were normalized to protein and represented
as a percent of NonTg. ***p<0.001, NS=not significant via an unpaired student’s T-test,
n=4, error bars indicated SEM. B. Mitochondria were isolated from lumbar spinal cord
and cortex of end-stage (~120 days old) G93A mutant SOD1 (hSOD1G93A) and agematched WT (NonTg) mice as described in Figure 5.3. Isolated mitochondria were
incubated with 2 mM GSH at 37 °C, 300 rpm for 4 h. After which, mitochondria were
washed 3x and total GSH was measured using a DTNB colorimetric assay. All
measurements were normalized to protein and represented as μmoles/mg of GSH loaded
per hour. *p<0.05, NS=not significant, via a paired student’s T-test, n=7, error bars
indicated SEM.
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5.3 Mechanisms of decreased mitochondrial glutathione transport in ALS
There are several mechanisms by which mitochondrial GSH transport could be
compromised within the context of ALS disease pathology. First, Bcl-2 expression and
function are compromised in ALS and as this thesis has depicted, Bcl-2 contributes a
significant role in mitochondrial GSH transport. Second, the expression levels of other
mitochondrial GSH carriers could be down-regulated in the lumbar spinal cord, such as
DIC and OGC. Finally, post-translational modifications that occur with increased
oxidative and nitrosative stress (such as S-nitrosylation, thiol oxidation, or
carbonylation), may compromise function of Bcl-2 or the previously identified
mitochondrial GSH transporters. All of these hypotheses are discussed below.
5.3.1 Aberrant changes in Bcl-2 function and expression as a mechanism of
decreased mitochondrial glutathione transport in ALS
The compromise of Bcl-2 function and expression in ALS could lead to a
profound impact on the ability of mitochondria to transport GSH. In the G93A mutant
SOD1 mouse model of ALS, Bcl-2 adopts a “toxic” conformation induced through its
interaction with mutant SOD1 (Pasinelli et al., 2004; Pedrini et al., 2010). This “toxic”
conformation exposes the pro-apoptotic BH3- domain of Bcl-2, potentially transforming
it into a death inducing protein (Pedrini et al., 2010). Bcl-2 also interacts with WT SOD1
however; Bcl-2 associates more strongly with high molecular weight aggregates of
mutant SOD1, particularly at mitochondria (Pasinelli et al., 2004). WT SOD1 does not
induce the same “toxic” conformational change in Bcl-2 as that observed with mutant
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SOD1 (both G93A and G37R) (Pedrini et al., 2010). Moreover, the interaction between
Bcl-2 and high molecular weight aggregates of mutant SOD1 was specific to lumbar
spinal cord in both mice and ALS patients (harboring A4V SOD1 mutation specifically),
as the same observation was not found in liver (Pasinelli et al., 2004). It was shown in
Chapter 2 of this thesis, that a BH3-mimetic (HA14-1) prevented the interaction between
Bcl-2 and GSH, while also specifically depleting mitochondrial GSH. Combined with the
data presented above showing that G93A mutant SOD1 mice have compromised
mitochondrial GSH tranpsort, the ability of G93A mutant SOD1 to disrupt the interaction
between GSH and Bcl-2 was investigated. As shown in Figure 5.5, upon incubation of
recombinant Bcl-2 with recombinant mutant G93A SOD1, GSH-agarose beads failed to
pull Bcl-2 out of solution, while incubation with WT SOD1 had no effect on this Bcl2/GSH interaction. Incubation of isolated rat brain mitochondria with G93A mutant
SOD1 also led to an inhibition of GSH uptake when compared to WT SOD1 (Figure 5.5).
While more experiments are necessary, the aberrant interaction between mutant SOD1
and Bcl-2 could contribute to deficits of mitochondrial GSH transport within this ALS
mouse model.
In addition to altered function of Bcl-2 through an interaction with mutant SOD1,
previous studies have shown that Bcl-2 levels are decreased in patients and mouse
models of ALS. Decreased Bcl-2 levels were not observed pre-symptomatically, but were
apparent post-symptomatically in the G93A mutant SOD1 mouse model and this effect
was specific to spinal cord (Vukosavic et al., 1999). In addition, Bcl-2 mRNA levels are
decreased in lumbar spinal cord tissues isolated post-mortem from sporadic ALS patients
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(Mu et al., 1996). Therefore, while inhibition of Bcl-2 function may contribute to
decreased mitochondrial GSH transport, diminished Bcl-2 expression levels may also
play a role in this deficit.
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Figure 5.5 Effects of G93A mutant SOD1 on the ability of Bcl-2 to bind GSH and
mitochondrial GSH transport A. Recombinant Bcl-2 was incubated with GSH-agarose
beads (GSHAg), Agarose beads (Ag), GSH-agarose beads with 25 ng of recombinant
G93A mutant SOD1 (25ng G93A SOD1) all in the presence of 1 mM DTT in lysis
buffer, for 1 h at 4°C, mixing by inversion. Samples were spun down and washed 3x
(with lysis buffer) and proteins were resolved by SDS-PAGE. Immunoblots were
completed against Bcl-2, n=2. B. Samples were prepared as in A, except using 25 ng WT
SOD1 (25 ng WT SOD1), n=2. C. Mitochondria were isolated from rat brain using a
Percoll gradient and incubated for 4 h at 37°C, 300 rpm in the presence of either 25 ng
WT SOD1 (25 ng WT) or 25 ng G93A SOD1 (25 ng G93A) and 2 mM GSH.
Mitochondria samples were washed 3x and total GSH was measured using a DTNB
colorimetric assay. Data are indicated as percent of Control (Con), n=2.
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5.3.2 Alterations in protein levels of mitochondrial glutathione transporters as a
mechanism of decreased mitochondrial glutathione transport in ALS
While alterations in Bcl-2 function and expression are a likely contributor to
decreased mitochondrial GSH transport, decreased expression of mitochondrial GSH
carriers could also lead to similar deficits. A previous study compared mitochondrial
protein composition from lumbar spinal cord, between WT and G93A mutant SOD1
mice, and found a subset of proteins were either upregulated or down-regulated in the
G93A mutant SOD1 mouse model (Li et al., 2010). Two carriers from the SLC family
(Slc25a4 and Slc25a5; ADP/ATP translocase ANT 1 and 2) were down-regulated,
however the study did not find any previously identified mitochondrial GSH carriers to
have altered expression levels (Li et al., 2010). This study is in agreement with
immunoblotting completed from lumbar spinal cord in the G93A mutant SOD1 mouse
model, examining OGC and DIC protein levels, which did not show a difference
compared to WT mice in expression levels (data not shown). While it appears a downregulation in mitochondrial GSH transporter protein levels has not yet been observed,
two caveats need to be discussed. First, it is impossible to distinguish between cell types
with immunoblotting, therefore, immunohistochemical studies are needed to determine if
mitochondrial GSH transporter protein level alterations are possibly cell type specific.
However, given the data showing mitochondrial GSH and transport are decreased from
mitochondria isolated from whole lumbar spinal cord, this may not be the case. Finally,
the specific carriers responsible for mitochondrial GSH transport in lumbar spinal cord
motor neurons versus astrocytes needs to be distinguished so those specific proteins can
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be examined. However, current observations do not support a role for decreased protein
expression of known mitochondrial GSH carriers in mitochondrial GSH transport deficits
within the G93A mutant SOD1 mouse model of ALS.
5.3.3 Protein modifications of mitochondrial glutathione transporters or Bcl-2, as a
mechanism of decreased mitochondrial glutathione transport in ALS
Protein function can be significantly altered by modifications of key residues,
particularly in environments of enhanced oxidative and nitrosative stress, such as that
observed in ALS. Therefore, the last hypothesis for the mechanism of reduced
mitochondrial GSH transport within the G93A mutant SOD1 mouse is oxidative or
nitrosative modification of amino acid residues within mitochondrial GSH transporters or
Bcl-2, leading to disrupted function of these proteins.
Cysteine residues are often cited as critical for protein function and this is based
on their role in active sites as well as intra- and inter-molecular disulfide bridge
formation. In particular, OGC contains three cysteine residues (C184, C221, and C224),
two of which form an intramolecular disulfide bridge (C221 and C224). Mutagenesis of
C221 and C224 into serine residues significantly reduces the transport ability of OGC
(Xu et al., 2006). In comparison, DIC has five cysteine residues, and when mutated to
serine or alanine, no effect on DIC transport function was observed (Lash, 2006).
However, isolated recombinant DIC is very susceptible to thiol oxidation, which leads to
its subsequent inactivation. Bcl-2 contains two cysteine residues and mutagenesis of both
leads to a reduced capacity in its anti-apoptotic function while retaining its ability to
interact with the pro-apoptotic protein, Bax (Maser et al., 2000). Evidence of alterations
163

in cysteine residues has been found in the plasma of ALS patients, which have a
significant reduction in free thiol content compared to control subjects (Baillet et al.,
2010). Therefore, oxidative or nitrosative modifications to key cysteine residues within
OGC, DIC, or Bcl-2 may lead to decreased mitochondrial GSH transport as discussed
below.
There are several oxidative modifications of protein thiols which can affect
function, including thiyl radicals (-RS-), sulfenate (-SO-), sulfinate (-SO2-), and sulfonate
(SO3-) formation. Thiyl radical formation is extremely transient, resulting in disulfide
bond formation; sulfenic acid is a reversible modification, while sulfinate and sulfonate
are thought to be irreversible within mammalian systems (Jones, 2008). It has been
hypothesized that thiol containing proteins involved in redox signaling are susceptible to
oxidative modifications, especially by non-radical oxidants (i.e. H2O2) (Jones, 2008). In
particular, sulfenic acid formation through the oxidation of thiols has been proposed to
alter the biological function of proteins through the modification of allosteric cysteines
(Jones, 2008). This may be particularly relevant in regards to the hypothesis presented in
Chapter 2 of this thesis, where the interaction between Bcl-2 and GSH, possibly induces a
conformational change (allosteric) in Bcl-2 which increases its affinity for OGC.
Furthermore, the formation of sulfenic acid through the oxidation of the cysteine residues
of Bcl-2, by H2O2, has been shown to induce a down-regulation of Bcl-2 protein levels
and apoptosis (Luanpitpong et al., 2013). However, no evidence for sulfenic acid
modification has been observed currently for the mitochondrial GSH transporters, OGC
and DIC.
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Nitric oxide-induced modifications to cysteine residues, or S-nitrosylation, can
also induce an inhibitory effect on protein function. While no evidence has yet been
observed regarding S-nitrosylation of DIC, a previous study identified C184 of OGC as
an S-nitrosylation site within the myocardium (Kohr et al., 2011). C184 is not a part of
the intramolecular disulfide bridge of OGC, but is hypothesized to act as a redox sensor
for OGC function (Lash, 2006). Bcl-2 has been shown to be s-nitrosylated; however this
modification prevented the ubiquitination and subsequent degradation of Bcl-2; thus was
a protective mechanism from apoptosis (Azad et al., 2006). Overall, the literature
supports different consequences of s-nitrosylation for Bcl-2 and OGC functions.
While there are many other forms of oxidative and nitrosative modifications to
amino acids, protein carbonylation (oxidative) and 3-nitrotyrosine (3-NT; induced by
peroxynitrite) modifications are increased in ALS patients and the G93A mutant SOD1
mouse model (Beal et al., 1997; Ferrante et al., 1997; Siciliano et al., 2007; Andrus et al.,
1998). In addition, a recent study elucidated that depletion of GSH induced a significant
increase in protein carbonylation, an effect that was required for apoptosis, in a neuronlike PC12 cell line (Dasgupta et al., 2012). While it is not surprising that no evidence has
been published regarding carbonylation of OGC and DIC thus far, Bcl-2 has previously
been shown to be carbonylated prior to apoptotic cell death in the insulin-secreting
RINm5F cell line in response to nitric oxide (Cahuana et al., 2004). Currently, no
observations are published regarding 3-NT modifications of Bcl-2, OGC, or DIC.
Overall, the possible effects of oxidative or nitrosative modifications to Bcl-2 and
previously identified mitochondrial GSH transporters warrants investigation in the G93A
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mutant SOD1 mouse model of ALS. Based on current literature, evidence depicts that
oxidative modifications can inhibit the ability of Bcl-2 to prevent apoptosis; however no
current literature has examined the effect of oxidative modifications on OGC or DIC
function. Furthermore, the effects that these potential oxidative modifications induce on
the mitochondrial GSH transport functions of these proteins necessitate examination.
5.4 The role of decreased mitochondrial glutathione transport in the mechanism of
ALS disease pathology
While this thesis has provided evidence of decreased mitochondrial GSH
transport in the G93A mutant SOD1 mouse model of ALS, the relevance of this finding
to disease mechanism and pathology requires discussion. Reactive gliosis imparts a large
role on ALS disease onset and progression, as shown through the effect of targeted
overexpression of Nrf2 (Nuclear factor (erythroid-derived 2)-like 2); a transcription
factor which upregulates antioxidant defense proteins; such as GSH synthesis enzymes)
in astrocytes of mutant SOD1 mouse models. Vargas and colleagues showed that
overexpression of Nrf2 within astrocytes increased GSH content and secretion.
Astrocytes overexpressing Nrf2 protected co-cultured motor neurons from G93A mutant
SOD1 toxicity, an effect that was dependent on GSH secretion (Vargas et al., 2008). In
vivo, targeted Nrf2 overexpression in astrocytes significantly delayed disease onset and
extended survival in two distinct mutant SOD1 mouse models (Vargas et al., 2008).
Finally, exposure of astrocytes to peroxynitrite induces a neuroinflammatory phenotype,
apoptosis of co-cultured motor neurons, and an increase in nitrotyrosine levels (Cassina
et al., 2002).Therefore, the oxidative balance in astrocytes appears to greatly influence
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the induction of a neuroinflammatory phenotype and more importantly, disease
progression in mutant SOD1 mouse models.
In additional studies, the role of GSH in the ability of astrocytes to protect cocultured neurons has been extensively studied. Total cellular GSH depletion within
astrocytes prevented the protection of co-cultured neurons from nitrosative stress and
H2O2 (Drukarch et al., 1997; Chen et al., 2001). Furthermore, astrocytes depleted of
GSH and co-cultured with neurons, induced a loss in neuronal survival and dopamine
transport (Drukarch et al., 1997). GSH depletion of astrocytes has also been shown to
affect neuronal mitochondrial function. Specifically, GSH depleted astrocytes secreted
significantly less GSH and induced a decrease in co-cultured neuronal complex II, III,
and IV activities (Gegg et al., 2005). Finally, studies have elucidated that neurons are
more sensitive to GSH depletion when compared to astrocytes (Byrd et al., 2004).
Overall, the GSH status of both neurons and astrocytes greatly influences cell survival
and the susceptibility to oxidative and nitrosative stress in vitro.
A more recent study deciphered that astrocytes isolated from the G93A mutant
SOD1 mouse model induce cell death of WT co-cultured motor neurons(Cassina et al.,
2008).This effect could be recapitulated through the inhibition of the electron transport
chain within WT astrocytes (Cassina et al., 2008). More striking, is the result depicting
that treatment of G93A mutant SOD1 astrocytes with mitochondrial targeted antioxidants
prevents the death of co-cultured motor neurons (Cassina et al., 2008). These are the first
observations showing that mitochondrial oxidative stress within astrocytes is required for
the induction of cell death in co-cultured neurons.
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In addition to studies showing that MOS and GSH play an important role in the
ability of astrocytes to either be helpful or harmful neighbors to motor neurons, this thesis
has found several novel observations relating to the role of mitochondrial GSH transport
in neuronal viability. First, Bcl-2 and OGC work in a concerted manner in mitochondrial
GSH transport and subsequent inhibition of apoptosis. Second, discrete inhibition of a
single mitochondrial GSH transporter within neurons, is sufficient to increase
vulnerability to oxidative and nitrosative stress. Third, mitochondrial GSH has a potential
role in the regulation of Bcl-2 protein levels, possibly through a signaling mechanism to
the nucleus. Finally, while these data were not shown within my thesis, mitochondrial
GSH also appears to have a function in regulating mitochondrial dynamics (through
enhanced mitochondrial fission and/or biogenesis). Therefore, deficits in mitochondrial
GSH transport have the potential to affect many cellular processes either directly or
indirectly.
The observations presented within this thesis and discussed above have led to the
following hypothesis. Underlying oxidative and nitrosative stress, within astrocytes, leads
to deficits in mitochondrial GSH transport (this could be a consequence of any one of the
factors discussed above). The underlying oxidative stress is postulated to be a result from
either environmental exposures, genetic abnormalities, or both. Overall these events
culminate through the induction of a reactive gliosis phenotype, a decrease in GSH
secretion and an increase in the release of NO and ROS from the reactive astrocytes.
These effects then induce an elevation in the underlying oxidative stress within motor
neurons, increasing MOS and dysfunction, as mitochondrial GSH levels plummet.
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Decreased mitochondrial GSH levels (due to inhibited transport and increased oxidative
stress) will induce a reduction in Bcl-2 protein levels, increased production of ROS and
altered cell signaling pathways. These events culminate in motor neuron axon retraction
and degeneration, as depicted in Figure 5.6.
In conclusion, the pathogenic mechanisms of ALS are complicated, but deficits in
mitochondrial GSH transport, whether a cause or effect in the cascade of disease
progression, offers a unifying hypothesis between neuronal and astrocyte interactions.
While further evidence is necessary in order to determine more specific clinical trial
targets, I hypothesize that targeting mitochondrial GSH transport as a therapy in ALS
may provide efficacious treatment options for this devastating neurodegenerative disease.
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Figure 5.6 Working model regarding the role decreased mitochondrial GSH transport
may contribute to ALS disease pathogenesis Increased oxidative and nitrosative stress,
within astrocytes, leads to deficits in mitochondrial GSH transport, induction of a reactive
gliosis phenotype, decreased GSH secretion and increased release of NO and ROS. The
orange arrow represents the induction of effects within motor neurons as a result of
reactive gliosis onset within astrocytes. Where, an elevation in the underlying oxidative
stress within motor neurons can induce a deficit in mitochondrial GSH transport, altered
cell signaling pathways, axon retraction and motor neuron degeneration. I would like to
acknowledge Aimee Winter for drawing the astrocyte and motor neuron.
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APPENDIX A: ABBREVIATIONS
[3H]GSH; tritiated glutathione
32D; mouse immortalized myeloblast-like cell line
3-NT; 3-nitrotyrosine
5K; 5mM potassium
8-OHdG; 8-hydroxydeoxyguanosine
A4V mutant SOD1; alanine mutated to valine at amino acid position 4 in Cu/Zn
superoxide dismutase
ABT-737; BH3 mimetic 4-{4-[(4′-Chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-N-{[4({(1R)-3-(dimethylamino)-1-[(phenylsulfanyl)methyl]propyl}amino)-3nitrophenyl]sulfonyl}benzamide
ADP; adenine diphosphates
AIF; apoptosis inducing factor
AKAP121; A kinase anchoring protein
ALS; amyotrophic lateral scelorosis
AMPA; 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid
ANT; Slc25a5 or Slc25a4 adenenine nucleotide transporter
AP-1; activator protein 1 transcription factor
AP-2; activator protein 2 transcription factor
ARE/EpRE; antioxidant/electrophile response element
ATP; adenine triphosphate
Bcl-2; B cell lymphoma protein 2
BH; Bcl-2 homology domain
BM; butylmalonate
BSO; buthionine sulfoxide
Ca2+; calcium
CAD; caspase dependent DNAse
Cas; caspase
CGN; cerebellar granule neuron
CGN; cerebellar granule neurons
CHO; chinese hamster ovarian cell
CNS; central nervous system
Cox-IV; cytochrome c oxidase or complex IV
CREB; cyclic AMP response element binding protein
CSF; cerebral spinal fluid
CSM14.1; immortalized mesencephalic progenitor cell line
Cyt c; cytochrome c
DIC; Slc25a10 dicarboxylate carrier
DISC; death inducing signaling complex
DMSO; dimethylsulfoxide
DNA; deoxyribonucleic acid
DSS; disuccinimidyl suberate
DTNB; 5’-dithiobis(2-nitrobenzoic acid)
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DTT; dithiothreitol
E2F1; E2F transcription factor 1
E2F4; E2F transcription factor 4
EA; ethacrynic acid
EAAT-excitatory amino acid transporter
ER; endoplasmic reticulum
ETC; electron transport chain
FasL; Fas ligand
FDC-P1; mouse bone marrow lymphoblast cell line
FL5.12; mouse pro-B-cell lymphoid cell line
G37R mutant SOD1; glycine mutated to arginine at amino acid position 37 in Cu/Zn
superoxide dismutase
G6PD; glucose-6-phosphate dehydrogenase
G93A mutant SOD1; glycine mutated to alanine at amino acid position 93 in Cu/Zn
superoxide dismutase
GAPDH; glyceraldehyde 3-phosphate dehydrogenase
GCL; γ-glutamylcysteine ligase
GCLC- γ-glutamylcysteine ligase catalytic subunit
GCLM- γ-glutamylcysteine ligase modulatory subunit
GPx; glutathione peroxidase
GR; glutathione reductase
GS; glutathione synthetase
GSH; glutathione
GSH-MEE; glutathione monoethylester
GSNO; s-nitrosoglutahione
GSSG; glutathione disulfide
GST; glutathione S transferase
GT1-7; mouse immortalized gonadotropin-releasing hormone neurons
H2O; water
H2O2; hydrogen peroxide
H4IIE; rat hepatoma cell line
HA14-1; 2-Amino-6-bromo-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid
ethyl ester
HeLa; human epitheloid cervix carcinoma
HL-60; Human promyelocytic leukemia cell line
HNE; hydroxyl noneal
hSOD1G93A- human G93A SOD1 transgenic mice
ID2; inhibitor of DNA binding 2
IMM; inner mitochondrial membrane
IP; immunoprecipitation
IP3; Inositol trisphosphate
L929; murine aneuploid fibrosarcoma cell line
LY-ar; mouse lymphoma cells
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MCF-7; Michigan cancer foundation 7 human breast adenocarcinoma cell line
mM; millimolar
MOMP; mitochondrial outer membrane permeabilization
MOS; mitochondrial oxidative stress
mPTP; mitochondrial permeability transition pore
mRNA- messenger ribonucleic acid
NAC; n-acetylcysteine
NAD+; nicotinamide adenine dinucleotide
NADPH/NADP+; nicotinamide adenine dinucleotide phosphate
NAM; n-acetylmethionine
NFκB; nuclear factor kappa-light-chain-enhancer of activated B cells transcription factor
NMDA; N-methyl-D-aspartate
NO; nitric oxide
NonTg-non-transgenic
Nrf1/2; nuclear respiratory factor 1 or 2 also known as nuclear factor (erythriod-derived)like transcription factors
Nrk52E; rat renal proximal tubular cell line
NSC; neocarzinostatin
NSC34; mouse immortalized motor neuron cell line
NT2/D1; pluripotent human testicular embryonic carcinoma cell line
O2-; superoxide
OGC; Slc25a11 2-oxoglutarate carrier
PBS; phosphate buffered saline
PC12; rat pheochromocytoma adrenal medulla cell line
PD; parkinson’s disease
PhS or PS; phenylsuccinate
PKA; protein kinase A
PM; plasma membrane
Pro-cas; caspase
PS; phenylsuccinate
RNA-ribonucleic acid
ROS; reactive oxygen species
RS-; thyil radical
Sin-1; Amino-3-morpholinyl-1,2,3-oxadiazolium NO donor
Sk-N-MC; human neuronal epithelioma cell line
SLC; solute carrier family
SNAP; S-Nitroso-N-acetyl-DL-penicillamine NO donor
SNP; sodium nitroprusside
SO-; sulfenate
SO2-; sulfinate
SO3-; sulfonate
SOD; superoxide dismutase
SOD1; Cu/Zn superoxide dismutase
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SOD2; manganese superoxide dismutase
SP-1; specificity protein 1 transcription factor
STS; starausporine
TCC; Slc25a1 tricarboxylate carrier
TM; transmembrane
TNF; tumor necrosis factor
VDAC; voltage dependent anion channel
WT; wild-type
XAG-;Slc1a1 glutamate transporter
Xc-; Slc7a11 cysteine/glutamate transporter
μM; micromolar
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Chapter 2 entitled: “Bcl-2 is a novel interacting partner for the 2-oxoglutarate
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